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Abstract 
 
Numerous disease states can be traced back to an excessive or uncontrolled leukocyte 
accumulation to sites of inflammation or tissue injury. This recruitment of leukocytes, under 
normal conditions a vital defense mechanism against invading pathogens, is mediated by the 
interaction of the selectins with their physiological carbohydrate determinant sLex (3) as 
binding epitope of the natural selectin ligands. SLex (3) served as lead structure in the 
development of selectin antagonists, which have been considered as a promising therapeutic 
approach against these diseases. C-glycosidic structures play a prominent role in developing 
hydrolytically stable mimetics as well as in understanding conformational issues relevant for 
the binding process. 
 
 
 
C-glycosidic sLex mimetics 81a and 82 were designed to investigate the influence of the exo-
anomeric effect on the conformational stability and the biological activity of these 
tetrasaccharide mimetics. Flexibility of target compound 81a should be enhanced due to the 
lacking exo-anomeric effect around the C-glycosidic linkage. Implementation of steric 
constraints as the methyl group in compound 82 should proof the hypothesis, that the 
missing exo-anomeric effect can be compensated by steric factors. Furthermore, comparison 
of binding affinity should allow a quantification of the entropy contribution to the inhibitory 
potential caused by the exo-anomeric effect. 
We successfully developed a synthesis for the target tetrasaccharide mimetics 81a and 82 
based on the Giese radical addition of an anomeric fucosyl radical to the electron deficient 
double bond of an enone system. Conformational investigation of the target molecules 
revealed the possibility to compensate for the loss of the exo-anomeric effect by the 
introduction of sterically demanding substituents next to the C-glycosidic linkage. The 
influence of the 20-30% larger distance of H-5Fuc and H-2Gal in compound 82 compared to O-
glycosidic mimic 33 on biological activity  has to be proven by current investigation. 
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1. Introduction 
 
 
 
The interaction of E-, P- and L-selectin, a family of cell-adhesion proteins, with their natural 
carbohydrate ligands, plays a crucial role in many physiological processes and disease 
states. Inflammation as a response of the organism to microbial pathogens or physical and 
chemical insults is an important defense mechanism. However, it can also lead to destructive 
effects, if the regulation of the complicated  mechanism gets out of control or if the immune 
response towards microbial products or altered tissue components causes a permanent 
inflammatory response. This can lead to destruction of the tissue as it is the case in 
reperfusion injuries, asthma, allergies, rheumatoid arthritis etc.  
A key event in inflammation is the extravasation of leukocytes from the blood stream through 
the vascular endothelium to sites of inflamed tissue. This process is controlled by numerous 
molecular interactions and is called the inflammatory cascade. In the early stage, the 
selectins initiate the tethering of leukocytes from the blood stream to the activated endothelial 
cell layer and their rolling along the endothelial surface by interaction with glycan structures 
presented by their natural ligands. Tethering and rolling is followed by integrin-mediated firm 
adhesion and final transendothelial migration.  
The development of selectin antagonists applied in cases of excessive leukocyte 
extravasation leading to many disease states is a very attractive therapeutic target in 
pharmaceutical industry and academic research. 
 
1.1. The selectins and their ligands 
 
1.1.1. The selectin family 
 
The lectins are carbohydrate-binding proteins with exception of carbohydrate-converting 
enzymes and are divided in four groups [1]:  
• the C-type lectins, which incorporate one or more calcium ions in the binding site as 
requirement for binding activity,  
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• the S-lectins or galectins containing free thiol groups,  
• the P-lectins for their ability to recognize phosphorylated mannose residues and 
• other lectins not fitting in one of the above categories.  
In the course of their molecular characterization, all three known selectins (E-, P- and L-
selectin) have been identified as C-type lectins. In addition to the requirement of calcium ions 
for binding,  they have a Carbohydrate Recognition Domain (CRD) of ~ 130 amino acids, five 
disulfide bridges and 18 conserved amino acid residues [2] in the CRD [3]. Other examples 
for C-type lectins are the asialo-glycoprotein receptor (AGPR) [4] and the mannose binding 
protein (MBP) [5,6]. 
The prefixes of the three selectins indicates the cell types were the molecules were first 
identified: E-selectin on activated endothelial cells, L-selectin on most types of leukocytes 
and P-selectin in storage granules of platelets. In addition, in case of an inflammatory 
stimulus, P-selectin is also exposed to the surface of endothelial cells from Waibel-Palade 
bodies. 
L-selectin was first described in 1983 as a “lymphocyte homing” receptor which is blocked by 
the rat monoclonal antibody Mel 14. Mel 14 blocks the binding of lymphocytes to lymph node 
high endothelial venules (HEV) in lymph node tissue [7]. Later, it was also found on 
neutrophil granulocytes and monocytes and was shown to be generally involved in leukocyte 
entry into sites of inflamed tissue [8,9]. Weissman [10] and Lasky [11] reported concurrent 
work on the molecular characterization of L-selectin. It was isolated by immunoaffinity 
chromatography as a protein with a molecular mass of ~90’000. Cloning uncovered, that the 
protein is highly glycosylated and consists of 372 amino acids corresponding to a mass of 42 
kDa. 
In 1984, the groups of McEver [12] and Furie [13] independently discovered P-selectin by a 
monoclonal antibody approach as membrane glycoprotein antigen that is exposed on human 
blood platelets only after activation of these cells by thrombin or histamine. It was suggested, 
after analyzing the total extracts of resting platelets, that P-selectin is constitutively 
expressed in the membrane of α-granules of platelets [14,15]. Later, P-selectin was also 
found to be expressed constitutively in the membrane of Waibel-Palade bodies of human 
endothelial cells [16]. Cloning and PAGE analysis enabled the characterization of P-selectin 
as a C-type lectin with a molecular mass of 140’000 in the natural state. The mature protein 
contains 789 amino acids with a molecular mass of ~86 kDa [17,18]. 
E-selectin was discovered in the late 1980’s by Bevilacqua et al. [19,20] as antigen of two 
cell adhesion mouse monoclonal antibodies named H 18/7 and H 4/18. These mAbs 
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inhibited cell-cell adhesion in an assay [21] of polymorphonuclear neutrophils (PMN) or HL-
60 cells to cytokine-activated human umbilical vein endothelial cells (HUVEC). Cloning and 
molecular characterization using a cDNA library [22,23] in 1989 revealed the C-type lectin 
nature of E-selectin. The mature protein consists of 589 amino acids and has a molecular 
weight of 64 kDa, the native protein has a molecular mass of 115’000. Investigation of a 
number of oligosaccharides for their ability to inhibit the adhesion of HL-60 cells to COS cells 
transformed with E-selectin led to the conclusion [23], that the adhesive function of E-selectin 
might rely on complex carbohydrate structures. 
All three selectins contain five different protein domains [24] (see figure 1). The extracellular 
part contains the CRD, an N-terminal domain of ~ 120 –130 amino acids that shares some 
features of the lectin domain of C-type animal lectins [2]. It bears the carbohydrate binding 
site [25] conformationally stabilized by a calcium ion. There is more than 50% homology 
among the lectin domains of the selectins and about 30% homology between the lectin 
domain of E-selectin and the mannose binding protein (MBP) [6].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The CRD is followed by a sequence of 35-40 amino acids, the so-called EGF-domain, 
resembling a sequence found in the epidermal growth factor. The EGF-domain contains six 
cysteins located at equivalent positions in the “EGF-repeats” of several proteins. Although 
L-selectin 
P-selectin 
E-selectin 
Lectin domain  
(N-terminal) 
EGF domain
SCR domain 
Transmembrane 
domain 
Cytoplasmatic tail 
(C-terminal) 
Plasma membrane 
Figure 1: Domain organization of the selectin family.  
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the binding site was identified on the CRD [25], the EGF-domain is required for binding the 
carbohydrate ligand. The EGF-domain is believed to contribute important impacts to the 
binding conformation of the CRD [26,27]. Between the EGF-domain and the transmembrane 
domain lies a variable number of short repetitive elements, each ~60 amino acids long, which 
resemble motives found in complement regulatory proteins, named “complement binding” 
(CB) elements or short consensus repeats (SCR). In human, E-selectin contains six, P-
selectin contains nine, and L-selectin contains two SCR. Among other species, the number 
of SCR of E- and P-selectin varies form four to eight, whereas in L-selectin of mouse and rat 
the number of SCR is equal to that found in human. Truncating several of these elements in 
P-selectin was found to impair the efficiency of P-selectin to contribute to leukocyte rolling 
[28]. This findings led to the suggestion, that the CB-elements are responsible for keeping 
the CRD of P-selectin at a proper distance from the cell surface. The transmembrane domain 
is followed by a short C-terminal cytosolic tail of 17 amino acids in L-, and 32 and 34 amino 
acids in human E- and P-selectin, respectively. It is supposed to be involved in signal 
transduction [29]. 
 
1.1.2. The natural glycoprotein ligands of the selectins and their carbohydrate 
epitopes 
 
Due to the nature of the selectins as carbohydrate binding proteins, their natural ligands are 
comprised of a scaffold protein or lipid carrier molecule which presents glycan structures as 
binding motifs. The debate over the physiological ligands for the three selectins is still 
ongoing, caused by the fact that selectin-binding can be transferred to usually physiologically 
irrelevant carrier proteins by modifying their glycosylation pattern [30]. Thus, Berg et al. 
[31,32] could demonstrate that sLex-substituted BSA shows selectin-binding affinity.  
It is the current opinion that carbohydrates containing the trisaccharides Lewisx (1) and 
Lewisa (2) or their sialylated derivatives sialyl Lewisx (3) and sialyl Lewisa (4) are present in 
selectin-binding ligands (figure 2). In general, fucosylated and sialidated glycans such as 
sLex are required for function [31,33,34]. In some cases, additional sulfation is needed to 
obtain binding affinity.  
Soluble recombinant forms of the selectins as well as selectin-IgG fusion proteins have been 
used as affinity probes to isolate and identify their natural glycoprotein ligands. Five 
glycoproteins have been identified so far as natural ligands for L-selectin: Gly-CAM-1 [35], 
CD34 [36], MAdCAM-1 [37,38], podocalyxin-like protein [39] and Spg200 [40]. All of them are 
expressed by HEV in lymph node tissue as L-selectin-binding glycoforms. Gly-CAM-1 and 
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CD34 are both sialomucins, which carry large clusters of sialic acid-rich O-linked 
carbohydrate side chains essential for L-selectin binding. Both proteins are also found in 
other tissue, however lacking the correct carbohydrate modifications. Gly-CAM-1 is a 
secretory protein, which is not found on the cell surface, but in cytoplasmic granula [41,42]. 
MAdCAM-1 is usually a ligand for the lymphocyte integrin α4β7, but a subpopulation can also 
be recognized by L-selectin. It contains both a mucin- and an immunoglobulin-like domain.  
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The posttranslational modifications of Gly-CAM-1 have been intensively studied. Sulfation, 
fucosylation and sialidation was found to be essential for binding affinity [35,43,44]. Major 
capping structures of mouse Gly-CAM-1 were found to be 6’-sulfo sialyl Lewisx (5) [45] and 
core-2 based 6-sulfo sialyl Lewisx (6) (figure 2), which are incorporated in glycan motivs 7 
and 8 shown in figure 3a and 3b. 6 was found to block binding of L-selectin-IgG to Gly-CAM-
1 [46].  
A 250kDa homodimeric protein linked by two disulfate bridges called PSGL-1 has been 
identified as natural occurring P-selectin ligand [47]. Similar to the ligands for L-selectin, 
PSGL-1 is a sialomucin with a high degree of O-linked glycan modifications. It requires 
sialidation and fucosylation for its binding affinity [48-52]. Detailed analysis of the 
carbohydrate side chains of PSGL-1 revealed a trifucosylated core-2 structure 9 with a 
terminal dimeric sLex (figure 3). As a special structural feature it was found, that PSGL-1 has 
to be sulfated at two of the three N-terminal tyrosine residues (Tyr46 and one of the two 
tyrosines Tyr48 or Tyr51) for binding to P-selectin and probably also to L-selectin [53-56]. 
The structural requirements necessary for the binding to E-selectin are different to that 
elucidated for P- and L-selectin. In contrast to the ligands for L-selectin, ligands for E-selectin 
are not sulfated. A glycoprotein called ESL-1 was isolated on mouse myeloid cells and 
mouse neutrophils [57] and was characterized as 150kDa glycoprotein, which, in contrast to 
the sialomucin-type selectin ligands discussed above, requires N-linked glycans for binding 
to E-selectin and only binds to E-, but not to P-selectin [58]. Cloning revealed five putative N-
glycosylation sites and 16 cysteine-rich repeats [59].  
Three glycans were identified as physiologically relevant high-affinity ligands of E-selectin 
[60]. All three contain the sialyl di-Lex structure on the β-D-GlcNAc-(1→4)-α-D-Man-(1→3)-
branch of tetraantennary N-glycans (see e.g. 10 in figure 3d). All glycans incorporate the 
trimannosyl chitobiosyl core typical of N-glycans. The specifity of these glycans as ligands of 
E-selectin was confirmed on an affinity column of recombinant, soluble E-selectin on agarose 
[61]. 
E-selectin also binds PSGL-1 [50,51,58,62-64]. However, tyrosine sulfation is not necessary 
for binding. [50,63]. Due to the fact, that L-selectin is consecutively expressed on leukocytes 
to fulfill its roll in permanent lymphocyte homing, its role in inflammation has to be controlled 
by the inducibility of its endothelial ligands. E-selectin is able to bind to carbohydrates 
present on L-selectin on human neutrophils, but not on lymphocytes [65,66]. Figure 4 [67] 
summarizes the appearance of the three selectins and their binding partners. 
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Figure 4: Selectins, integrins and their binding partners. The depicted selectin ligands are those, 
which have been identified by affinity isolation with the respective selectin as affinity probe. [67] 
Leukocyte 
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1.2. Significance of selectin-ligand interaction in pathophysiology 
 
1.2.1. Biological background of selectin-carbohydrate interaction 
 
The interaction of the selectins with their natural glycoprotein ligands plays a predominant 
role in cell-adhesion processes [9,68] during inflammation. Experimental observation of 
tethering, rolling and extravasation of leukocytes during acute inflammation have been 
reported since the 19th century [69-71]. The inflammatory cascade is initiated by a variety of 
inflammatory mediators such as chemokines or platelet activating factors [72,73] upon 
stimulation by invading pathogens or responding monocytes. These stimuli induce vascular 
endothelial cells to express E- and P-selectin. P-selectin, which is stored in α-granules of 
platelets and Waibel-Palade bodies of endothelial cells, can be rapidly presented to the cell 
surface within seconds to minutes upon fast stimulation of endocytosis by proinflammatory 
mediators such as thrombin or histamine [74,75]. Expression is maximal after 5-10 min after 
stimulation, and the protein is taken up from the endothelial surface after 30-60 min by 
endocytosis. Beside this fast exposure of P-selectin, a second regulatory mechanism similar 
to that found for E-selectin exists. TNF-α was found to stimulate the expression of P-selectin 
on the transcription level in mouse and bovine endothelial cells with similar kinetics found for 
that of E-selectin [76-78]. E-selectin in contrast to P-selectin is transcriptionally induced by 
TNF-α, IL-1 or lipopolysaccharide (LPS) [20,79]. Peak levels at the cell surface are reached 
within 3-4 h after stimulation [22] and basal levels can be found again after 16-24 h. The 
presentation of E- and P-selectin at the surface of endothelial cells and thus the interaction 
with ESL-1 and PSGL-1 present at the surface of leukocytes leads to tethering and rolling 
[80,81] of white blood cells along the vessel wall. L-selectin, which is constitutively expressed 
on leukocytes, contains carbohydrate structures that serve as ligands for E-selectin [66]. 
Interaction of L-selectin with PSGL-1 [82] leads to the tethering of leukocytes to leukocytes 
which are already adhering to the endothelium [83]. This mechanism expands the pool of 
leukocytes attracted to sites of inflamed tissue.  
Cell activation causes rapid downregulation of L-selectin within minutes [84] by proteolytic 
activity cleaving L-selectin at an extracellular cleaving site [85]. This proteolytic cleavage 
occurs on neutrophils within 1-5 min and is speculated to facilitate detachment of leukocytes 
from endothelial cells prior to migration through the endothelial layer. Indeed, Walcheck et al. 
[86] showed in an elegant study, that neutrophils rolled at considerably lower velocity in the 
presence of a protease inhibitor, and that the neutrophil accumulation rate increased. 
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Shedding seems to be important to prevent too strong attachment of leukocytes via L-
selectin. 
Rolling of leukocytes enables further adhesion events [87,88] between chemokine-activated 
integrins on the leukocyte surface and endothelial integrin ligands ICAM-1 and VCAM-1, 
which are members of the immunoglobulin superfamily. This firm adhesion, which is another 
target of drug development [89-93], leads finally to the migration of leukocytes through the 
endothelial layer. 
 
 
The involvement of all three selectins in leukocyte rolling has been clearly established and 
confirmed by numerous investigations [94-97]. Experiments with gene-deficient mice (k.o. 
mice) delivered a large amount of knowledge about the physiological role of the selectins. 
Lymphocyte homing was significantly reduced in L-selectin k.o. mice [98,99]. L-selectin 
deficiency also affected the successful execution of an immune response [100-102]. P-
selectin k.o. mice showed reduced neutrophil emigration into the inflamed peritoneum, 
especially 1-2 h after stimulus [103,104]. In contrast, E-selectin k.o. mice showed no 
abnormalities in inflammatory responses [105,106]. Severe defects were observed in E-
selectin k.o. mice, whose P-selectin function was blocked by P-selectin antibodies [107]. E-
/P-selectin k.o. mice showed an increased susceptibility to bacterial infections. Leukocyte 
rolling was significantly reduced and neutrophil emigration was completely absent within the 
first 4 h after stimulation [106,108].  
In vitro flow chamber experiments established a two-step model for leukocyte adhesion [88] 
under flow in vivo, with the selectins mediating the tethering and rolling, and the integrins 
acting subsequently to arrest rolling leukocytes prior to transmigration. In the flow chamber 
experiments, an artificial lipid bilayer was intercalated with P-selectin, ICAM-1 or a mixture of 
both. Leukocyte rolling was observed in the flow chamber under physiologically relevant 
Figure 5: Photographs of leukocytes rolling along the vasculature (left) and a 
leukocyte in the state of migration through the endothelium (right). 
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shear stress using lipid bilayers containing only P-selectin. Instead, the velocity of free 
flowing leukocytes was not affected, if only ICAM-1 was incorporated. Neutrophils rolling on a 
bilayer containing P-selectin and ICAM-1 were brought to a halt by adding neutrophil integrin 
activators. Under static conditions however, leukocytes were found to attach to membranes 
containing fourfold lower concentrations of ICAM-1.  
 
These data indicate that under physiological shear stress conditions, rolling mediated by the 
selectins is a prerequisite for the firm attachment of leukocytes enabled by integrin-ICAM-1 
interaction and subsequent migration through the vascular endothelium. 
 
1.2.2. Endothelial-leukocyte adhesion in human diseases 
 
The selectins have been found to be involved in a number of acute and chronic diseases 
[109]. Ischemia-reperfusion injury is an important example of inflammatory conditions, in 
which selectin-ligand interactions play a role [110]. Typical of the condition is a rapid burst of 
oxygen-derived radicals that arise shortly after reperfusion of the ischemic tissue. As a 
consequence, P-selectin is transferred to the cell surface, resulting in strong accumulation of 
neutrophils. This accumulation in the damaged tissue induces vascular dysfunction and 
causes further injury to heart muscle cells. The prevention of reperfusion injury became, 
therefore, a highly desirable therapeutic goal in case of cardiac infarction, which is 
necessarily followed by reperfusion of the ischemic heart tissue. Antibodies against P-
selectin significantly protected myocardial necrosis in a feline model [111] and administration 
of sLex-related oligosaccharides showed similar protective effects [112]. 
Eosinophil granulocytes, which are activated and recruited to extracellular sites by E-selectin 
together with the integrin receptors ICAM-1 and VCAM-1 [113], play a prominent role in 
allergic inflammation and asthma [114]. Groves et al. [115] found significant expression of E-
selectin on vascular endothelium in cutaneous inflammatory disorders such as allergic 
contact dermatitis, atopic dermatitis and psoriasis as well as in skin infiltrates associated with 
benign, premalignant and malignant proliferation of keratinocytes. 
Redl et al. [116] studied the expression of E-selectin under the conditions of septic vs. 
traumatic shock in baboons. Septic shock, which was induced with living e. coli bacteria, 
induced a widespread expression of E-selectin in capillaries, venules, small veins, arterioles 
and arteries. Expression was most pronounced on vessels of lung, liver and kidneys. By 
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contrast, animals with traumatic shock showed only minimal evidence of increased E-selectin 
expression. 
In 1992, a rare genetic disorder called “type 2 leukocyte adhesion deficiency” (LAD-2) was 
discovered [117]. Patients suffering from this disease show mental retardation, short stature 
and recurrent bacterial infections accompanied by high leukocyte counts. Examination of the 
patient’s blood group phenotype revealed the presence of the Bombay (hh) blood group 
antigen [118]. This rare blood group results from failure to attach fucose in an α-(1→3)-
fashion to form the blood group H determinant. LAD-2 patients were also negative for the 
secretor, Lex and Lea blood group antigens. Neutrophils from LAD-2 patients were found not 
to bind to HUVEC activated with interleukin-1β. These findings led to the assumption, that 
neutrophils of LAD-2 patients have an adhesion deficiency due to the lack of sLex epitopes 
and that LAD-2 underlies a general defect in fucose metabolism. Another human disease, 
LAD-1, is due to the lack of functional integrin β2-chains (CD18), essential for neutrophil 
extravasation. Such patients suffer from life-threatening infections [119]. 
Increased expression of endothelial adhesion molecules has been observed at the rejection 
of human renal [120], cardiac [121,122] and liver transplants [123]. The enhanced expression 
results from several factors, including cytokines generated during the immune response to 
foreign antigens and the effects of ischemia-reperfusion injury. In monkeys, anti-ICAM-1 
antibodies reduced lymphocyte infiltration and prolonged kidney allograft survival [124].  
Recipients of bone marrow transplantation may develop “graft vs. host disease” (GvHD), a 
multiorgan disease caused by immune response of donor leukocytes against host tissue. 
GvHD-associated lesions showed increased E-selectin and VCAM-1 expression close to the 
sites of leukocyte infiltration [125,126]. In a mouse model, therapy with anti-ICAM-1 
antibodies reduced the severity of the disease and prolonged the survival of mice receiving 
allogenic bone marrow [127]. 
Some of the carbohydrate epitopes serving as selectin ligand glycans have been identified 
as tumor-associated antigens [128,129]. Evidence has been found that profound changes in 
surface carbohydrate structures occur upon malignant transformation of cells [130]. Among 
others, Lex, Lea and their sialidated derivatives sLex and sLea are increasingly expressed 
during expression of cancer [131,132]. The significance of these surface glycan changes in 
conjunction with tumor progression and metastasis has been discussed in a recent review 
[133]. Several studies showed a significant correlation between sLea expression and a poor 
prognosis in a total of more than 500 patients with colon cancer in Japan [131]. 
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1.3. Affinities and kinetics of selectin-ligand interactions 
 
Capturing of leukocytes from the rapidly flowing blood stream is a special kind of cell-cell 
interaction requiring special forms of molecular mechanisms. Fast association (kon) [88,134] 
and dissociation rate constants (koff) together with special mechanical properties as tensile 
forces are supposed to be required to fulfill this purpose. The selectins seem to be ideally 
suited for this task, as they incorporate the above mentioned characteristics [88,135,136]. It 
was often argued that the affinity of the selectins to their ligands does not need to be high. 
Indeed, the selectins have been found to bind synthetic oligosaccharides like sLex and sLea 
with comparable low affinities (KD ~ 0.1 – 5 mM) [9,46,137-139].  
 
 
 
In a recent study [140], binding affinities as well as kinetic and thermodynamic parameters of 
E-selectin binding to ESL-1 was determined using surface plasmon resonance (SPR). The 
data has been compared to those earlier obtained for the binding of PSGL-1 to P-selectin 
[142] and Gly-CAM-1 to L-selectin [141] (table 1). 
The KD of monomeric E-selectin binding to ESL-1 of 62 µM was found to be only slightly 
higher than that of L-selectin/Gly-CAM-1. However, P-selectin/PSGL-1-interaction has a 
much higher affinity (KD = 0.32 µM), mainly due to a faster kon. The kon of E-selectin/ESL-1 
lies within the range of reported values for protein-carbohydrate interactions [143] and is 
marginally slower than is typical for protein-protein interactions (105 to 106 M-1 s-1) [144]. The 
fact, that kon of P-selectin/PSGL-1 is nearly 2 orders of magnitude larger than the kon 
measured for E-selectin/ESL-1 cannot be explained by greater conformational 
rearrangements, because kon for E-selectin/ESL-1 is not unusually temperature-dependent 
Interaction Species Temp. KD kon koff Refs. 
  °C µM M-1 s-1 s-1  
E-selectin / ESL-1 Mouse 37 62 7.4 x 104 4.6 [140] 
  25 56 4.8 x 104 2.7 [140] 
L-selectin / GlyCAM-1 Mouse 25 108 > 1 x 105 >10 [141] 
P-selectin / PSGL-1 Human 25 0.32 4.4 x 106 1.4 [142] 
Table 1: Comparison of affinities and kinetics of selectin-ligand interactions measured by SPR 
[140]. 
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and because P-selectin itself undergoes substantial conformational changes upon binding to 
PSGL-1, as found by Camphausen et al. [145]. It is more likely, that favorable electrostatic 
interactions due to the sulfated tyrosines on PSGL-1 result in the faster kon-values. The key 
observation in the thermodynamic investigations was, that there were no significant changes 
in affinity with temperature, implicating that binding is mostly driven by favorable entropic 
contributions with only small impact from enthalpic changes.  
 
1.4. Structure-activity relationship of E-selectin binding to sLex 
 
The development of low-molecular weight, high affinity sLex mimetics as E-selectin 
antagonists requires a profound understanding of the mechanisms of selectin-carbohydrate 
interactions on a molecular level. NMR-spectroscopic investigation, X-ray crystallography 
and molecular modeling as well as binding-affinity studies with modified sLex derivatives 
delivered detailed information about the structure-activity relationship, yet the picture drawn 
with the aid of these information changed slightly in the course of growing knowledge and 
some details are still controversially discussed. 
 
1.4.1. Pharmacophores 
 
All functional groups of sLex have been chemically modified in a systematic fashion to identify 
those groups being critical to maintain binding affinity. Those functional groups being 
significant for binding are called pharmacophores (figure 6).  
• Gaeta et al. [146] and Hasegawa et al. [147] determined the role of the hydroxyl groups 
of fucose by replacing them with hydrogen. In analogy to the mannose binding protein 
MBP-A [6], fucose was correctly assumed to be responsible for calcium binding. 
Replacement of any hydroxyl group resulted in completely inactive deoxy-derivatives. 
Substitution of fucose by arabinose to elucidate the influence of the methyl group of 
fucose led to a five-fold less active compound [146]. There are, however, distinct 
differences between the three selectins. Thus, in case of P-selectin, only the 3-hydroxyl 
group was found to be critical for sLex binding.  
• The role of the galactose hydroxyl groups was determined synthesizing deoxy- and 
fluoro-derivatives of sLex [148]. Reduced affinity could be observed on substituting the 4- 
and 6-hydroxyls implicating that those groups are important rather than crucial for 
binding. In contrast, derivatives modified at the 6-position of galactose were found to be 
1. Introduction                                                                                                                                        15 
 
inactive (IC50 > 10 mM) [149], leading to the suggestion, that the 6-hydroxyl group is 
optimally suited for binding to E-selectin.  
• The contribution of the functional groups of NeuNAc (the glycerol side chain, the 4-
hydroxyl group, the amide residue and the carboxylate) has also been examined in detail 
[147,150,151]. Modification of the glycerol side chain as well as removal of the amide 
group showed little to no effects. The carboxylate, however, was found to be highly 
significant for binding.  
• The GlcNAc moiety does not directly contribute to protein-ligand contacts, as several 
studies discussed [152-154]. It was rather suggested, that the GlcNAc serves as a spacer 
unit to arrange the crucial functional groups at the fucose and galactose in the required 
spacial orientation.  
 
 
 
 
 
 
 
 
 
 
 
1.4.2. Solution conformation vs. bioactive conformation 
 
NMR studies with labeled and unlabeled compounds have been used in combination with 
molecular dynamics calculations to gain valuable information about conformational 
preferences of sialyl Lewisx free in solution as well as bound to the receptor. Early work 
aimed at defining the solution conformation of sLex.  
Bednarski et al. [155] and Ishikawa et al. [156,157] agreed in their findings of a single stable 
conformation of sLex in solution. ROESY and NOESY NMR-spectroscopy revealed 
significant interglycosidic nuclear Overhauser effects (nOe) between H-3 of GlcNAc and H-1 
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Figure 6: Structure/function map of sialyl Lewisx. Pharmacophores 
for binding to E-selectin are highlighted.
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of Fuc, H-4 of GlcNAc and H-1 of Gal, H-2 of Gal and H-5 and H3C(6) of Fuc as well as 
between H-3 of Gal and H-3(ax) of NeuNAc (figure 7). ROESY measurements in 
combination with MM2 calculations identified the interglycosidic dihedral angles Φ and Ψ 
[158] corresponding to the solution conformation as NeuNAc(α2-3)Gal {163°, -61°}, Gal(β1-
4)GlcNAc {48°, 15°} and Fuc(α1-3)GlcNAc {22°, 30°} (see table 2). In a subsequent study of 
the same group [156], four energy minima for the NeuNAc-Gal linkage was found with the 
dihedral angles A, B, C and D being {163°, -57°}, {-170°, -8°}, {-79°, 7°} and {68°, -20°} (see 
table 2). Poppe [159] and Breg [160] found three different energy minima for the NeuNAc-Gal 
linkage with angles of A = {-70°, 5°}, B = {-160°, -20°} and C = {-95°, -45°}. Studies by other 
groups [161,162] confirmed the high flexibility around the glycosidic bond between NeuNAc 
and Gal. 
 
 
 
 
 
 
 
 
 
 
 
The bioactive conformation of sLex (the conformation adopted while binding to E-selectin) 
was investigated by Peters et al. [163-165] and Cooke et al. [161] by transfer-NOE (trNOE) 
[166,167] spectroscopy. Peters and colleagues found significant changes in nOes in the free 
saccharide and the corresponding tr-nOes in the bound oligosaccharide. A prominent nOe 
between the H-3(ax) of NeuNAc and H-3 of Gal in the free ligand was completely absent in 
the bound oligosaccharide. Instead, a tr-nOe was found between H-8 of NeuNAc and H-3 of 
Gal. The interglycosidic dihedral angles were deduced from these data as NeuNAc,Gal {-76° 
± 10°, 6° ± 10°}, Gal,GlcNAc {39° ± 10°, 12° ± 6°} and Fuc,GlcNAc {38° ± 7°, 26° ± 6°} for the 
bioactive conformation (see table 2). This bound conformation refers to solution-conformer A 
of Breg concerning the NeuNAc-Gal glycosidic bond. These findings imply a profound 
change in conformation around the NeuNAc-Gal glycosidic bond switching from the free to 
Figure 7: Nuclear Overhauser effects observed in the NMR-spectra of sLex in solution.
The nOe between H-3axSia and H-3Gal is absent in the bioactive conformation [163].
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the bound state. The Lex trisaccharide part of sLex, however, shows no conformational 
changes upon binding and seems to be rather rigid even in the free state. In contrast, Poppe 
and Breg argue that no conformational changes are needed upon binding of sLex to E-
selectin, because the bioactive conformation adopts one of the most stable free 
conformations.  
 
 
 
 
The bioactive conformation claimed by Peters et al. [163,168] is shown in figure 8. One 
decisive element of the bioactive conformation is the stacking of the fucose and galactose 
moiety above each other with the GlcNAc unit acting as a spacer. This spacial arrangement 
 
 Ishikawa, solution conf. [156,157] 
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Table 2: Interglycosidic dihedral angles Φ and Ψ as determined for the solution 
conformation and the bioactive conformation of sLex . 
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is stabilized by a hydrophobic interaction of the two touching monosaccharide faces as 
clarified by the loss of activity, if the methyl group of fucose is changed by substituents of 
different size or polarity. The carboxyl function of NeuNAc is situated perpendicular to the 
GlcNAc-plane. This conformation arranges all pharmacophores within a row along one side 
of the tetrasaccharide, pointing towards the reader in figure 8. This allows the 
pharmacophores to bind to a hydrophilic, relatively shallow cleft in the surface of E-selectin, 
which constitutes the binding site of the selectins together with the calcium-ion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.3. Hypothetical models for the binding mode of sLex/E-selectin 
 
The effect of mutations in the lectin domain of a lectin/EGF construct of E-selectin on binding 
of anti-E-selectin mAbs as well as immobilized sLex-glycolipids was studied by Erbe et al. 
[25]. As a result of the mutagenesis studies, they claimed a relatively small, shallow patch of 
the lectin domain to be responsible for sLex binding, in which the amino acids Arg-97, Lys-
111, Lys-113, Ser-47 and Tyr-48 are directly involved in the binding process. The group 
developed a three-dimensional model of the E-selectin CRD by superposition of the 
functional residues onto the crystal structure of MBP-A [5]. 
Figure 8: Conformation of sLex bound to E-selectin as 
determined by Peters et al. [163,168]. 
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The crystal structure of MBP-A complexed with a mannose-containing oligosaccharide 
published by Drickamer et al. [6] was the first crystal structure of a saccharide bound to a C-
type lectin domain and manifested a complexation of the calcium ion by the equatorial 3- and 
4-hydroxyl groups of mannose. This crystal structure directly influenced all subsequent 
models developed to explain the molecular interaction of sLex with the CRD of E-selectin. 
The basis of all these following models was the superimposing of the fucose-hydroxyls 2 and 
3 (both equatorially oriented) onto the 3- and 4-hydroxyls of mannose allowing the fucose to 
occupy the same space when binding to calcium. The third axial hydroxyl of each 
monosaccharide overlaid as well being able to interact with protein side chains. While this 
assumption was rational on the background of the data available by that time, it later turned 
out to be incorrect.  
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Figure 9: Binding mode of sLex binding to E-selectin as proposed by Ernst et al. [168] showing the 
contacts of the pharmacophores with the protein surface. As can be clearly seen, the GlcNAc moiety 
is not involved in direct binding. 
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The first genuine insight into the binding site of E-selectin was provided by Graves et al. 
solving the x-ray crystal structure of the E-selectin CRD/EGF domains. Further details 
delivered the crystal structure of sLex bound to a selectin-like mutant of MBP-A [169], that 
confirmed the binding of the 2- and 3-hydroxyl groups of fucose to the calcium ion. It was, 
however, unexpected, that the carboxylate group of sialic acid did not interact with the 
protein, despite earlier findings that it is a pharmacophore for binding of sLex to E-selectin. 
Two theories were discussed: either sLex binds differently to E-selectin than to MBP triple 
mutant, or the importance of the sialic acid was not related to a direct binding  to the protein.  
Many different models for the binding mode of sLex/E-selectin has been developed over the 
years. All of them showed to be correct in some parts while showing some failures in other 
parts when compared to the crystal structure of sLex bound to E-selectin published in 2000 
by Camphausen et al. [145].  
Three models, which in fact are rather similar, will be discussed here in more detail. Kogan et 
al. [170] developed a model of sLex/E-selectin binding based on the bioactive conformation of 
sLex as proposed by Cooke [161], which was docked to E-selectin. Prior to energy 
minimization, the MBP-A structure was superimposed onto E-selectin to orientate the fucose 
unit of sLex identical to that of mannose binding to MBP-A. Protein-ligand contacts emerging 
from this model are listed in table 3. Ernst et al. [168] presented a binding mode (figure 9, 
table 3) based on docking of the bioactive conformation of sLex obtained from own NMR 
investigations into the crystal structure published by Graves.  
Both models agree in the binding of the 2- and 3-hydroxyl groups of fucose to the calcium 
ion, the 6-OH of Gal binding to Tyr94 and the carboxylic acid maintaining contact to Arg97. 
Slight differences lie in coordination of the calcium ion by the protein residues, the contact of 
the 4-OH of Gal to Asn105 being not predicted by Kogan and the mode of binding of Asn82 
to one of the three fucose hydroxyls.  
The most direct insight into the possible binding mode of sLex/E-selectin was given by the 
crystal structure of sLex bound to E-selectin published by Camphausen et al. [145] (figure 
10). The most striking difference to all other previous predictions suggests the fucose 
complexing the calcium ion with the 3- and 4- hydroxyl groups. The 2-hydroxyl group is 
indirectly binding to Asn83 and Glu107 via hydrogen bonds to an intercalated water 
molecule. Further, the 4-OH of Gal is binding to Glu92 instead of Asn105. The carboxylic 
acid is coordinating Tyr48 in addition to Arg97. Camphausen and colleagues did not discuss 
the conformation of sLex found in the crystal structure in detail. Thus, it is not obvious, 
whether sLex adopts the bioactive conformation observed in solution, or if crystal packing 
leads to slight changes in the conformation of sLex in the crystal. 
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Residue Kogan [170] Ernst [168] Camphausen [145] 
Fuc O-2 Ca2+ Ca2+ H2O – Glu 107 
 Asn 105 Asn 105 H2O – Asn 83 
Fuc O-3 Ca2+ Ca2+ Ca2+ 
 Glu 80 Glu 80 Asn 105 
 Asn 82  H2O – Asn 83 
Fuc O-4  Asn 82 Ca2+ 
   Glu 80 
   Asn 82 
Gal O-4  Asn 105 Glu 92 
Gal O-6 Tyr 94 Tyr 94 Tyr 94 
NeuNAc COOH Arg 97 Arg 97 Arg 97 
   Tyr 48 
Ca2+ Glu80 Glu 80 Glu 80 
 Asn 82 Asn 82 Asn 82 
   Asn 83 
 Asn 105 Asn 105 Asn 105 
 Asp 106 Asp 106 Asp 106 
Table 3: Contacts of sLex with E-selectin as defined in several models. 
Figure 10: SLex bound to E-selectin as found from the crystal structure by Camphausen 
et al. Left: focus on fucose interactions; right: focus on Gal-NeuNAc interactions [145]. 
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1.5. Approaches towards the development of sLex mimetics as selectin-
antagonists  
 
After the demonstration that, under flow conditions, tethering and rolling of leukocytes 
initiated by selectin-carbohydrate ligand interaction is a necessary, preliminary event [88] 
prior to the firm adhesion of leukocytes mediated by the interaction of integrins with the 
immunoglobulins ICAM-1 and VCAM-1, a keen interest arose on developing inhibitors of 
selectin-ligand interactions as anti-inflammatory agents to cure diseases based on 
uncontrolled inflammatory reactions. The terminal carbohydrate epitope sialyl Lewisx served 
as lead in the drug development process to find antagonists fulfilling two main objects:  
• modification of the lead structure towards molecules that overcome the pharmacokinetic 
(i.e. hydrolytical instability, fast renal excretion, and high polarity leading to low 
bioavailability) and pharmacodynamic disadvantages typical of carbohydrates, and  
• simplification of the complex structure of sLex to small molecules that are easier to 
prepare, combined with an enhancement of the low binding affinity of the natural ligands.  
Approaches to this goal implied substitution of substructures by simplified linker groups while 
retaining the pharmacophores critical for binding. An important aspect in this respect is the 
annihilation of conformational preorganization of the pharmacophores, that is caused by the 
displacement of the relatively rigid Lewisx core structure with much more flexible linkers. As 
we will see later, high entropic costs have to be paid leading to decreased binding affinity. 
In addition, approaches aiming at affinity enhancement by mimicking nature’s use of 
polyvalency [171] or even more complex carbohydrate structures [172-175] compared to sLex 
itself have been reported. These approaches in part showed promising improvements, but 
the compounds developed are not feasible for oral drug formulations. Several reviews cover 
this field of research, that will not be taken into account here [171,176-183]. 
The following overview of contributions in the field of sLex mimetics will be sorted in a 
reductionist fashion starting with mimics in which only NeuNAc has been replaced by anionic 
residues, then moving to those mimics in which two carbohydrates have been replaced 
(NeuNAc and GlcNAc, or Gal and GlcNAc). Finally, mimics containing only one carbohydrate 
(Fuc, Gal, or Man) will be discussed. Within these categories, further strategies like 
addressing secondary binding sites for hydrophobic interactions or preorganization of 
pharmacophores in the bioactive conformation by rigidification will be incorporated. 
 
1. Introduction                                                                                                                                        23 
 
1.5.1. Three-sugar mimetics: deletion of sialic acid or GlcNAc 
 
The carboxylic acid is the only pharmacophore contributed by the neuraminic acid part of 
sLex. In addition, neuraminic acid is the most expensive building block of sLex. Therefore, the 
replacement of NeuNAc with a negatively charged group at the 3-position of galactose is a 
logical first step. Substitution of NeuNAc by sulfate groups led to the known sulfo-Lex and 
sulfo-Lea natural ligands or related derivatives [147,184,185]. Also phosphate has been used 
as replacement for NeuNAc. Hasegawa et al. [147] and Kondo et al. [186] as well as 
Kiessling et al. [187] prepared 3’-sulfate- and 3’-phosphate-bearing derivatives of Lex and Lea 
(figure 11).  
 
Affinities reported were similar to those of sLex [186]. 3’-phospho-Lea (13) showed equal 
affinity to E-selectin as 3’-sulfo-Lea (14) and both showed a 20-fold better affinity compared 
to 3’-sulfo-Lex (15) [187]. The most common substitution used is CH2COO-. Compound 16 
showed an affinity comparable to that of sLex towards E-selectin [188]. Duthaler et al. [189] 
fixed the freely rotatable carboxylic acid in a conformation opposite to the bioactive 
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conformation by embedding it into a cyclic six-membered acetal. Compound 17 turned out to 
be inactive. Other NeuNAc replacements will be introduced in the next section when used in 
combination with GlcNAc-substitutions. 
Some work has been done on replacing only the GlcNAc unit in sLex keeping the three other 
sugar units intact (figure 12). Since the GlcNAc moiety contains no pharmacophores, it is 
most likely that it functions only as a spacer important for preorganizing the pharmacophores 
of fucose and galactose. Generating mimics as active or even more active as sLex by 
replacing GlcNAc requires linker, that keep the core structure of sLex unchanged. Hanessian 
[190] reported on a mimic that replaced GlcNAc by an indolizidinone type heterocycle (18, 
figure 12). 
 
 
The compound showed no affinity in an E-selectin cell free assay. Substitution of GlcNAc 
with quinic acid [191] produced mimic 19, which was equally active as sLex. Töpfer used a 
(1R,2R)-cyclohexanediol ring to replace GlcNAc and succeeded in obtaining the three-fold 
more active compound 20 compared to sLex [192]. 
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1.5.2. Two-sugar mimetics (I): replacement of NeuNAc and GlcNAc 
 
Several attempts have been reported to combine the effects of NeuNAc- and GlcNAc-
replacement to develop even more potent selectin antagonists. Replacing GlcNAc alone has 
shown to rarely improve binding affinity, yet leading to mimics to be prepared with less 
synthetic expenditure. A large variety of GlcNAc substitutions has been tested in combination 
with glycolic acid or alkyl- and aryl lactic acid residues mimicking the sialic acid part (figure 
13, figure 14).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Wong claimed [176], that (1R,2R)-cyclohexanediol seems to be energetically neutral in cases 
where the carboxymethyl group was used as NeuNAc surrogate, leading to mimetic 32 
(figure 13) [193] being as potent as sLex. Surprisingly, compound 21 [193-197], containing 
the much more flexible ethylenglycol linker, was almost as active as compound 32.  
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The introduction of differently substituted, but still too flexible 1,2-diols as GlcNAc 
replacement lead to compounds 22 to 25, which all showed weaker affinity to E-selectin as 
sLex itself. Incorporation of a rigid ortho-substituted benzene ring as in compound 26 was 
even less successful. Also substitution of GlcNAc by four-carbon-units as butane, a cis-olefin 
or an epoxide as in C-glycosidic mimetics 27-29 did not result in an improvement of binding 
affinity. Introduction of the previously mentioned quinic acid and indolizidinone templates in 
combination with the carboxymethyl group by Hanessian et al. [190,191] was rather fruitless 
and generated inactive mimics 30 and 31.  
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Ernst et al. [198] investigated mimetics containing (2S)-cyclohexyl- or (2S)-phenyl-lactic acid 
residues as sialic acid replacement (figure 14). In their approach to develop preorganized 
mimics adopting the bioactive conformation of sLex by the aid of a molecular modeling tool 
[199,200], mimic 33 bearing a cyclohexanediol ring was 10-12 times more active than sLex, 
whereas mimic 43 containing only an ethylenglycol linker turned out to be inactive. The 
introduction of residues at the carbocycle in the position neighbored to the fucose linkage, 
that impose more steric constraints to the fucose moiety, led to even more active compounds 
37-41, being 25-fold more active than sLex. Using (2R)-alkyl- or aryl-substituted lactic acid 
derivatives (34, 36) instead of the (2S)-substituted ones (33, 35) as a sialic acid replacement 
extinguishes the activity of the mimics completely [168,200] (figure 14). Various modifications 
of the 6-position of Gal in mimic 33 carried out by the same group led to inactive compounds 
[149]. Rigidification of mimic 33 on linking the fucose and the galactose directly as done in 
macrocyclic mimic 44 did not improve binding affinity [201]. Mimic 44 turned out to be three 
times less active than sLex.  
Further results have been published by Thoma et al. [202] (figure 14), indicating, that mimics 
45-47 bearing a benzoyl group at the 2-position of the galactose due to incomplete 
deprotection were up to three times more active than the corresponding mimics with a free 2-
OH group.  
 
1.5.3. Two-sugar mimetics (II): replacement of the N-acetyl-lactosamine 
disaccharide 
 
Another approach being explored is the replacement of the central N-acetyl-lactosamine part 
consisting of Gal and GlcNAc. Using unfunctionalized mimics lacking hydroxyl groups 
imitating the 4- and 6-hydroxyls of galactose generally showed disappointing affinity. Another 
factor contributing to poor potency was the incorporation of too flexible alkyl chains burdened 
with extremely high entropic costs (figure 15). 
Töpfer et al. [192] used propanediol-cyclohexane moieties (48-50 in figure 15) to substitute 
the GlcNAc-Gal part and found a drop in activity against E- and P-selectin. Rigid 
benzylmethoxy groups as in compounds 51 and 52 [203] resulted in 20-fold less active 
compounds compared to sLex. Spiroketal substitution (53) [204] led to even less potent 
inhibitors. Molecules 54 and 55 bearing very flexible alkyl chains turned out to be inactive 
[205]. Allanson and co-workers [206,207] introduced 6-membered chains as scaffolds ready 
to be functionalized with groups representing the pharmacophores of Gal (see 56 and 57 in 
figure 15). These mimics showed practically no affinity or were inactive in cell culture assays. 
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Finally, incorporation of the carboxymethyl group into a thiazine-derived spiro 1,1-galactosyl 
mannoside as in 58 [208] did not result in potent selectin inhibitors. 
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1.5.4. Mimetics containing one sugar: L-fucose-based inhibitors 
 
The L-fucose unit of sLex binds to the calcium atom in the CRD of the selectins and contains 
three of the six pharmacophores of sLex. The largest group of antagonists known to date 
consists of molecules containing only one sugar unit, namely fucose, which in some cases 
has been replaced by mannose or galactose.  
Additional functional groups on the residues attached to the monosaccharide were installed 
to mimic the pharmacophores of the omitted sugar moieties Gal and NeuNAc. Some 
approaches use substitutes that proofed suitable in former mimetics like the cyclohexyllactic 
acid residue to mimic NeuNAc or the trans-cyclohexanediol unit to replace GlcNAc. Most 
common linkers used were polyamides as in the glycopeptide libraries of Wong et al. [209-
214] or polyaryl spacer as in the biphenyl-based glycoaromatics of Kogan et al. [215-217]. In 
addition, the two- and four-component Ugi-reaction has been used by Armstrong et al. [218] 
and Wong et al. [219].  
The groups of Ernst [220] and Liu [221] prepared fucose-based mimetics containing 
cyclohexanediol as GlcNAc replacement and different disubstituted aryl groups to mimic 
NeuNAc-Gal (59–61 in figure 16). Ernst et al. [220] used their well fitting cyclohexyl- and 
phenyllactic acid unit as NeuNAc substitute (59a-d, 61). All molecules within these series 
were inactive, except the ones reported from Liu [221] containing a benzyl protected hydroxyl 
group rather than a free hydroxyl group (60b, 60d). 
Mimics containing malonic acid derivatives (62-64) [222] or piperidine carboxylic acid (65-67) 
[223] have also been reported. Malonic acid seems to suit better than piperidine carboxylic 
acid, however, none of these compounds showed better activity than sLex itself. 
Kogan et al. [215,216] developed a library of overall 45 different glycoaromatics based on 
derivatized biphenyl residues linked to the anomeric position of mannose (i to iii, figure 17). 
With the exception of three compounds out of this library (68-70, figure 17), all of them were 
less active than sLex itself, probably due to the lacking hydroxyls of the galactose as well as 
conformational issues. Many compounds, however, showed increased activity against P-
selectin. Nine molecules had activities 2- to 20-fold better than sLex. In addition, dimeric 
glycoaromatics have been studied by the same group [217] to mimic extended sialyl di-
Lewisx structures isolated from human neutrophils [60]. Dimer 70 was found to be 6-fold 
more active than sLex in antagonizing E-selectin binding to HL-60 cells. 70 is currently in 
phase II clinical trials by Texas Biotechnology [224] for the treatment of asthma, reperfusion 
injury and psoriasis. 
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Large efforts have been invested to create a large library of fucose-, mannose-, or galactose-
based glycopeptides by the group of Wong [209-214]. Two design elements have been 
chosen as variables: “turns” mimicking the GlcNAc unit, and “hydroxyls” mimicking the 
galactose unit. Figure 18 gives an overview over the variations introduced and a selection of 
the most potent E-selectin inhibitors. Generally, activity improvement is much more distinct 
for P-selectin binding than for E-selectin, and rationalization of a structure-activity 
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relationship is very difficult due to substantial differences among the molecular structures 
showing activities ranging from “no activity” to low µM values. Nevertheless, this series of 
molecules contains some of the most active inhibitors known to date. A detailed discussion of 
these compounds can be found in a recent review [176].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Another approach using combinatorial synthesis of compound libraries has been realized by 
Armstrong et al. [218] and Wong et al. [219]. They used the two- and four-component Ugi-
reaction condensating an aldehyde, a primary amine, an isonitrile and a carboxylic acid and 
thereby produced a variety of glycopeptide structures (figure 19). 
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Armstrong [218] used a C-fucosidic aldehyde, six different amino acids or amines, two 
isonitriles and four different di-carboxylic acids as reactive pool to create mimetics of the type 
76. Unfortunately, no activities have been reported to date. Wong [219] produced a series of 
mannose-based inhibitors (77, 78). Only two compounds being macrocyclic molecules 
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showed better activity than sLex towards E-selectin. Here again, activity upon P-selectin 
binding is much more enhanced compared to sLex than binding  to E-selectin. 
 
 
 
 
 
 
 
 
 
 
 
1.5.5. Groups addressing secondary binding sites 
 
Many rational design approaches described aimed at the improvement of binding affinity by 
minimizing entropic costs. This was achieved by the development of inhibitors in which the 
pharmacophores were preorganized in the bioactive conformation of sLex, thus avoiding 
unfavorable conformational changes prior to docking to the binding site. Another possibility to 
improve affinity is the enhancement of the enthalpic contribution by additional protein-ligand 
contacts. It was suggested and later confirmed, that incorporation of lipophilic groups without 
changing the main interactions of the ligand’s pharmacophores could lead to interaction with 
hydrophobic patches on the protein surface near the binding site.  
Hayashi [225] and DeFrees [226] published sLex derivatives functionalized with hydrophobic 
groups like alkyl chains or naphthoyl derivatives either at the reducing end or by variation of 
the N-acetyl group of GlcNAc (figure 20). They found increased binding affinities of these 
compounds. Wong reported an improvement of activity by adding long alkoxy chains to the 
6-OH of mannose in some of their glycopeptide inhibitors [209]. Compound 74 in figure 18 
shows a three times stronger binding affinity to E-selectin compared to the same compound 
with a free 6-OH group at the mannose. Hasegawa et al. [227] performed molecular 
dynamics calculations that implied interactions of this groups with a hydrophobic cleft on the 
surface of the selectins. Ernst et al. [168] investigated the effect of aliphatic, aromatic and 
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heteroaromatic acyl substituents at the GlcNAc-nitrogen and found a substantial 
improvement of binding affinity. The best antagonists showed an up to 60-fold increase 
compared to sLex. Aliphatic substitutions instead did not improve the affinity to E-selectin. 
Mimetic 80e is one of the most potent inhibitors known to date. 
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1.6. C-glycosidic compounds as E-selectin antagonists 
 
Due to the acetal nature of the glycosidic linkages, carbohydrates and carbohydrate 
derivatives are prone to hydrolytic degradation by the acidic environment in the stomach and 
by glycosidase activities. Therefore, these compounds posses only limited suitability as orally 
formulated therapeutics. This draw-back has been addressed by the development of C-
glycosidic carbohydrate mimics which are resistant to metabolic processes and show an 
improved chemical stability [228-231]. However, substitution of the anomeric oxygen by a 
methylene group leads to structural changes (C-O = 1.42 Å, C-C = 1.55 Å;  C-O-C angle = 
109°, C-C-C angle = 115°) [232] as well as to drastic changes of the stereoelectronic 
properties of the glycosidic linkage. In addition, the exo-anomeric effect [233-240], besides 
steric 1,3-diaxial interactions the most important factor influencing the conformational 
relationship of two monosaccharide moieties, is no longer effective in C-glycosides [241].  
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It is based on a mesomeric n→σ* interaction between a lonepair of the anomeric oxygen and 
the antibonding σ*-orbital of the C1-O bond (anomeric carbon – ring oxygen). This results in a 
stabilization of the gauche-conformation in respect to the aglyconic residue (structure iii, 
figure 21).  
Ab initio calculations in vacuo estimated the contribution of the exo-anomeric effect to be 
between 1.5 and 4.0 kcal/mol [233-240,242]. For simple systems related to C-glycosides, the 
preference for the gauche conformation was calculated lying between 0.3 and 0.8 kcal/mol 
[232,238]. Jimenez-Barbero [243] determined the exo-anomeric effect in O-glycosides in 
water solution to be >2.3 kcal/mol for α-O-mannosides. The additional contribution of 1,3-
diaxial type effects in the β-O-gluco- and β-O-galacto series bearing an equatorial O-2 
substituent was determined to be about 1 kcal/mol. 
Kolb et al. [244] calculated the rotational energy curves for both the O- and the C-fucosidic 
linkage of sLex using an MM2 force field (see figure 22). They found, that in both cases the 
absolute energy minimum is located at a torsion angle of 300°, corresponding to the gauche-
conformation. In the C-glycosidic case, however, a second low energy minimum close to the 
anti-conformation (Φ = 210°) exists, which is about 1 kcal/M less in energy compared to the 
210°-conformation of O-fucosidic sLex and only approximately 1.5 kcal/M higher in energy 
than the gauche-conformation. This second minimum is accessible by a low activation 
barrier. A considerable amount of the population should adopt this “anti”-like conformation. In 
addition, the conformational space between 0° and 120° is up to 6 kcal/M lower in energy 
containing a local energy minimum at about 90°. These figures indicate a higher flexibility of 
the C-fucosidic bond with a lower contribution of the gauche-conformation to the total 
population.  
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Figure 22: Rotational energy diagrams of the O-fucosidic (upper) and C-fucosidic (lower) linkage 
in sLex as calculated by Kolb et al. [244]. 
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No clear agreement can be found in literature whether C-glycosides have similar 
conformational behavior as the parent O-glycosides or whether they show different 
conformational preferences. Kishi et al. [245-259] claimed, that the conformational behavior 
of C- and O-glycosides is very similar and that this similarity is a general phenomenon. He 
further proposed, based on semiquantitative NMR-analysis, that the preferred conformation 
of C- and O-glycosides can be predicted on the basis of 
(1) the preference of the O- and C-glycosidic bond for those conformations which are in 
accordance with exo-anomeric effect and  
(2) avoiding 1,3-diaxial-like interactions, which can be revealed by superposition of the 
conformers on a diamond lattice.  
A further conclusion from their NMR-experiments with deoxy-derivatives was, that the 
preference of the gauche conformation around the glycosidic bond is so dominant, that 
structural deviations from the ideal staggered conformation to avoid 1,3-diaxial steric 
interactions occur by rotating primarily around the aglyconic bond rather than the glycosidic 
one. The exo-anomeric effect being the major factor why O-glycosides adopt their preferred 
conformation around the glycosidic bond was questioned. 
In contrast to these findings, Jimenez-Barbero reported that the conformational behavior of 
C-disaccharides is clearly different to their O-glycosidic analogues. He used a combination of 
NMR spectroscopy (J and NOE data) and molecular mechanics (MM3, AMBER) and 
dynamics (MACROMODEL) calculations [243,260-266]. In agreement with the results from 
Kolb et al. [244], the C-glycosidic compounds possessed more minima on the potential 
energy surface than the corresponding O-glycosides, as found by MM3 calculations. The 
higher flexibility of the C-glycosides in general was shown by the fact, that C-glycosides 
populated a higher percentage of the total potential energy surface than the corresponding 
O-glycosides. In the β-gluco- and β-galacto cases, the most stable conformations adopt the 
same torsion angle Φ around the glycosidic bond, but differs in respect to the torsion angle Ψ 
around the aglyconic bond, indicating a higher flexibility around this bond. In some cases (α-
manno and α-sia), even conformations around Φ, which are not in agreement with the exo-
anomeric effect, were preferred by the C-glycosides, indicating that the exo-anomeric effect 
is indeed a key-factor determining the conformational behavior around Φ of O-glycosides.  
As far as the conformational similarities of C- and O-glycosides is concerned, Jimenez-
Barbero showed, that in the case of O-glycosides, the global minimum is populated up to 
97%, whereas the C-glycosidic counterpart possesses two or more almost equally populated 
minima with low energy barriers in between. The most populated global minimum is not the 
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same as in the O-glycosidic case, but occupies a conformation that is accessible also for the 
O-glycoside. 
Numerous C-glycosidic analogues of sLex mimetics have been reported in literature (see 
compounds 27-29, 55, 71, 74, 76-78 in chapter 1.5 and references cited therein). However, 
only few examples allow a direct comparison with their O-glycosidic counterparts to derive 
the influence of the substitution of the anomeric oxygen by a methylene group on binding 
affinity. From the limited data available, Wong [176] suggested a 20-fold difference in affinity 
between O- and C-glycosides as can be seen in compounds 21 and 27 (see figure 23), but 
no generality has been established for this trend. 
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Figure 23: O- glycosidic mimic 21 and C-glycosidic mimic 27 allow a direct 
comparison of the binding affinities of O- and C-glycosides.
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2. Thesis 
 
The interest in C-glycosides is primarily based on their improved pharmacokinetic properties, 
e.g. their stability against acidic hydrolysis and metabolic degradation. However, the switch 
from O- to C-glycosidic bonds leads to a higher conformational flexibility due to a lack of 
stabilization by the exo-anomeric effect. This stereoelectronic effect strongly determines the 
preference of distinct conformations of O-glycosides. The missing exo-anomeric effect in C-
glycosides leads to higher flexibility and therefore, as a consequence of increased entropic 
costs upon binding, to a reduction of affinity. 
 
 
The conformational stabilization by the exo-anomeric effect has been estimated by molecular 
modeling calculations [232-240]. However, the quantitative consequences for the binding 
affinity can hardly be predicted, since they depend on a series of molecular characteristics 
unique for each compound. 
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Figure 24: Parent O-glycosidic sLex-mimetic 33 and C-glycosidic target molecules 81a and 82.
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The O-glycosidic sLex-mimetic 33 turned out to be a potent E-selectin antagonist 
[168,198,199] with an  IC50 of  80 µM (sLex: 1mM), binding 10 to 12 times stronger to E-
selectin than sLex itself.  
This Ph.D. thesis summarizes our approach towards the design and synthesis of C-
glycosidic analogues 81a and 82 of parent structure 33 (figure 24). In the target structures 
81a and 82 the O-fucosidic bond, highly sensitive towards hydrolysis in acidic environments, 
is replaced by the corresponding C-fucosidic bond. In compound 82 an additional equatorial 
substituent adjacent to the C-fucosidic linkage was introduced to compensate the missing 
exo-anomeric effect by steric constraints. The amount of compensation should be estimated 
by investigation and comparison of conformational preferences by NMR-spectroscopy. 
Finally, a comparison of the binding affinities of compounds 33, 81a and 82 should allow a 
quantification of the entropy contribution to the inhibitory potential caused by the exo-
anomeric effect.  
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3. Results and Discussion 
 
3.1. Retrosynthetic considerations and synthetic approach 
 
The main objective of the project was the development of a synthetic route for the E-selectin 
antagonists 81a and 82, which contain a C-fucosidic bond in place of the O-fucosidic bond in 
the parent compound 33. Since the synthetic strategy should be applicable to target 
molecules with structurally different GlcNAc replacements, the concept should be flexible 
enough to cope with a variety of structural modifications.  
From a retrosynthetic point of view (see scheme 1) the key steps in the synthesis are:  
1. Alkylation of the galactose moiety at the 3-position, 
2. β-selective galactosylation of the GlcNAc replacement and 
3. α-selective C-glycosidic bond formation. 
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Numerous methodologies have been described for the synthesis of C-glycosides [267,268], 
showing variable stereoselectivity at the anomeric center. We decided to apply the radical 
addition methodology [269-276], in which a radical generated from a glycosyl bromide 
precursor is added to an electron poor double bond. Giese et al. [275,277-282] have shown 
that this approach leads with good to excellent selectivity to the α-anomer. With fucosyl 
bromide i as radical donor and the methylene ketones 83 and 84 as radical acceptors, the 
strategic C-glycosidic bond can be obtained in both target molecules. Other key 
intermediates resulting from this retrosynthetic analysis are the cyclohexyllactic acid 
derivative ii containing a leaving group for nucleophilic substitution and the selectively 
protected galactosyl donor iii (scheme 1).  
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Our synthetic approach is outlined in scheme 2. It distinguishes itself by its high convergency 
and the possibility to introduce different GlcNAc replacements making this strategy even 
interesting for a combinatorial approach. 
Fucosyl bromide i is available by standard bromination procedures [283-286] (see chapter 
3.2.1). The synthetic strategy for the methylene ketones 83 and 84 is discussed in chapter 
3.2.2 and 3.2.3. The C-fucosidic ketone iv obtained via radical addition (see chapter 3.2.4) 
will be converted to the equatorial alcohol v (see chapter 3.2.5), which in turn will be 
glycosylated with galactose donor 90 (see chapter 3.2.6) obtained via a tin acetal mediated 
[287-289] nucleophilic substitution of the triflate derivative 88 (see chapter 3.2.6). Since a 
thiogalactoside was successfully applied in the synthesis of the O-glycoside 33 [168,199], we 
planned to adopt this approach [290,291] for the synthesis of 81a and 82. The exclusive 
formation of the β-anomer is expected based on neighboring group participation by the 
benzoate at the 2-position of the galactose donor 90. Finally, deprotection will lead to the 
target molecules 81a and 82.  
The major drawback of our approach is the reported Diels-Alder dimerization of sterically 
unhindered methylene ketones of the type of 83 and 84 [292-295]. 
 
3.2. Synthesis of the C-fucosidic sLex-mimetics 81a and 82  
 
3.2.1. Synthesis of fucosylbromides 92, 94 and 97 
 
For the radical addition three differently protected fucosyl bromides were prepared. The 
acetate-protected fucoside 92 was obtained by standard procedures (scheme 3). To study 
the influence of different protective pattern on the selectivity of the radical addition step, the 
benzoate- and pivaloate-protected radical donors 94 and 97 were also synthesized (scheme 
3). 
According to standard procedures [283-286], fucose 85 was first converted to the 
tetraacylated fucosides 91, 93 and 96. Acylation with acetic anhydride or benzoylchloride at 
0°C to rt yielded almost quantitatively the corresponding products 91 and 93. With pivaloyl 
chloride, however, pivaloylation was incomplete even at elevated temperature (→ 95). For a 
complete pivaloylation elevated temperature, DMAP activation and extended reaction time 
have to be applied (→ 96) [285]. 
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The peracylated fucosides 91, 93 and 96 were then transformed into the corresponding 
fucosyl bromides 92, 94 and 97 in good to excellent yields using HBr in acetic acid 
[285,296,297].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.2. Synthesis of α-methylene cyclohexanone (83) 
 
Numerous preparative methods for the synthesis of α-methylene ketones have been 
reported over the last decades. Many approaches are based on a Mannich type 
condensation of an enolizable ketone with an aldehyde and an amine followed by thermal β-
elimination of an ammonium salt [298-301]. Other examples use the desilylbromination of β-
trimethylsilylketones [302] or the Aldol condensation of formaldehyde with ethyl 
oxalylketones followed by elimination under basic conditions [303]. Also Wittig approaches 
have been described [304,305]. All these methods, however, encounter only limited 
regioselectivity and low yields.  
α-Methylene cyclohexanone (83) was first obtained, although mainly described as a dimer in 
1920 by C. Mannich et al. [306] by thermal decomposition of the Mannich base 2-
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Scheme 3: Synthesis of the radical donor fucosyl bromides: a) Ac2O, pyr, rt, 7h (95%); b) HBr/HOAc
(33%), CH2Cl2, rt, 2h (86%); c) BzCl, pyr, 2h at 0°C + 1h at rt (96%); d) HBr/HOAc (33%), CH2Cl2, rt, 2h 
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piperidinomethyl-cyclohexanone hydrochloride. Some 20 years later, the same author 
described the synthesis of α-methylene cyclohexanone (83) and its dimerization behavior in 
more detail [293,307]. 
In our first attempt, we applied the procedure of Gras et al. [295] to achieve the α-methylene 
cyclohexanone (83) by the Aldol condensation of formaldehyde to cyclohexanone (98) 
promoted by N-methylanilinium trifluoracetate (TAMA). The desired methylene ketone could 
be detected in the reaction mixture by NMR, but could not be isolated due to dimerization 
during reaction and workup. 
For a successful preparative approach, the synthesis and purification of methylene ketone 83 
had to be carried out under mild conditions. Therefore, the method described by Tsuji et al. 
[308,309] was applied, which is based on a palladium-catalyzed decarboxylation-
deacetoxylation of allyl α-acetoxymethyl-β-keto carboxylates (as e.g. 102), and where the 
final olefination step proceeds under very mild conditions and a short reaction time.  
The methylene ketone precursor allyl 1-acetoxymethyl-2-oxo-cyclohexanecarboxylate (102) 
[308,309] was obtained in four steps in high yields (scheme 4). In the first step, 
cyclohexanone (98) was carboxylated using dimethyl carbonate (→ 99) followed by 
transesterification with allyl alcohol. The resulting allyl β-ketocarboxylate (100) was then 
hydroxymethylated by treatment with aqueous formaldehyde and KHCO3 as a base to yield 
101 in quantitative yield.  
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Scheme 4: Synthesis of α-methylene cyclohexanone (83): a) (MeO)2CO, NaH, C6H6, 70°C, 4 h (82%); 
b) AllOH, AllONa, reflux, 48 h (73%); c) KHCO3, H2CO, THF/H2O, rt, 7 h (100%); d) Ac2O, pyr, rt, 4 h 
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After acetylation of the primary hydroxyl group (→ 102), the palladium catalyzed 
decarboxylation-deacetoxylation step using tris(dibenzylideneacetone)-dipalladium in 
acetonitrile at 20-25°C yielded quantitatively the desired radical acceptor α-methylene 
cyclohexanone (83). As already described by Mannich [307], 83 can easily be identified by its 
characteristic odor. For a successful radical reaction it is very important to isolate the 
methylene ketone 83 in pure form. However, purification and handling of the pure methylene 
ketone 83 is complicated by its tendency to undergo dimerization by Diels-Alder cyclization. 
Our investigation of the thermal stability of 83 revealed that dimerization cannot be 
suppressed during workup and is also the main side reaction during the subsequent radical 
reaction. Since only limited information on the stability of 83 are reported [294], a detailed 
study of its dimerization behavior was undertaken. 
The Diels-Alder dimerization (→ 103) under various conditions was analyzed by NMR-
spectroscopy. For the Diels-Alder reaction the dimerization rate should be 2nd order in 
monomer concentration. For its determination, different fractions of 83 were investigated at 
different time points (see table 4). Entry 4 and 5 in table 4 clearly indicate that methylene 
ketone 83 cannot be produced and be stored over an extended period of time but rather has 
to be prepared immediately prior to use in the radical reaction.  
 
Table 4: Investigation of dimerization behavior of α-methylene cyclohexanone (83). 
Monomer:dimer ratios were determined by comparison of the integral of one 
methylene proton of the monomer (5.14 ppm) with the integral of the axial CH2-C=O 
proton of the dimer (2.75 ppm) in the 1H-NMR spectra. 
 
entry conditions % monomer 
1 crude product, without purification (CDCl3) 100 
2 pure product after distillation (CDCl3) 69 
3 entry 2 + 15 h at rt in CDCl3 43 
4 entry 2 + 2 d at rt  without solvent 0 
5 entry 2 + 12 h at -20°C without solvent 52 
6 entry 2 + 1 h at 80°C in C6D6 46 
7 entry 2 + 2 h at 80°C in C6D6 37 
8 entry 2 + 3 h at 80°C in C6D6 27 
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Standard reagents for the subsequent radical addition reaction to olefins are AIBN 
(azobisisobutyronitrile) as initiator for the radical chain reaction and Bu3SnH as hydrogen 
donor. Thermal decomposition of AIBN into the initial radicals, which have a half-life of about 
1 hour, occurs at 80°C [269]. At this temperature, the half-life of α-methylene ketone (83) in 
deuterated benzene was determined to be approximately 3-4 hours (entry 6 to 8).  
 
3.2.3. Synthesis of  (2R)-2-methyl-3-methylene-tetrahydropyran-4-on (84) 
 
For the synthesis of the tetrahydropyran derivative 84, peracetylated D-glucal 104 was used 
as chiral starting material. It already contains the chiral center of the building block 84 and it 
is therefore not necessary to perform diastereoselective reaction steps.  
The synthesis starting from the commercially available peracetylated D-glucal (104) involves 
the following transformations: 
• orthogonal protection of the three hydroxyl groups of 105, 
• dehydroxylation of the C-6 primary alcohol to establish the methyl group,  
• hydrogenation of the double bond, 
• oxidation of the C-4 hydroxyl group and olefination of the resulting ketone and 
• oxidation of the C-3 hydroxyl group into a ketone. 
 
A first synthetic attempt is shown in scheme 5. The reaction protocol for the orthogonal 
protection [310] is based on the different reactivities of the three hydroxyl groups: The 
primary hydroxyl group at C-6 is the most reactive one followed by the allylic alcohol at C-3 
and the least reactive secondary alcohol at C-4. TBDMS-, benzyl- and benzoyl-protecting 
groups were chosen due to their orthogonal stability towards cleaving conditions. After 
deacetylation of triacetylglucal (104), glucal 105 was instantly used without prior purification 
in the next step. Silylation and benzoylation were done in a one-pot reaction to yield 106 in 
75% overall yield. A bulky silyl residue was chosen in order to support the reactivity 
difference by steric factors in favor of the primary alcohol. Additionally, low reaction 
temperatures were applied to improve selectivity. In both steps more than one equivalent of 
reagent was needed to completely consume the starting material. Consequently, undesired 
double-protection with TBDMSCl leading to the byproduct 4,6-bis(TBDMS)-glucal, could not 
be totally avoided. Benzyl ether formation of the secondary hydroxyl group in C-4 was 
achieved with benzyl bromide and NaH in DMF (→ 107).  
3. Results and Discussion                                                                                                                    49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The silyl protection was removed using tetrabutylammonuimfluoride (TBAF) and the 
corresponding alcohol 108 iodinated by a procedure originally developed by Mukaiyama 
[311-314], in which the primary alcohol is activated by the oxophilic phosphonium salt [PPh3-
I]+ I- generated from PPh3 and I2. Ph3P=O serves as leaving group to be displaced by the 
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Scheme 5: Synthesis of the methyl substituted α-methylene ketone 84; pathway (I): a) NaOMe, MeOH, 
rt, 2 h (quant.); b) TBSCl, pyr, CH2Cl2, 2 h at 0°C + 12 h at rt; c) BzCl, pyr, CH2Cl2, 14 h, rt (75% for two
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nucleophilic iodide. 1-H-imidazole was used as a base to quench the emerging HI. This 
method allows the direct in situ conversion of the hydroxyl group into the iodide 109. In the 
next step, the iodide 109 was reduced by radical dehalogenation using Bu3SnH as hydrogen 
donor. The yield of 110 was rather low emerging from the difficulty of completely removing 
the phosphonium oxide, which interferes with the radical reaction.  
Since hydrogenation of 110 under standard conditions (H2, Pd/C, HOAc) was not successful, 
it was carried out in a Parr shaker using Pd(OH)2/C at 4 bar H2. Oxidation of alcohol 111 with 
pyridinium dichromate (PDC) delivered ketone 112 in high yields. In order to convert the keto 
function into a methylene group we investigated two different methodologies: the Wittig 
olefination with H2C=PPh3 [315,316] and methenylation using the Tebbe methylene transfer 
reagent bis-(cyclopentadienyl)-µ-chloro-(dimethylaluminum)-µ-methylenetitanium [317,318].  
Wittig olefinations with unstabilized phosphorous ylides often suffer from low yields and the 
strong basic reaction conditions leads to side reactions. Therefore, we suspected that the 
benzoyl protecting group in 112 could be partially cleaved. The Wittig ylide can be easily 
prepared by deprotonation of the inexpensive phosphonium bromide salt by n-BuLi.   
The experiment showed indeed that the Wittig olefination of 112 to 113 proceeds with only 
moderate yields (60%), and 17% of the olefin undergoes benzoyl cleavage (→ 114). Workup 
of the reaction and isolation of the product was complicated by the difficulty of removing the 
excessive phosphorous compounds from the crude reaction mixture. 
Tebbe reactions often perform with better yields than Wittig olefinations. The Tebbe reagent 
converts esters to enolethers  [319-321] which are easily hydrolysed to alcohols during 
workup. However, the Tebbe reagent is very expensive and extremely sensitive to moisture 
and oxygen, making the experimental effort very complicated. 
The alternative Tebbe-reaction performed similar concerning yields (60%). As in the Wittig 
reaction we found debenzoylated 114 as byproduct of the olefination. Isolation of the 
products from the aluminum- and titanium salts turned out to be as difficult as purification 
after the Wittig reaction. 
Overall, both methods are equal in respect to the chemical yields. However, Wittig olefination 
is favored because of the high costs of the tebbe reagent. 
After saponification of 113 to 114,  the oxidation of the hydroxyl group at C-3 was performed 
using PDC  (→ 84). 
  
With this synthetic strategy building block (2R)-2-methyl-3-methylene-tetrahydropyran-4-on 
(84) was obtained in a 12-step synthesis and an overall yield of 8% (scheme 5). 
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In the second approach (scheme 6), the strategy was changed in two points. The double 
bond was hydrogenated right in the beginning of the synthesis and a different deiodination 
method was applied. 106 was obtained as already described in scheme 5. Now, the double 
bond was hydrogenated with quantitative yield to obtain 116. Benzylation of 116 to 117 
followed by cleavage of the silyl ether and iodination of the primary alcohol 118 yielded 119.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The reduction of iodide 119 was accomplished by hydrogenation (H2, Pd/C, NaOAc) 
[322,323] (→ 120). By switching to this method, the yield of the reductive step could be 
improved from 52% to 95%. The following transformations (120→111→84) are identical to 
those used in the first strategy described in scheme 5. 
 
In the second 13-step synthesis of (2R)-2-methyl-3-methylene-tetrahydropyran-4-on (84) the 
overall yield could be improved from 8% to 17%. 
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Scheme 6: Synthesis of the methyl substituted α-methylene ketone 84; pathway (II): a) Pd/C, 4 bar H2, 
MeOH, 2 h, rt (quant.); b) BnBr, NaH, DMF, 6 h, rt (75 %); c) TBAF, THF, 1 h at 0°C + 4 h at rt (96%); 
d) I2, PPh3, imidazole, CH2Cl2, 17 h, rt (91%); e) Pd/C, NaOAc, 4 bar H2, MeOH, 17 h rt, (95%); f) 
Pd(OH)2/C, 4 bar H2, MeOH, 21 h rt (97%).
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As for the α-methylene cyclohexanone (83), dimerization problems (table 5) forced us to 
freshly synthesize 84 prior to its use in the radical addition reaction. In the first 
approximation, half-life and dimerization rate for 83 and 84 are similar.  
 
 
Table 5: Investigation of dimerization behavior of  (2R)-2-methyl-3-methylene-tetra-
hydropyran-4-on (84). Monomer:dimer ratios were determined by comparison of the 
integrals of one methylene proton (5.30 ppm) and the proton H-5 (q, 4.44 ppm) of the 
monomer with the integral of the proton H-5 of the dimer (q, 4.10 ppm) in the 1H-NMR 
spectra. 
 
entry conditions % mono 
1 crude product without purification (CDCl3) 100 
2 purification and solvent evaporation at 0°C (CDCl3) 59 
3 entry 2 + 14 h at rt in CDCl3 57 
4 entry 2 + 26 h at rt in CDCl3 55 
5 entry 4 + 1.5 h at 40°C without solvent 27 
6 entry 1 + 16 h at rt in C6D6 80 
7 entry 1 + 24 h at rt in C6D6 72 
8 entry 7 +1 h at 80°C in C6D6 50 
9 entry 7 +2 h at 80°C in C6D6 40 
 
 
 
3.2.4. Synthesis of the C-fucosidic ketones 122, 123 and 124 by radical addition 
 
With the two α-methylene ketones 83 and 84 for the replacement of the GlcNAc-moiety of 
sLex in hand, the addition of the radicals generated from the fucosyl bromides 92, 94 and 97 
to the olefins 83 and 84 could be investigated. 
In order to reach high yields of C-fucoside v and to suppress the formation of deoxyfucose 
iii, the rates of the reactions (c) (ii → iv) and (d) (iv → v) in the radical propagation cycle 
(scheme 7) have to be higher than the rate of direct H-atom transfer (b) (ii → iii). The 
terminal hydrogen transfer (d) from Bu3SnH to the C-fucosidic radical iv controls the radical 
cycle by regenerating the tin radical needed for the next cycle. Therefore, the concentration 
of the hydrogen donor can be seen as variable to influence product distribution. 
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Another very important aspect of the reaction is the stereochemical outcome concerning both 
newly formed stereogenic centers, the anomeric center of the fucoside and the ring-carbon 
next to the carbonyl group. 
The stereoselectivity of reactions at the anomeric center of carbohydrate radicals is mainly 
controlled by stereoelectronic and not by steric effects. The axial orientation of the radical-
bearing anomeric orbital in iax is stabilized by mesomeric interaction of this radical-bearing 
orbital with the axial lonepair of the ring oxygen (n→SOMO interaction or anomeric effect) 
and is favored in the equilibrium shown in figure 25a. In a radical addition, the olefin is mainly 
attacked by iax. In addition, the conformation of pyranosyl radicals is influenced by a second 
stereoelectronic effect, the so-called β-oxygen effect or quasi-homo-anomeric effect [324-
326]. This effect is based on a mesomeric interaction of the radical-bearing orbital with the 
coperiplanar σ*-orbital of the β-C-O bond (see figure 25b). In analogy to the conformation 
preferred by the 2,3,4,6-tetra-O-acetyl-D-glucopyranos-1-yl radical (B2,5 conformation) [326], 
the 2,3,4-tri-O-acyl-L-fucopyranos-1-yl radical ii adopts a slightly twisted B1,4-like 
conformation.  
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Scheme 7: Propagation steps for the radical addition of the fucosyl bromide i to 
the methylene ketone 83 / 84.
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In contrast, the 2-O-tert-butyldimethylsilyl-3,4-O-isopropylidene-L-fucopyranos-1-yl radical 
121 [327] (see figure 25b) was found to adopt a 2,5B conformation [328], forced by the 
isopropylidene ring. As a consequence the β-oxygen effect is slightly weakened. The α-
anomer, however, is still favored because of a pseudo-equatorial attack from the exo-face of 
the radical center. 
  
Radical addition with 2-methylene cyclohexanone (83): 
The radical acceptor 83 suffers from dimerization (see table 4). Therefore, the crude product 
of 83 – obtained by filtration of the reaction mixture – was used in the subsequent reaction 
with bromide 92. The radical reaction with crude 83 was performed in acetonitrile (applied for 
the formation of 83) as well as in dimethoxyethane (used by Giese at al. [275]). Since this 
approach did not yield the desired C-fucoside 122, we raised the hypothesis, that 
PPh3/PPh3O traps the intermediate radicals before the radical chain reaction is initiated. To 
verify this hypothesis, the methylene ketone 83 was purified prior to the radical reaction by 
distillation accepting partial dimerization to 103. 
Using an excess of the “purified” α-methylene cyclohexanone (83) and tri-O-
acetylfucosylbromide (92) with Bu3SnH and AIBN in dimethoxyethane at 80°C, the C-
O
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Figure 25: Stereoelectronic effects in pyranos-1-yl radicals.
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fucoside 122 was finally obtained (scheme 8), although only with low yield (35%). In addition, 
a large amount of 1-deoxy-2,3,4-tri-O-acetylfucopyranose and 2-deoxy-1,3,4-tri-O-acetylfuco-
pyranoside was formed, indicating, that the intermediate fucosyl radical is partly reduced 
before and after acyl migration. Probably the side products are formed due to the progressive 
dimerization of the olefin under reaction conditions. To optimize the formation of fucoside 
122, the hydrogen donor was slowly added with a syringe pump over a period of 12 h. The 
failure of this approach indicates, that the progressive dimerization of the olefin 83 causes 
the low overall yield. In addition, when benzene or toluene were used instead of 
dimethoxyethane, no positive influence on product distribution or yield of the C-fucoside 122 
could be observed.  
Yields of the analogous radical addition reactions with benzoyl- and pivaloyl-protected 
fucosylbromides 94 and 97 leading to the α-C-fucosides 123 and 124 were similar to those of 
the reaction with acetyl-protected fucosylbromide 92 (scheme 8, table 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OMe
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O
PGO OPG
Me OPG
+
Scheme 8: Results for the radical addition of fucosyl bromides to α-methylene cyclohexanone; a) 2.5 
eq. 83, Bu3SnH, AIBN, dimethoxyethane, 85°C, 15 - 18 h. Yields and selectivities are given in table 6.
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As predicted based on stereoelectronic effects (see figure 25), exclusive formation of the α-
C-fucosides was observed in all cases (scheme 8, table 6). Vicinal coupling constants 
between 5.3 and 5.8 Hz for the J1,2 coupling of fucose are in good agreement with α-C-
fucosides described in literature [329-331].  
In contrast to the high stereoselectivity at the anomeric center, the hydrogen transfer to the 
C-fucosyl radical (see iv in scheme 7) was not stereoselective. In general, reactions of 
substituted and unsubstituted cyclohexyl radicals behave similar in stereochemistry as the 
reduction of related cyclohexanones [332]. There, the axial attack is thermodynamically 
favored, whereas kinetically favored equatorial attack suffers from steric 1,3 diaxial repulsion 
in the product. Ortho-substituted cyclic radicals are preferentially attacked anti to the 
substituents present in the ring system [333]. In special cases, this anti-rule can be 
outweighted by stereoelectronic effects (as discussed in figure 25) or by large exocyclic 
substituents next to the radical center leading to syn addition (see e.g. 126 in scheme 10). 
 
Table 6: Yields and stereoselectivities obtained in the radical coupling with α-methylene 
cyclohexanone (83). 
 
 
 
 
 
fucosylbromide product ketones diastereomeric ratio  a:b  yield 
PG = Ac 92 122a + 122b 43 : 57 35 % 
PG = Bz 94 123a + 123b 35 : 65 26 % 
PG = Piv 97 124a + 124b 33 : 67 30 % 
 
 
In the radical reactions with α-methylene cyclohexanone (83) only poor to moderate 
selectivities (between 57:43 and 67:33) was obtained at the carbon α to the carbonyl  
because of the absence of shielding and thus directing substituents (table 6). The C-fucosyl 
radical i (scheme 9) contains a planar sp2-hybridized radical center, which is stabilized by 
mesomeric interaction with the π-orbital of the carbonyl group. Attack of the hydrogen radical 
from the re-face leads to the desired diastereomer ii with S-configuration at the carbon α to 
O O
H
H
R =a = ,       b =
R
R
OH3C
PGO
OPG
OPG
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the carbonyl, whereas by attack from the si-face, the undesired diastereomer iii with R-
configuration is obtained (see scheme 9). 
Comparing the results of the radical coupling reactions, a slight tendency depending on the 
protecting groups in favor of the diastereomers with R-configuration is observed (see table 
6). The increasing steric demand of the fucosyl residue could be responsible for this trend. 
The main problem we were facing at that point of the synthesis was the impossibility to 
assign the absolute configuration at the newly formed chiral center by NMR-spectroscopy. 
Consequently, we were not able to decide which of the two obtained diastereomers was the 
one mimicking sLex. The correlation shown in scheme 8 is based on the data obtained later 
from the x-ray analysis discussed in chapter 3.3.3. Due to this assignment problem we 
continued the synthesis with both diastereomers. 
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Scheme 9: Reaction mechanism of the radical addition leading to a diastereomeric 
mixture of desired (ii) and undesired (iii) C-fucosidic ketones.
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Radical addition with (2R)-2-methyl-3-methylene-tetrahydropyran-4-on (84): 
In contrast to the results of the radical reaction with α-methylene cyclohexanone (83), the 
reaction of 2,3,4-tri-O-benzoyl-fucosylbromide (94) with the methyl substituted methylene 
ketone (2R)-2-methyl-3-methylene-tetrahydropyran-4-on (84) performed with absolute 
stereocontrol at both newly formed stereocenters (scheme 10).  
The single C-fucoside formed showed α-configuration at the anomeric center (J1,2 = 4.58 Hz) 
and R-configuration at the chiral center next to the ketone function. This 2,3-trans-
configuration can be proofed by the large coupling constant of 9.99 Hz for the two 
corresponding protons (scheme 10).  
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Scheme 10: Radical addition to the methyl substituted tetrahydropyrane methylene ketone 84. The 
transition states 126-syn and 126-anti are shown in projection along the bond between the methylene 
bridge and the carbon radical in the pyrane ring. Steric hindrance between the fucose residue and the 
methyl group of the tetrahydropyrane ring makes transition state 126-anti unfavorable. Hydrogen  
transfer occurs via 126-syn leading to the observed product 125. a) Bu3SnH, AIBN, dimethoxyethane, 
85°C, 18 h (11%).
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The 2,3-trans-configuration results from an attack of the hydrogen radical syn to the methyl 
group in 84 as shown in transition state 126-syn in scheme 10. The orientation of the large 
fucose residue opposite to the methyl group avoids steric hindrance as in the transition state 
126-anti. This stereochemical outcome is typical for cyclic radicals with large exocyclic 
substituents at the prochiral center. 
 
3.2.5. Stereoselective reduction of the C-fucosidic ketones 122, 123 and 124 
 
Following the synthetic strategy depicted in scheme 2, the C-fucosidic ketones 122, 123 and 
124 obtained from the radical reactions had to be transformed stereoselectively into the 
corresponding equatorial alcohols. Since the reduction of carbonyl compounds by complex 
metal hydride reducing agents is a well-elaborated transformation, a number of reagents 
have been developed for various substitution pattern.  
4-tert-Butylcyclohexanone is reduced by small reducing agents like NaBH4 or LiAlH4 with  
selectivities of 7:3 and 9:1 respectively in favor of the thermodynamically more stable 
equatorial alcohol [334-337]. In contrast, when hydride reagents with bulky substituents like 
K(i-PrO)3BH, L-Selectride or Li(Siamyl)3BH were used, the axial alcohol was obtained. The 
reduction of 2-methylcyclohexanone should provide a suitable model system to predict the 
behavior of the C-fucosidic ketones 122, 123 and 124 towards different reducing agents. 2-
Methylcyclohexanone shows similar selectivities as 4-tert-butylcyclohexanone towards the 
above-mentioned reducing agents. However, opposite selectivity was obtained with Li(t-
BuO)3AlH, which reduces 2-methylcyclohexanone with a selectivity of 73:27 in favor of the 
trans-alcohol [334]. To avoid undesired reduction of the acyl protecting groups present in our 
ketones 122, 123 and 124 we were restricted to the use of chemoselective reducing agents 
like e.g. NaBH4 or Li(t-BuO)3AlH. 
In a first approach, we reduced the unseparable mixture of the two diastereomers 122a/b 
containing acetate protecting groups with NaBH4 in methanol. Surprisingly no selectivity was 
observed and a mixture of the four alcohols 127a-d in a ratio of 1 : 1.3 : 1 : 1.3 was obtained 
(see scheme 11, table 7). Lowering the temperature to –20 °C did not show any effect on the 
stereochemical outcome. However, reduction of the diastereomeric mixture of 122a/b with 
Li(t-BuO)3AlH led to the expected selectivity in favor of the equatorial alcohol (4:1, scheme 
11, table 7). In a control experiment with L-Selectride the predicted selectivity was confirmed: 
only the two axial alcohols 127c and 127d could be detected in the product mixture (scheme 
11, table 7).  
3. Results and Discussion                                                                                                                    60 
 
 
 
The reduction of the diastereomeric mixture of 122a/b delivered in all three cases the 
corresponding alcohols in excellent to quantitative yields (see scheme 11). However, the Rf-
values of the four alcohols were almost identical (Rf = 0.42 for the two axial alcohols 127c/d 
and Rf = 0.38 for the two equatorial alcohols 127a/b) and the isolation of the pure substances 
was not possible. However, relative yields and selectivities could be determined by partial 
chromatographic separation and comparison of the NMR-signals with those of the crude 
mixtures. 
The equatorial and axial alcohols can be easily distinguished by the spin coupling pattern in 
the 1H-NMR spectrum (figure 26). The values of the vicinal coupling constants depend on the 
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Scheme 11: Reduction of the C-fucosidic cyclohexanone derivatives; a) NaBH4, MeOH, 1 h, -20°C 
(98%); b) Li(t-BuO)3AlH, THF, 4 h at -5°C + 3 h at 0°C (quant.); c) L-Selectride, THF, 1.5 h, 0°C 
(92%); d) Li(t-BuO)3AlH, THF, 5 h at 0°C (86%); e) Li(t-BuO)3AlH, THF, 3 h at 0°C + 20 h at rt (81%); 
selectivities are given in table 5.
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torsion angle between the two corresponding protons and can be calculated by the Karplus-
equation [338]. The equatorial proton Heq, which is geminal to the secondary hydroxyl group 
in the axial alcohol i has three small couplings resulting in a narrow multiplet, whereas the 
axial proton Hax in the equatorial alcohol ii shows two large and one small coupling leading to 
a triplet-like coupling pattern (figure 26). 
 
Table 7: Yields and stereoselectivities in the reduction of the C-fucosidic ketones 122a/b, 123a/b and 
124a/b. 
 
starting 
material 
 
    
yield 
 R = CH2-Fuc(Ac)3, NaBH4 
127a 
1 
127b 
1.3 
127c 
1 
127d 
1.3 98 % 
122a/b R = CH2-Fuc(Ac)3, Li(t-BuO)3AlH 
127a 
4 
127b 
5.2 
127c 
1 
127d 
1.3 100 %
 R = CH2-Fuc(Ac)3, L-Selectride 
127a 
0 
127b 
0 
127c 
1 
127d 
1.3 92 % 
123a/b R = CH2-Fuc(Bz)3, Li(t-BuO)3AlH 
128a 
3 
128b 
5.7 
128c 
1 
128d 
1.9 86 % 
124a/b R = CH2-Fuc(Piv)3,
a) 
Li(t-BuO)3AlH 
129a 
2 
129b 
2 
129c 
1 
129d 
1 81 % 
a) diastereomeric mixture of ketones used in the reduction was in a ratio of 1 : 1  
 
 
With Li(t-BuO)3AlH as reducing agent showing the desired stereoselectivity in favor of the 
equatorial alcohol, the reduction of the benzoyl- and pivaloyl-protected ketones 123a/b and 
124a/b was performed under the same conditions as previously described for ketone 122a/b. 
As for 122a/b, the diastereomeric mixtures had to be used due to separation problems. This 
leads to complex product mixtures which are difficult to analyze and separate. 
Selectivities were lower as in the reduction of the acetate-protected ketones (see table 7). 
From the reduction of the benzoyl-protected ketones 123a/b, the four corresponding alcohols 
128a-d were obtained in 86% yield in a 3 : 5.7 : 1 : 1.9 ratio, indicating a selectivity of 3 : 1 in 
favor of the equatorial alcohols 128a/b (scheme 11, table 7). In case of the pivaloyl-protected 
HO
R HOR
HO R
OH
R
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ketones 124a/b, the observed selectivity was only 2 : 1. The four alcohols 129a-d were 
isolated in a total yield of 81% (scheme 11, table 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As observed in the radical addition, the selectivity of the reductions is influenced by steric 
parameters. A very bulky protecting group (Ac vs. Piv) lowers the predicted selectivity. 
As previously described for the C-fucosidic ketones, it was not possible to determine the 
absolute configuration at the tertiary carbon center by NMR-analysis. The correct assignment 
of the absolute configuration as shown in scheme 8 and scheme 11 was obtained by X-ray 
(chapter 3.3).  
The difficult separation of the diastereomeric alcohols could most efficiently be realized for 
the benzoate protected alcohols 128a-d, which were therefore used for continuation of the 
synthesis. 
The NMR-data of the twelve synthesized C-fucosidic alcohols show some interesting 
regularities, which are illustrated in table 8.  
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Figure 26: a) Predicted vicinal coupling constants for the axial and equatorial alcohols depending on 
torsion angles ϕ; b) observed coupling pattern of protons Heq and Hax in alcohols i and ii, respectively.
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Table 8: Comparison of NMR-shifts of some selected protons of the C-fucosidic alcohols 
 
 # (H) 
    
 127a 127b 127c 127d 
Ha 1.14 1.39 
Hb 2.16 
1.74 
1.85 
1.63 R = Fuc(Ac)3 
Hc 3.20 3.29 3.88 3.94 
 128a 128b 128c 128d 
Ha 1.25 1.49 
Hb 2.44 
1.86 
2.02 
1.80 R = Fuc(Bz)3 
Hc 3.17 3.26 3.88 3.92 
 129a 129b 129c 129d 
Ha 1.16 1.37 
Hb 2.28 
1.21 
1.91 
1.65 R = Fuc(Piv)3 
Hc 3.29 3.29 3.87 3.93 
 
 
The methylene protons of the C-glycosidic linkage (Ha and Hb) show an identical chemical 
shift in the alcohols with the undesired R-configuration at the tertiary ring-carbon 
(127b/128b/129b, 127d/128d/129d), whereas significantly different shifts for each methylene 
proton can be observed in the case of the alcohols with the desired S-configuration 
(127a/128a/129a, 127c/128c/129c). Another regularity is the large shift difference of about 
0.8 to 1.2 ppm between the two methylene protons in the diastereomers 127a/128a/129a 
implicating a special magnetic influence of the surrounding due to conformational 
characteristics. Possibly one proton is unshielded by the oxygen of the hydroxyl group. As a 
third regularity, the proton Hc (being geminal to the secondary hydroxyl group) shows a 
significant downfield shift of about 0.6 ppm in the axial alcohols 127c/128c/129c and 
127d/128d/129d compared to the equatorial alcohols 127a/128a/129a and 127b/128b/129b. 
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3.2.6. Stereoselective reduction of the C-fucosidic ketone 125 
 
The results obtained by using Li(t-BuO)3AlH as reducing agent encouraged us to apply these 
conditions for the reduction of the C-fucosidic tetrahydropyranone intermediate 125 as well. 
This time the reduction proceeded stereospecifically. Only the axial attack of the hydride, 
which is leading to the equatorial alcohol 130a (93% yield), could be observed (scheme 12). 
The methyl group next to the C-fucosidic side chain enhances the conformational stability of 
the cyclohexyl ring. Furthermore, the methyl group restricts the rotational flexibility of the 
fucosyl residue leading to a more efficient shielding of one face of the cyclohexanone ring. 
As in case of the derivatives 127-129, the orientation of the hydroxyl group can be 
determined by the vicinal coupling constants in the 1H-NMR spectrum: the coupling constants 
of the proton geminal to the hydroxyl group being 4.27, 9.75 and 10.64 Hz proof the 
equatorial orientation of the hydroxyl group. 
 
 
 
 
 
 
 
 
 
The downfield-shift for one of the two methylene protons – as observed in the cyclohexanol-
substituted C-fucosides – could not be confirmed in this case (δ = 1.61 and 1.96 ppm) 
indicating the influence of the methyl group on the conformational preference of alcohol 
130a.  
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Scheme 12: Stereoselective reduction of the tetrahydropyranone intermediate 125. Equatorial alcohol 
130a  was formed exclusively. a) Li(t-BuO)3AlH, THF, 20 h, 0°C to rt (93%).
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3.2.7. Glycosylation of alcohols 128a, 128b and 130a with the                               
galactose building block 90 
The next step in the synthesis of the sLex-mimetics 81a and 82 incorporated the 
glycosylation of the C-fucosidic alcohols 128a, 128b and 130a with the cyclohexyllactic acid-
substituted galactosyl building block 90.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Derivatization of galactose (87) at position 3 to obtain the functionalized galactosyl building 
block 90 was done by a co-worker in our group [339] and is illustrated in scheme 13. 87 is 
transformed in three steps into ethyl thiogalactoside 132. The alkylating agent benzyl-(R)-2-
cyclohexyl-1-trifluoromethanesulfonyloxypropionate (88) was obtained from R-2-phenyllactic 
acid (86) [340,341]. The triflate serves as a leaving group rather than a protecting group for 
the following nucleophilic substitution with the unprotected thiogalactoside 132. 
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Scheme 13: Synthesis of the galactose building block  90 containing a cyclohexyllactic acid residue: a) 
Ac2O, pyr, rt, 12 h (90%); b) EtSH, BF3
.OEt2 (64%); c) NaOMe/MeOH, rt, 1h (98%); d) 5 bar H2, 10% 
Pd/C, MeOH (98%); e) 1) Cs2CO3, MeOH, H2O; 2) BnBr, DMF (92%); f) Tf2O, pyr, CH2Cl2 (86%); g)  
Bu2SnO, MeOH, reflux, 2 h; h) CsF, 88, DME, rt, 2 h (67% over 2 steps); i) BzCl, pyr, DMAP, rt, 4 h (91%).
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Regioselectivity is achieved by increasing the nucleophilicity of the hydroxyl group at position 
three by formation of the tin-acetal intermediate 89 [287,289]. 134 could be obtained in 67% 
over 2 steps. Benzoylation of 134 delivers galactosyl donor 90 in 91% yield, which was used 
to glycosylate the C-fucosidic alcohols 128a, 128b and 130a (see scheme 14). Both 
diastereomeric alcohols 128a and 128b were glycosylated due to the previously mentioned 
assignment problem (chapter 3.3). 
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Scheme 14: Glycosylation of the equatorial C-fucosidic alcohols with the thiogalactoside building block 
90. Absolute configuration of the chiral centers at the spacer rings are given. a) NIS, 4Å-MS, TfOH, 
CH2Cl2, -20°C, 4 h (82%); b) NIS, 4Å-MS, TfOH, CH2Cl2, -20°C, 4 h (90%); c) NIS, 4Å-MS, TfOH, 
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A huge pool of glycosylation methodologies [342] has been developed over the last decades 
to find a method suitable for almost any problem in the synthesis of oligosaccharides and 
glycoconjugates [343]. However, still research is going on to find even milder, more selective 
and more generally useful glycosylation methods. 
Glycosylations using thioglycosides [290,344] as glycosyl donors turned out to be a broadly 
applicable methodology. Thioglycosides can be used under mild reaction conditions and are 
more stable than glycosyl halides used in the Koenigs-Knorr-glycosylation [345-347] or 
trichloroacetimidates [348].  
For the synthesis of all three tetrasaccharide mimetics 135a, 135b and 136 shown in scheme 
14, N-iodosuccinimide (NIS)/trifluoromethanesulfonic acid (TfOH) was used as promoter. The 
mimetics 135a and 135b containing a cyclohexyl spacer was obtained in 90% and 82% yield 
respectively. Mimic 136 bearing the tetrahydropyran spacer was obtained in 69% yield using 
this method. Using dimethyl(methylthio)sulfonium triflate (DMTST) [349,350] as promoter the 
yield could be increased to 80% for mimic 136. All three reactions showed excellent β-
selectivity induced by neighboring group participation of the benzoyl protecting group at C-2 
of the galactose moiety.  
 
3.2.8. Deprotection of the tetrasaccharide-mimetics 135a, 135b and 136 
 
The last steps in the synthesis of target molecules 81a, 81b and 82 incorporate the  
deprotection of the hydroxyl groups and saponification of the carboxylic ester of the complete 
tetrasaccharide mimics 135a, 135b and 136. All hydroxyl groups of the mimics were 
protected by benzoyl esters making deprotection possible in a single reaction step under 
basic reaction conditions. The benzyl ester was expected to be cleaved under these 
conditions as well. 
Treatment of derivatives 135a, 135b and 136 with a solution of sodium methoxide in 
methanol should deliver the unprotected target molecules 81a, 81b and 82. However, in 
contrast to all other benzoyl groups, the benzoylate at C-2 of the galactose was inert under 
the conditions applied. Only the partially deprotected derivatives 137a, 138b and 140 could 
be isolated in high yields (scheme 15). The benzyl esters at the lactic acid moiety were trans-
esterified to the methyl esters due to the large stochiometric excess of sodium methoxide 
used. 
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Scheme 15: Deprotection of the tetrasaccharide mimetics 135a, 135b and 136. 135a could not be 
completely deprotected under standard conditions. a) NaOMe/MeOH, rt, 1 h and then 40°C, 2 h (89%); 
b) NaOMe/MeOH, rt, 2 h (88%); c) NaOMe, MeOH, 55°C, 42 h (94%); d) NaOMe/MeOH, rt, 11 h (87%); 
e) 1) LiOH, dioxane/water (1:1), rt, 3 h; 2) HCl to pH 4; 3) Dowex 50 basic sodium ion exchange (60%).
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By treatment of the 2-O-benzoyl-protected intermediates 137a, 138b and 140 with LiOH or 
NaOH in dioxane/water at room temperature the methyl ester was cleaved, but the benzoate 
at C-2 of galactose was not affected. Even extended reaction times in combination with 
elevated temperatures up to 55°C did not solve the problem. One exception was mimic 135b, 
which could be deprotected to the target molecule 139b after reaction at 55°C for 42 h (see 
scheme 15). 
 
Model compound for the investigation of deprotection conditions 
In order to determine whether the cyclic spacer, the fucose moiety or the cyclohexyllactic 
acid residue is responsible for the unusual stability of the benzoate at the 2-position, the 
isopropyl derivative 142 was synthesized in 98% yield (scheme 16) by reaction of 
thiogalactoside 90 with isopropanol and DMTST as promoter.  
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Scheme 16: Synthesis of the model compound 142 and results of the debenzoylation experiments. The 
concentration of the starting material in b) was 20 times higher than in d). a) iPrOH, DMTST, CH2Cl2, 
3Å-MS, -5°C, 24 h (98%); b) NaOMe (0.02 mol/l, 0.5 equiv.), MeOH, rt, 20 h (85%); c) 1) NaOMe (0.03 
mol/l, 3.0 equiv.), MeOH, microwave-radiation 40W, 70°C, 2 h and then without mw, rt, 20 h; 2) Dowex 
basic sodium ion exchange (94%); d) 1) NaOMe (0.04 mol/l, 20 equiv.), MeOH/toluene (1:1), rt, 26 h; 2) 
Dowex basic sodium ion exchange (99%).
144 : 145 = 1:1
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Treatment of the isopropyl galactoside 142 with sodium methoxide led to the same results as 
observed in case of the tetrasaccharide mimetics: the 4- and 6-hydroxyl groups of the 
galactose were deprotected, whereas the benzoate at position 2 was not cleaved. The 
benzyl ester at the lactic acid residue was converted to the methyl ester. The 2-O-
benzoylated methyl ester 143 could be isolated in 85% yield. These results clearly indicate, 
that the cyclohexyllactic acid residue is responsible for the unusual stability of the benzoyl 
ester, probably due to steric effects.  
The derivatives 135a, 135b, 136 and 142 contain two hydrophobic substituents, the 
cyclohexyl ring of the lactic acid residue and the benzoyl group at C-2 of the galactose. In 
addition, they consist of a hydrophilic part contributed by the hydroxyl groups of fucose and 
galactose. These properties probably force the molecules, especially in polar solvents like 
methanol or water, to form aggregates which allow to burry the hydrophobic part in the inside 
and to orient the hydrophilic part towards the polar surrounding. As a consequence, it is no 
longer possible for the nucleophilic methoxide to reach the benzoyl ester group hidden inside 
the aggregate. This situation is comparable to the organization in micelles, where the 
lipophilic parts are hidden inside the aggregate and the hydrophilic parts are pointed to the 
water.  
Two different strategies were investigated to cleave the stable benzoyl group and to check 
the proposed hypothesis. In the first approach the debenzoylation was investigated under 
microwave conditions. It has been shown for numerous reactions, that they proceed much 
faster when carried out under microwave conditions rather than under conventional reaction 
conditions [351-362]. We assumed, that microwave irradiation could probably break up the 
proposed aggregates. The second approach aimed at breaking up the aggregates by solvent 
interaction. Changing the polarity of the solvent by adding a lipophilic component should lead 
to a stronger interaction of the cyclohexyl- and phenyl-residues with the lipophilic component 
of the solvent mixture, thus weakening or even avoiding aggregation. Performing the reaction 
with lower educt-concentration but the same methoxide concentration should further 
decrease the tendency to form aggregates. 
Stirring the model compound 142 in a solution of NaOMe/MeOH under microwave irradiation 
led to a 1:1 mixture of the totally unprotected isopropyl galactosides 144 and 145 (scheme 
16). Based on the differences for the chemical shift for the α-proton of the lactic acid and the 
H-4 and H-5 of galactose (figure 27) we assumed that isomerization had taken place.  
Treatment of 142 in a 1:1 mixture of methanol and toluene with a 20-fold dilution of the 
starting material in comparison to the former debenzoylation experiments led to 50% 
cleavage of the benzoyl group. 50% of the starting material could be recovered in form of the 
2-O-benzoylated but saponificated lactic acid derivative 146 (scheme 16). Previous tests 
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showed, that sodium methoxide is soluble in methanol/toluene mixtures up to an amount of 
50% toluene. Higher toluene ratios lead to a precipitation of the methoxide. These results 
support the proposed aggregation, that can be suppressed or at least weakened by using 
more lipophilic solvent mixtures.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Application of the optimized deprotection protocol 
The two above described methods were applied to the deprotected sLex mimetics 135b, 
137a and 140/141. Derivative 137a could be successfully deprotected to yield 55% of the 
mimetic 81a using microwave technology (scheme 17). The isomerized side product in 
analogy to 144/145 was not formed. Unfortunately cleavage of the benzoyl group using a 
less polar solvent mixture could not be investigated due to a lack of starting material.  
When tetrahydropyran mimic 141 was treated with a solution of NaOMe/MeOH under 
microwave conditions, a 1:1 mixture of 82 and 147 was obtained in 89%. The two 
compounds showed very similar NMR-spectra (see figure 28) with the complete set of 
signals expected, as previously described for the model 141. Obviously, in this case 
isomerization has taken place as well. 
 
1Gal 
Figure 27: NMR-spectra of the two fractions of model compound 144/145 obtained from the 
debenzoylation under microwave conditions. a) less polar fraction (TLC: CH2Cl2/MeOH 2:1); b) more 
polar fraction (TLC: CH2Cl2/MeOH 2:1). Both spectra are calibrated to D2O (4.79 ppm). 
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Treatment of the partially debenzoylated compound 141 with NaOMe in a 1:1 mixture of 
toluene and methanol led to a single product in 80% yield. The NMR signals were identical to 
those found for one of the two compounds obtained from the microwave cleavage, namely 
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microwave radiation, 40 W, 70°C, 2 h and then 2 drops water, rt, 1 h (55%); b) 1) NaOMe/MeOH, 
50°C, 40 h; 2) LiOH, dioxane/water (1:1), rt, 4 h; 3) Dowex 50 (70%); c) 1) NaOMe, MeOH/toluene 
(1:1), rt, 26 h; 2) Dowex 50 (80%); d) 1) NaOMe/MeOH, microwave radiation, 40 W, 70°C, 4 h and 
then without mw, rt, 15 h; 2) LiOH, dioxane/water (1:1), r.t., 4 h; 3) Dowex 50 (89%).
82   +
3. Results and Discussion                                                                                                                    73 
 
the one with the lower Rf-value (82). As in the case of model compounds 144/145, the 
signals of the protons H-5Gal, H-4Gal and the α-proton of the lactic acid show a shift difference 
of about 0.1 ppm, whereas the other signals possess almost identical shifts indicating an 
isomerization at the α-proton of the lactic acid (see figure 28). 
Comparison of the NMR-spectra of the two fractions of the model compound 144 and 145 
(figure 27) with the NMR-spectra of the two fractions 82 and 147 of the sLex-mimic (figure 28) 
shows for the more polar fraction on TLC a highfield shift of the signals H-2Lac and H-4Gal, 
whereas the signal H-5Gal is shifted lowfield.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: NMR-spectra of the two fractions of compound 82 and 147 obtained from the debenzoyl-
ation under microwave conditions in comparison to the spectrum of 82 obtained from the 
debenzoylation in toluene/methanol. a) product 82 from cleavage in toluene/methanol;  b) microwave 
reaction: lower spot in reference to TLC; c) microwave reaction: upper spot in reference to TLC. All 
spectra are calibrated to D2O (4.79 ppm). 
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3.3. Assignment of  the absolute configuration of 81a and 81b 
 
In the radical coupling reaction, which was used for the synthesis of the core of the sLex-
mimic 81a, a mixture of diastereomers was obtained. At no step during the synthesis it was 
possible to assign the absolute configuration based on NMR data. To solve this problem, X-
ray (see chapter 3.3.3) and circular dichroism spectroscopy (see chapter 3.3.1 and 3.3.2) 
was applied. CD-spectroscopic investigation aimed at an indirect conformational assignment 
by comparison of the CD-data of the two O-glycosidic compounds 33 and 148 with the CD-
data obtained for the C-glycosidic compounds 81a and 81b (see figure 29). 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.1. Synthesis of the (1S,2S)-cyclohexanediol derivative 148  
 
The fucosylation of (1S,2S)-cyclohexanediol (150) was performed by the in-situ-
anomerization procedure [363,364]. In this reaction, the ethylthio fucoside 149 is transformed 
into the corresponding α-fucosylbromide by treatment with bromine at 0°C. In the presence 
of Et4NBr, isomerization to the more reactive β-bromide occurs, which reacts with (1S,2S)-
cyclohexanediol (150) in 74% yield. Galactosylation of 151 with ethylthio galactoside 90 was 
O
H2C
O
HO OH
OHMe
O
OH
O
HO OH
COONa
81b
O
H2C
O
Me
HO
OH
OH
O
OH
O
HO OH
COONa
H
81a
H
(1S,2R)(1R,2S)
O
O
O
HO OH
OHMe
O
OH
O
HO OH
COONa
O
O
O
Me
HO
OH
OH
O
OH
O
HO OH
COONa
H
H(1R,2R) (1S,2S)
33 148
Figure 29: Correlation of the configuration of the two C-fucosidic derivatives 81a and 81b as well as the
two O-fucosidic sLex derivatives 33 and 148. Synthesis of compound 148  allowed us to compare 
structural information collected by NMR- and CD-spectroscopy.
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performed using DMTST as promoter yielding 152 (92%). Thiogalactosylation with NIS/TfOH 
as promoter, as applied successfully in case of the C-fucosidic mimetics, failed due to 
cleavage of the O-fucosidic linkage under the acidic reaction conditions.  
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Scheme 18: Synthetic pathway leading to the (1S,2S)-cyclohexanediol derivative 148. a) Br2, 
NEt4Br, CH2Cl2, 4Å MS, rt, 17 h (74%); b) 90, DMTST, CH2Cl2, -2°C, 18 h (92%); c) NaOMe/MeOH, rt,
15 h (98%); d) 10% Pd/C, H2, dioxane, rt, 24 h (94%); e) NaOMe/MeOH, rt, 20 h (92%); f) 1) NaOMe, 
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The final deprotection steps (152 → 148, scheme 18) incorporated the basic cleavage of the 
benzoyl- and benzyl esters at the galactose and lactic acid units as well as hydrogenolysis of 
the benzyl ethers at the fucose. During the cleavage of the benzoyl esters at the galactose, 
the same problems arose as in case of the C-fucosidic mimetics 135 and 136. The benzoyl 
group at C-2 of the galactose could not be cleaved using standard cleaving conditions 
(NaOMe/MeOH), neither at room temperature nor at elevated temperatures. Furthermore, it 
didn’t matter whether the benzyl ethers at the fucose were present during the debenzoylation 
or whether they had been removed hydrogenolytical before the benzoyl cleavage (see 
scheme 18). In both cases, only the benzoyl groups at C-4 and C-6 of the galactose could be 
removed.  
152 was converted into the debenzylated acid 154 in 94% yield using standard 
hydrogenation conditions (H2, Pd/C, MeOH). After its partial debenzoylation (→ 155) 
microwave conditions were successfully applied (→ 148, 71%). In a second approach, 152 
could not be debenzoylated completely in a mixture of toluene and methanol at low starting 
material concentration, as performed with model compound 143. This indicates, that the 
lipophilic benzyl groups at the fucose even intensify the proposed tendency of lipophilic 
interaction in hydrophilic media.  
 
3.3.2. Circular Dichroism Spectroscopy of the four sLex derivatives 33, 148, 81a 
and 81b 
 
CD-spectroscopy became an important methodology in protein research [365-367] for the 
investigation of secondary structures of proteins in solution. In addition, it allows to determine 
the ratio of different secondary structural elements present in a protein. CD-spectroscopy is 
based on the principles of UV-spectroscopy, but uses circularly polarized instead of 
unpolarized light. The measured circular dichroism (ellipticity) is defined as the difference 
between the absorption of right circularly polarized and left circularly polarized light by an 
optically active molecule [368].  
Differences in ellipticity of secondary structural elements of a protein emerge from slightly 
different torsion angles around the amide bonds in the polyamide backbone. This leads to 
different absorption behavior of the n → π* transition of the amide bonds. These differences 
allow to distinguish e.g. β-sheets from α-helices by CD-spectroscopy (figure 30). 
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The CD of carbohydrates [369-371] is a challenging area of research. Data analysis is more 
complex for carbohydrates than for peptides and proteins, since they contain a large number 
of different chromophores that differ in distance and connectivity. They can be linear or 
branched and the monomers can occur in both isomeric forms, the common D-form and the 
less common L-form. Some chromophores like amides, acyl groups or carboxylic acids 
absorb in the detectable region observed for proteins and give rise to n → π* and π → π* 
transitions. Chromophores of unsubstituted carbohydrates like the ring oxygen, the glycosidic 
linkage and the hydroxyl groups make data acquisition even more difficult, since these 
chromophores absorb outside the range of commercially available instruments. They give 
rise to higher energy transitions like n → σ* or σ → σ* and therefore have an effect on the 
CD-pattern [372,373]. The transitions of the acetal oxygen for instance are centered at 
175nm and 150nm. The latter transition can only be investigated using specialized 
techniques such as vacuum CD [374].  
Figure 30: Example of proteins with different portions of secondary structural elements and the 
corresponding CD-spectra (lower right). In contrast to the CD-spectra, the UV-spectra (lower left) of 
the four proteins are very similar. 
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The fact that we were confronted with molecules of different chirality with a slightly helical 
conformation encouraged us to measure CD-spectra of the four mimetics 33, 148, 81a and 
81b shown in figure 29. They all contain a carboxyl group of lactic acid  and should therefore 
give rise to a n → π* transition in the lower UV range.  
Kenne et al. [375] compared the CD-spectra of 1-carboxyethyl substituted monosaccharides 
at different pH-values with the CD-spectra of (R)- and (S)-lactic acid. They reported, that the 
absolute configuration of the 1-carboxyethyl substituent can be assigned by comparison of 
the CD-spectra. (S)-1-carboxyethyl substituted glycosides showed a positive CD-band 
around 210 nm, whereas (R)-1-carboxyethyl substituted glycosides had a negative CD-band 
around 210 nm. 
We collected the CD-spectra of the two derivatives 33 and 81b at three different pH-values, 
but the pH-dependence of the intensities was much smaller than those reported by Kenne et 
al. [375]. In both cases, the intensity is about twice as strong at pH 2 compared to pH 4 and 
pH 7. The spectra at pH 4 and pH 7 are almost identical (λmax = 205 nm). At pH 2, λmax is 
shifted to 213 nm (figure 31). The CD-spectra of all four derivatives of interest (33, 148, 81a 
and 81b) are shown in figure 32. The shift of λmax upon switching from pH 2 to pH 7 can be 
observed for any of the four compounds. Except the differences in intensities, the CD-spectra 
of the four compounds are identical. The positive CD-bands are in accordance with the data 
published from Kenne et al. [375] and confirm the (S)-configuration at the chiral center of the 
cyclohexyllactic acid. As far as the configuration at the ring-carbon next to the C-glycosidic 
linkage is concerned, no clear correlation between the four investigated derivatives could be 
observed. 
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Figure 31: CD-spectra of the O-fucosidic mimic 33 and of the C-fucosidic mimic 81b at three 
different pH-values. O-fucoside 33: pH 7: 4.3 *10-4 g/ml in H2O;  pH 4: 4.0 * 10-4 g/ml in diluted 
HOAc; pH 2: 4.5 * 10-4 g/ml in diluted HCl. C-fucoside 81b: pH 7: 4.1 *10-4 g/ml in H2O;  pH 4: 
4.0 * 10-4 g/ml in diluted HOAc; pH 2: 3.5 * 10-4 g/ml in diluted HCl. 
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Figure 32: Comparison of the CD-spectra of the four tetrasaccharide mimetics 33, 81a, 81b 
and 148 shown in figure 29. The upper graph shows the spectra of the four compounds at pH 
7 in water, the lower graph shows the spectra of the four compounds at pH 2 in diluted HCl. In 
the upper graph, concentrations were adjusted in terms of maximal UV-absorption lying 
between 0.8 and 1.0.  
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3.3.3. X-ray crystal structure determination 
 
In a second approach, the absolute configuration of the C-glycosidic mimetics 81a and 81b 
was determined by X-ray analysis. Crystal structures of oligosaccharides can hardly be found 
in literature due to the great difficulties to obtain crystals of appropriate regularity and size. In 
contrast to the crystal structure of Lex [376,377], the crystal structure of sLex has not been 
published to date. However, the crystal structure of sLex co-crystallized with the natural 
receptor E-selectin was recently published by Camphausen [145]. 
In order to determine the absolute configuration of the tertiary carbon center arising during 
the radical addition step, we decided to crystallize derivatized intermediates of the synthesis 
of 81a and 81b, which already contain the chiral center of interest (scheme 19). 
The synthesis of triflate derivatives of the benzoate- and pivaloate-protected alcohols 128 
and 129 as well as p-NO2-benzoate- and p-Br-benzoate-protected derivatives of alcohol 
128b was planned. The synthesis of the triflate derivatives led to the elimination products 
156-159. Fortunately, the three equatorial triflates eliminated to olefins 156, 157 and 158 
without affecting the stereocenter, whereas the axially oriented triflate eliminated in an anti-
elimination to 159 while destroying the chiral center of interest (see scheme 19). 
We tried to crystallize the compounds shown in scheme 19 from different solvents and 
solvent mixtures. With di-isopropyl ether inhomogeneous crystals were obtained. We 
therefore chose solvents with different polarities as well as solvent mixtures, which 
lipophilicity rises during the evaporation of the more volatile polar component. 
Each of the derivatives shown in scheme 19 as well as the two C-fucosidic alcohols 128b 
and 128c was dissolved for crystallization in one of the following solvents or solvent 
mixtures:  
 
• ethyl acetate / heptane • toluene 
• THF / hexane • CHCl3 
• toluene / octane • ethyl acetate 
• Bu2O • THF 
• i Pr2O • MeOH 
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Scheme 19: Derivatives of the C-fucosidic alcohols synthesized for crystallization experiments; 
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The substances 156, 158 and 161 crystallized from THF, CHCl3, ethyl acetate/heptane, 
iPr2O  and methanol, but the crystals had not the necessary quality or size for an x-ray 
crystal structure determination with the exception of the crystals obtained of compound 158 
from methanol. The size of the crystals was critical being only 0.05 mm in one dimension 
(figure 33).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In contrast to the atoms in the two ring systems, the pivaloyl residues on the fucose showed 
large thermal motion within the crystal. Nevertheless, the configuration at the critical stereo 
center could be clearly assigned as R. This means that compound 158 with the higher Rf-
value has the undesired configuration. As a consequence, the second fraction of the two 
equatorial alcohols (157, lower Rf-value) bears the correct S-configuration. Assuming that by 
Figure 33: Stereoview of the crystal structure of compound 158. The absolute configuration of the 
tertiary cyclohexenyl carbon near the methylene bridge can be assigned as R. α-configuration at the 
anomeric center is also confirmed by the crystal structure. 
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changing the protecting groups, the relative polarity among the four alcohols and thus the 
order on the TLC should remain unchanged, the configuration of the benzoyl-protected C-
fucosidic alcohols was assigned in analogy to those of the pivaloyl-protected ones. 
Consequently the benzoyl-protected alcohol 128a possessing the lower Rf-value should bear 
the desired S-configuration, whereas alcohol 128b with the higher Rf-value should posses R-
configuration. This TLC-based correlation is clearly confirmed by the NMR-data shown in 
table 8 in chapter  3.2.5. 
 
3.4. Investigation of conformational preferences 
 
The rigid conformation of the Lewisx core of sLex in solution as well as the characteristic 
stacking of the galactose and fucose unit are reflected by the nuclear Overhauser effect 
(nOe) between the protons H-2 at galactose and H-5 and CH3 of fucose 
[156,157,159,161,164,378]. This same solution conformation is adopted in mimetics, in 
which the glucosamine unit has been replaced by simpler cyclohexanediol spacers, as 
demonstrated by Ernst et al. [198,378] (see also chapter 1.4.2).  
The same group demonstrated, that nOe intensities and chemical shift differences of the 
proton H-5Fuc correlate with the biological activity [198]. It increases with decreasing distance 
between fucose and galactose, caused by the introduction of steric constraints by equatorial 
substituents next to the fucosidic linkage. 
In case of the C-glycoside 81a, more flexibility around the C-fucosidic bond is expected due 
to the lack of the stabilizing exo-anomeric effect. This should also lead to a reduced 
biological activity. To compensate for the lacking exo-anomeric effect, steric factors can be 
introduced. The following discussion shows, that our hypothesis proofed well-founded. 
To compare the core conformation of the synthesized mimetics with that of mimic 33, 2-
dimensional ROESY experiments were performed with compounds 81b, 82, 147 and 148. 
Unfortunately, not enough material of compound 81a was available for these experiments. 
Experimental details are given in chapter 5.  
The ROESY spectra of both compounds 82 and 147 show a clear nOe between the H-2Gal 
and the H-5Fuc as well as between the H-2Gal and the CH3Fuc, indicating a close proximity 
between the galactose and the fucose unit (figure 34). In the ROESY spectra of compounds 
81b and 148, no nOe crosspeaks between the fucose- and galactose protons could be found 
(figure 35). The different linkage of the fucose and galactose to the spacer cyclohexane ring 
leads to a completely changed core conformation compared to 33 or sialyl Lewisx. 
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 compound 82 
5Fuc – 2Gal 
 compound 147 
5Fuc – 2Gal 
Figure 34: Section of the 2D-ROESY spectra of compounds 82 and 147. The ROE’s of H-5Fuc 
and H-2Gal are encircled. 
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 compound 81b 
5Fuc 2Lac
2Lac – 3Gal 
 compound 148 
2Lac – 2Gal 
5Fuc – 2Gal 
Figure 35: Section of the 2D-ROESY spectra of compounds 81b and 148. The chemical shifts of H-
5Fuc and H-2Lac of compound 81b are that similar, that the lacking ROE between H-5Fuc and H-2Gal 
can only be seen by zooming very close into the region of interest. 
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To quantitatively compare the intensities of the nOe signals as indicator of the proximity of 
the fucose and the galactose unit, we performed selective excitation ROESY spectra [379] 
for compounds 33 and 82. The source of the magnetization in each experiment was proton 
H-5Fuc. Each 1-dimensional experiment was performed with different spin-lock times.  
The intensity of the positive signals grows with increasing mixing time and indicates the 
relative spacial proximity of a particular proton to that of the source proton (figure 36).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The nOe’s of the H-2Gal proton (intcross) were normalized to the intensity of the diagonal peak 
of H-5Fuc (large negative signal, intdiag). Plotting these normalized intensities against the 
mixing time results in a straight line for each compound (figure 37). After equation (3), the 
5Fuc 2Gal 
 
4Fuc/3Fuc 
 
Figure 36: Selective excitation ROESY spectra for compound 82. The time scale contains the 
different mixing times needed to obtain the ROE build-up rates. 
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slopes of these build-up curves deliver the crossrelaxation rates σ [380] or the rates for the 
rotating frame nuclear Overhauser effect (ROE), which can be used to calculate relative 
distances of pairs of protons after equation (1) [381] and (2) [380]. 
 
 
 
 
 
 
 
 
 
 
In the linear approximation, the tanh(x) is a straight line for small x, which is true for the 
range of mixing times used in these experiments. This simplification results in equation (3). 
 
 
 
 
 
Linear regression of the normalized ROE intensities delivers a slope of -0.093 (±0.013) for 
compound 33 and a slope of -0.024 (±0.0012) for compound 82 (figure 37). Combination of 
equation (2) and (3) results in equation (4), which delivers the relative distances of H-5Fuc to 
H-2Gal for both compounds:  
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These numbers indicate, that the two protons H-5Fuc and H-2Gal are 25(±4)% closer to each 
other in compound 33 than in compound 82. Based on the determined distance of 3.5 Å for 
H-2Gal and H-5Fuc in compound 33 [378], the distance in compound 82 should be 4.2 – 4.5 Å. 
These results demonstrate the possibility to partly compensate the loss of the exo-anomeric 
effect by steric factors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Surprisingly, the postulated downfield shift [198] for proton H-5Fuc as from δ = 4.12 ppm in 
compound 43 to δ = 4.77 ppm in compound 41 could not be observed in compound 82. 
Proton H-5Fuc of compound 82 shows only a small absolute downfield shift to δ = 4.29 ppm. 
However, compared to compound 81a with a chemical shift of δ = 3.82 ppm for H-5Fuc, the 
chemical shift difference of ∆δ = 0.47 ppm in the row of the C-glycosidic compounds is 
comparable to ∆δ = 0.65 ppm between 41 and 43. Compared to the chemical shift of 
compounds 41 (δ = 4.77) and 33 (δ = 4.60), the downfield shift in the C-glycosidic row is even 
more distinct (table 9). The observed trend in both classes of compounds is also confirmed 
by the chemical shifts of H-5Fuc of 148 (δ = 4.12 ppm) and of 81b (δ = 3.80 ppm), which didn’t 
show any nOe’s between H-5Fuc or CH3Fuc and H-2Gal and therefore lack a close proximity of 
the fucose and galactose unit.  
Figure 37: ROE build-up curves for compounds 33 and 82 arising from the selective 
excitation ROESY spectra. 
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The strong highfield shift of proton H-5Fuc of compound 81a in comparison to 82 and 
33 is an indication of the expected flexibility and low bioactivity of this compound. 
 
Table 9: Comparison of the chemical shifts of the proton H-5Fuc in key tetrasaccharide mimics. 
Literature-known compounds [198] are highlighted in gray, compounds synthesized in the course of 
this thesis are not highlighted. 
 
compound 
    
number 148 43 33 41 
δ (H-5Fuc) 4.12 4.12 4.60 4.77 
compound 
    
number 81b 81a 82 147 
δ (H-5Fuc) 3.80 3.82 4.29 4.29 
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4. Summary and Conclusion 
 
4.1. General background 
 
The recruitment of leukocytes from the blood flow to sites of inflammation or tissue injury is 
initiated by their rolling and their subsequent firm attachment on the activated endothelial cell 
layer [9,68-71,382,383]. Rolling as the first event of a multi-step process called the 
inflammatory cascade was found to be a prerequisite for firm attachment and final endothelial 
transmigration to take place. Capturing and rolling is mediated by the interaction of the 
selectins, a family of three related cell-adhesion molecules, with their natural glycoprotein 
ligands [94-97]. All three selectins recognize a common, terminal carbohydrate epitope, the 
tetrasaccharide sialyl Lewisx (sLex) 3 [31-34].  
Excessive leukocyte accumulation is related to many acute and chronic diseases [109-127] 
as ischemia reperfusion injury, asthma, rheumatoid arthritis, psoriasis or septic shock. 
Furthermore, a contribution of selectin-carbohydrate interaction to cancer metastasis [128-
131] could be shown. The blocking of the selectin-ligand interaction by potent sLex mimetics 
was proposed to be a highly promising therapeutic target to overcome these diseases.  
C-glycosidic structures play a prominent role in developing hydrolytically stable mimetics 
[228-231] as well as in understanding conformational issues relevant for the binding process. 
 
4.2. Aim of the thesis 
 
Within this thesis we describe the successful development of a synthesis of the two C-
glycosidic sLex mimetics 81a and 82, which are conformationally less stable than the 
corresponding O-glycosides due to the missing exo-anomeric effect. The hypothesis was 
raised, that the implementation of steric constraints as realized in mimic 82 can be used to 
compensate for the higher flexibility around the C-glycosidic bond in 81a. Furthermore, 
comparison of binding affinity should allow a quantification of the entropy contribution to the 
inhibitory potential caused by the exo-anomeric effect. 
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4.3. Synthetic strategy 
 
The synthetic pathways for 81a and 82 are based on the radical addition of an anomeric 
glycosyl radical to an activated olefin developed by Giese et al. [271,272,275]. This key step 
was expected to establish the C-glycosidic bond α-selectively. By selective reduction of the 
cyclohexanones, β-selective galactosylation of the C-fucosidic equatorial alcohols and 
derivatization of the galactose at position 3, the target molecules are obtained (see figure 
39). 
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Figure 38: SLex and the target molecules 81a and 82. 
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Figure 39: Retrosynthetic cleavage leading to the key building blocks for the synthesis of the two 
target tetrasaccharide mimetics 81a and 82. 
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4.4. Summary of Results  
 
4.4.1. Synthesis of the tetrasaccharide mimetic 81a and its diastereomer 81b 
 
α-Methylene cyclohexanone (83) used as radical acceptor was synthesized in a 5-step 
reaction sequence with an overall yield of 38% as described by Tsuji et al. [308,309] (see 
chapter 3.2.2). Compound 83 turned out to be highly susceptible to Diels-Alder dimerization. 
Temperature- and time-dependent stability of the methylene ketone 83 was investigated by 
NMR (see table 4, chapter 3.2.2). Half-life at a concentration of 15 mg/ml and 80°C was 
determined to be approximately 3-4 hours. 
The radical addition developed by Giese et al. [271,272,275] was performed under different 
reaction conditions. In addition, the influence of the protecting groups on yields and 
stereoselectivities was investigated (see chapter 3.2.4). In all cases, exclusive α-selectivity at 
the anomeric center of fucose was observed. In contrast, the selectivity at the chiral center 
formed during the hydrogen atom transfer was rather low (dr = 57:43 to 67:33). As expected, 
the yields of the radical reaction were rather poor (26 to 35%) due to the concurrent 
dimerization of the radical acceptor 83.  
Because the absolute configuration of the diastereomers 123a and 123b could not be 
assigned at that point, the synthesis was continued with both diastereomers. The assignment 
problem could be solved later by an X-ray analysis (see below). 
With different reducing agents as well as protecting groups, the subsequent reduction of the 
C-fucosidic ketones 122a/b, 123a/b and 124a/b was optimized (see chapter 3.2.5). 
Glycosylation of the equatorial alcohols 128a and 128b with the galactose building block 90 
led with excellent yields to the exclusive formation of the β-anomers (see scheme 20 and 
chapter 3.2.7). Finally, deprotection of the hydroxyl groups and the carboxylic acid led to the 
target molecule 81a and its diastereomer 81b. 
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4.4.2. Synthesis of the methyl substituted tetrasaccharide mimic 82 
 
The radical acceptor methylene ketone 84 leading to the sLex mimic 82 was synthesized in a 
13-step reaction sequence with an overall yield of 17% using D-glucal as chiral starting 
material (see scheme 21 and chapter 3.2.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As during the synthesis of α-methylene cyclohexanone (83), a strong tendency of the 
methylene ketone 84 to undergo dimerization was observed. In the radical addition, exclusive 
stereoselectivity on both newly formed chiral centers was observed (see chapter 3.2.4). The 
subsequent reduction of the cyclic ketone 125 could be performed stereoselectively in favor 
of the desired equatorial alcohol 130a (see scheme 21 and chapter 3.2.6). Glycosylation of 
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the equatorial alcohols with the galactose building block 90 gave 136 with high yield and 
exclusive β-selectivity (see chapter 3.2.7). Deprotection of tetrasaccharide mimetic 136 using 
the optimized deprotection protocol described in chapter 3.2.8 yielded the sLex mimetic 82. 
 
4.4.3. Determination of the absolute configuration of mimics 81a and 81b 
 
In order to solve the assignment of the absolute configuration of 81a and 81b, two different 
approaches were undertaken. First, circular dichroism spectroscopy was applied to indirectly 
assign the configuration relative to the two well-assigned O-glycosidic parent structures 33 
and 148. The O-glycosidic mimetic 148 was synthesized in an overall yield of 45% (see 
chapter 3.3.1). CD-measurements of the four compounds 33, 148, 81a and 81b showed no 
significant differences that could help to assign the absolute configuration (see chapter 
3.3.2). 
In a second approach, derivatized intermediates of the synthesis were crystallized (see 
chapter 3.3.3). Crystals of compound 158 obtained from methanol were used to perform an 
X-ray analysis (scheme 22, figure 39).  
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Correct assignment of the absolute configuration of both tetrasaccharide mimics was 
possible by a correlation of the TLC-Rf values of the crystallized compound with those of the 
intermediate C-fucosidic alcohols. This correlation could be confirmed by a comparison of the 
NMR data (see table 8, chapter 3.2.5). 
 
 
 
 
 
 
 
 
 
 
 
4.4.4. Investigation of conformational preferences in solution 
 
2D-ROESY experiments revealed nOe’s between the protons H-5 and H-6 of fucose and the 
proton H-2 of galactose in compound 82, which implicate the conformational similarity to the 
bioactive conformation of sLex (see chapter 3.4). The tetrasaccharide mimics 81b and 148 
bearing a different configuration at the cyclohexane spacer were lacking these nOe’s. 
Quantitative comparison of the intensities of nOe’s of 82 and 33 disclosed a 20-30% larger 
distance of H-5Fuc and H-2Gal in compound 82 than in compound 33.  
Another indicator for the spacial proximity of fucose and galactose, as found by Ernst et al. 
[198] for a series of O-glycosidic mimetics, could be confirmed in terms of a downfield 
chemical shift of H-5Fuc in compound 82 compared to compounds 81a, 81b and 148 (see 
table 9, chapter 3.4).  
 
 
 
Figure 40: Stereoview of the crystal structure of 158 
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4.5. Conclusion and outlook 
 
We successfully developed a synthesis for the target tetrasaccharide mimetics 81a and 82. 
The Giese radical addition reaction turned out to be a versatile method for the establishment 
of the C-fucosidic linkage in an α-selective manner. The main draw-back of our approach, 
however, is the tendency of the radical acceptors to dimerize in a Diels Alder cyclization 
reaction. By optimization of the workup and purification procedure of the methylene ketones, 
dimerization prior to the radical coupling itself can possibly be restricted. Concurrent 
dimerization under the high reaction temperatures needed for radical chain initiation can’t be 
avoided.  
The results of the debenzoylation experiments led to the conclusion, that problems can be 
avoided by modifying the reaction sequence: the lactic acid moiety is introduced after 
galactosylation of the C-fucosidic alcohols.  
Conformational investigation of the target molecules revealed the possibility to partially 
compensate the loss of the exo-anomeric effect by the introduction of sterically demanding 
substituents next to the C-glycosidic linkage. The measured distance of H-5Fuc and H-2Gal in 
mimic 82 indicates that the sterical demand of the methyl group next to the C-glycosidic 
linkage is not sufficient to force the fucose unit into the bioactive conformation. The 
introduction of even bulkier substituents at the spacer unit should therefore be investigated. 
To what extent the larger distance of H-5Fuc and H-2Gal in compound 82 has an effect on, and 
whether the observed downfield shift of H-5Fuc is in line with biological activity as shown by 
Ernst et al. [198] for O-glycosidic antagonists, has to be proven.  
Investigation of compounds 79a-e and 80a-e (see chapter 1.5.5) support the approach to 
introduce hydrophobic residues at the 2-position of GlcNAc of sLex to address a second 
binding site on the E-selectin surface. Our methodology opens the possibility to introduce 
spacer units functionalized with an azide group at the position next to the C-glycosidic 
linkage. This azide group can be used to build up a combinatorial triazole library containing a 
vide variety of differently modified triazole derivatives via 1,3-dipolar cycloaddition reactions 
(see scheme 23). In addition, this azide group can be converted into the amine in order to 
introduce hydrophobic residues like aromatic heterocycles via an amide bond. 
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5. Experimental Section 
 
5.1. General methods 
 
Nuclear magnetic resonance: 
Nuclear magnetic resonance spectroscopy was performed on a Bruker Avance 500 Ultra 
Shield spectrometer at 500 MHz (1H NMR) or 125 MHz (13C NMR). Chemical shifts are given 
in ppm and were assigned in relation to the solvent signals [384] on the δ-scale or to 
tetramethylsilane (0 ppm) as internal standard.  
 
1H: 7.26 ppm (CDCl3), 7.16 ppm (C6D6), 3.31 ppm (CD3OD), 4.79 ppm (D2O);  
13C: 77.16 ppm (CDCl3), 128.06 ppm (C6D6), 49.00 ppm (CD3OD). 
 
Coupling constants J are given in Hertz (Hz). Multiplicities were specified as follows: s 
(singlet), d (doublet), dd (double doublet), t (triplet), q (quartet), dq (double quartet), m 
(multiplet). Interpretation of the spectra was done according to 1st order [385]. 
 
For assignment of resonance signals to the appropriate nuclei the following abbreviations 
have been used: Fuc (fucose), Gal (galactose), Lac (lactic acid), Pyr (tetrahydropyran), Cyc 
(cyclohexane). In cases where the numbering of nuclei does not accord to the numbering in 
IUPAC nomenclature, the differences are illustrated in a formula scheme of the 
corresponding substance. 
 
Two-dimensional ROESY experiments: 
Spin-lock duration for ROESY was 200 ms. 128 increments were recorded in the indirect 
dimension, and 512 points were used for its Fourier transform (e.g. “zero-filling” by a factor of 
3). In the direct dimension (e.g. normal 1D spectrum) 4k points  were acquired and 4k used 
for the Fourier transformation of this dimension. Water suppression was achieved with 
presaturation during the interscan delay. The sweep-width was optimized by shifting the 
central frequency from H2O (for presaturation) to 0 ppm during the 200 ms ROESY spin-lock 
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(to minimize TOCSY artifacts) and to 3 ppm (center of spectrum) during acquisition of the 
FID. As no signals were observed to the left of the H2O, this frequency changing allowed 
smaller spectral-width in both dimensions, allowing for better resolution for a given number of 
increments in the indirect dimension (e.g. 128 t1 increments between 0-6 ppm, instead of 256 
if the FID was recorded centered on the H2O frequency). 
 
Selective ROESY spectra  
A selective pulse was applied to the proton H-5Fuc. Each 1-dimensional experiment was 
performed using a different mixing time (spin-lock). The intensity of the positive signals 
indicates the relative special proximity of a particular proton to that of the source proton (H-
5Fuc). The selective pulse was shaped in the form of an E-BURP-1 [386], to achieve better 
selectivity. 
The frequency was changed during the experiment as  
• f1 : start on H2O for presaturation 
• f2 : change to H-5Fuc for selective excitation 
• f3: change to 0 ppm during ROESY spin-lock (reduces TOCSY-artifacts) 
• f1 : change back to H2O for next scan (of 400 total) 
 
Infrared spectroscopy: 
IR spectra were recorded on a Perkin Elmer Spectrum One FT-IR spectrometer as KBr 
pellets or films. Most characteristic absorption bands of the spectrum were given in cm-1 and 
specified as vs (very strong), s (strong), m (medium), w (weak), b (broad). 
 
Optical rotation: 
Optical rotation was measured on a Perkin Elmer 241 polarimeter either in chloroform or in 
methanol. The optical rotation for the Na-D-line (589 nm) can be extrapolated from the lines 
of a mercury lamp (546 nm and 579 nm) using the Drude equation [387]: 
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        α = measured rotation 
       c = concentration in g/100 ml 
       d = cell length in dm 
       T = temperature in °C 
                                                                                               λ = wavelength in nm 
 
Microanalysis: 
Microanalysis was performed at the Institute of Organic Chemistry at the University of Basel, 
Switzerland. 
 
Mass spectroscopy: 
Mass spectra were recorded on an Agilent 1100 Series LC/MSD spectrometer in API-ES 
ionization mode or on a Bruker Daltonics Esquire 3000 plus ESI mass spectrometer at Gilson 
AG, Basel, Switzerland. 
 
Circular dichroism spectroscopy: 
CD spectra were measured using an Aviv 62A DS CD-spectrometer. The concentrations of 
the solutions were adapted in a way that the UV absorption A at λmax lay in the range from 
1.0 to 0.8. 
The following solvents have been used: pH = 7: H2O (dest.), pH = 4: HOAc, pH = 2: aqueous 
HCl. 
 
Molar circular dichroism ∆ε has been calculated with the following equation [375]: 
 
     ∆ε = molar circular dichroism 
     Θ = ellipticity angle [mdeg] 
     l  = cell length in dm; here: 0.1 dm 
     c = concentration in g/ml 
     M = molar mass 
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In cases where the concentrations were very similar, ellipticity angles as values produced by 
the CD-spectrometer were given instead of the molar CD-values due to equal molecular 
masses of the compounds. 
 
Crystallization experiments: 
Crystallization experiments were carried out by dissolving mg-samples of the compounds in 
2.5 ml flasks from Infochroma AG, Zug, Switzerland and sealing the flasks with a plastic-cap 
penetrated with a metal syringe-canule. Storing the flasks at room temperature, the solvent 
was able to evaporate slowly thus steadily increasing the concentration and/or the polarity of 
the solvent mixtures towards the polarity of the less volatile component.   
 
X-ray crystal structure determination: 
The crystal structure was solved at Hoffmann-La Roche, Pharmaceutical Division, Pharma 
Research 65/308, Basel, CH. The diffraction pattern was measured on an IPDS (Image Plate 
Diffraction System) diffractometer from STOE, Darmstadt, Germany using Mo-radiation with 
a wavelength of 0.71073 Å. Structure refinement was performed using the ShelX [388] 
software (G.Sheldrick, Göttingen, Germany). 
 
Thin layer chromatography: 
TLC was performed using silica gel 60 coated glass plates containing fluorescence indicator 
from Merck KGaA, Darmstadt, Germany using either UV light (254 nm) or Mostain solution [1 
g Cer(SO4)2, 50 g (NH4)6(Mo7O24) . 4 H2O dissolved in 1000 ml of 10% H2SO4] followed by 
heating to 140°C for 5 minutes to visibilize the substances. 
 
Chromatography: 
Column chromatography was performed using silica gel C-560 D (40-63 µm) from Uetikon 
AG, Switzerland. Reversed-phase column chromatography was carried out using LiChroprep 
RP-18 (40-63 µm) from Merck KGaA, Darmstadt, Germany.  
 
Microwave reactions: 
Microwave reactions were performed in a CEM Discover microwave apparatus. 
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Hydrogenations: 
Hydrogenation reactions were performed in a shaking apparatus of Parr Instruments 
Company, Moline, Illinois, USA in 250 ml or 500 ml bottles under a H2 pressure of 4 to 5 bar. 
 
Solvents: 
Solvents were purchased from Fluka and dried prior to use. Unpolar solvents (CH2Cl2, 
toluene, petroleum ether, hexane) were dried by filtration over basic aluminum oxide (Fluka). 
THF and methanol were dried by distillation from sodium. Pyridine was dried by distillation 
from CaH2.  
 
Numbering of experiments: 
For every experiment, volume and page of the lab journal as well as the number of the batch 
are given (e.g. “I-112, cm024” means: volume I, page 112, batch cm024). 
 
 
5.2. Experiments 
 
 
Sodium (2S)-3-cyclohexyl-2-O-{1-O-[(1S,2R)-2-(α-L-
fucopyranosyl-methyl)-cyclohexyl]-β-D-galactopyranos-
3-yl}propanoate (81a) (II-155, cm213):  
A solution of 135a (20.0 mg, 15.2 µmol) in methanol (2 ml) 
and NaOMe/MeOH (1 M, 100 µl) was stirred in a microwave 
oven at 70°C for 2 h. After adding 2 drops of water, the reaction mixture was stirred for 1 h at 
room temperature. The solution was neutralized with amberlyste ion-exchange resin (H+ 
form), filtered through celite and concentrated. The obtained oil was purified by silica gel 
chromatography (CH2Cl2/MeOH/H2O 10:4:0.8), passed over Dowex 50x8 resin (Na+ form) 
and chromatographed on a P2 gel column to yield 81a (5.00 mg, 8.40 µmol, 55%). 
 
Rf = 0.17 (CH2Cl2/MeOH/H2O 10:4:0.8); 
 
OO
OH
O
OH
OH
COONa
O
HO
OH
OH
1 2
3 4
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1H NMR (500 MHz, D2O): δ 0.74-1.95 (m, 20 H, H-2Cyc, H-4a+bCyc, H-5a+bCyc, H-6a+bCyc, H-
7a+bCyc, H-4Lac, H-5a+bLac, H-6a+bLac, H-7a+bLac, H-8a+bLac, H-9a+bLac), 1.03 (d, 3J5,6 = 6.3 Hz, 3 H, 
H-6Fuc), 1.03 (m, 1 H, H-1aCyc), 1.40 (m, 1 H, H-3aLac), 1.47 (m, 1 H, H-3bLac), 2.25 (m, 1 H, H-
1bCyc), 3.24 (dd, 3J2,3 = 9.7 Hz, 3J3,4 = 3.1 Hz, 1 H, H-3Gal), 3.35 (ddd, 3J = 4.7 Hz, 9.1 Hz, 9.2 
Hz, H-3Cyc), 3.40 (dd, 3J1,2 = 7.8 Hz, 3J2,3 = 9.5 Hz, 1 H, H-2Gal), 3.49 (m, 1 H, H-5Gal), 3.57-
3.62 (m, 3 H, H-4Fuc, H-6a+bGal), 3.72 (dd, 3J2,3 = 10.4 Hz, 3J3,4 = 3.4 Hz, 1 H, H-3Fuc), 3.76 (dd, 
3J3,4 = 3.1 Hz, 3J4,5 = 0.6 Hz, 1 H, H-4Gal), 3.78-3.83 (m, 3 H, H-2Fuc, H-5Fuc, H-2Lac), 3.99 (ddd, 
3J1,1a-Cyc = 3.1 Hz, 3J1,1b-Cyc = 12.6 Hz, 3J1,2 = 5.6 Hz, 1 H, H-1Fuc), 4.33 (d, 3J1,2 = 7.8 Hz, 1 H, 
H-1Gal); 
 
13C NMR (125 MHz, D2O): δ 16.2 (C-6Fuc), 24.6-41.3 (13 C, C-1Cyc, C-2Cyc, C-4Cyc, C-5Cyc, C-
6Cyc, C-7Cyc, C-3Lac, C-4Lac, C-5Lac, C-6Lac, C-7Lac, C-8Lac, C-9Lac), 72.5 (C-6Gal), 70.0 (C-4Gal), 
67.2 (C-5Fuc), 68.5 (C-2Fuc), 70.3 (C-3Fuc), 70.5 (C-2Gal), 73.0 (C-1Fuc), 74.6 (C-5Gal), 79.7 (C-
2Lac), 82.0 (C-3Cyc), 83.7 (C-3Gal), 100.8 (C-1Gal), 183.1 (COONa); 
 
MS (-40.0 eV, ES): calculated for C28H48O12 [M- - Na]: 575.67; found: 575.44. 
 
 
Sodium (2S)-3-cyclohexyl-2-O-{1-O-[(1S,2R)-2-(α-L-
fucopyranosyl-methyl)-cyclohexyl]-β-D-galacto-
pyranos-3-yl}propanoate (81b) (II-30, cm084):  
To a solution of 135b (62.0 mg, 0.048 mmol) in methanol (5 
ml), NaOMe/MeOH (1 M, 100 µl) was added and the 
reaction mixture was stirred at 50°C for 40 h. The solution 
was neutralized with amberlyste ion-exchange resin (H+ form), filtered through celite and 
concentrated. The residue (20.7 mg) and 10 equiv. of LiOH x H2O (15.0 mg) in dioxane/water 
(1:1, 5 ml) were stirred at room temperature for 4 h. After acidification with 7% aqueous HCl, 
evaporation of the solvent and purification by silica gel chromatography (CH2Cl2/MeOH/H2O 
10:4:0.8), the product was passed over Dowex 50x8 resin (Na+ form) followed by a P2 gel 
column to yield 81b (20.0 mg, 0.033 mmol, 70%). 
 
Rf = 0.27 (CH2Cl2/MeOH/H2O 10:4:0.8); 
 
OO
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[ ]22 D α  = -40.6 (c = 0.95, CH3OH); 
 
1H NMR (500 MHz, D2O): δ 0.78-1.80 (m, 18 H, H-2Cyc, H-5a+bCyc, H-6a+bCyc, H-7a+bCyc, H-4Lac, 
H-5a+bLac, H-6a+bLac, H-7a+bLac, H-8a+bLac, H-9a+bLac), 1.04 (d, 3J5,6 = 6.3 Hz, 3 H, H-6Fuc), 1.18 (m, 
1 H, H-4aCyc), 1.35 (m, 1 H, H-1aCyc), 1.38 (m, 1 H, H-3aLac), 1.40 (m, 1 H, H-4bCyc), 1.54 (m, 1 
H, H-3bLac), 1.98 (m, 2 H, H-1bCyc, H-2Cyc), 3.24 (dd, 3J2,3 = 9.5 Hz, 3J3,4 = 3.4 Hz, 1 H, H-3Gal), 
3.30 (dt, 3J = 3.9 Hz, 9.2 Hz, 9.2 Hz, H-3Cyc), 3.43 (dd, 3J1,2 = 8.1 Hz, 3J2,3 = 9.5 Hz, 1 H, H-
2Gal), 3.55 (m, 1 H, H-5Gal), 3.58-3.65 (m, 4 H, H-3Fuc, H-4Fuc, H-6a+bGal), 3.76 (m, 1 H, H-4Gal), 
3.78 (m, 2 H, H-2Fuc, H-2Lac), 3.80 (dq, 3J4,5 = 1.3 Hz, 3J5,6 = 6.3 Hz, 1 H, H-5Fuc), 4.01 (ddd, 
3J1,1a-Cyc = 3.5 Hz, 3J1,1b-Cyc = 9.3 Hz, 3J1,2 = 5.2 Hz, 1 H, H-1Fuc), 4.30 (d, 3J1,2 = 8.1 Hz, 1 H, H-
1Gal); 
 
13C NMR (125 MHz, D2O): δ 15.7 (C-6Fuc), 24.2, 24.8, 26.8, 27.0, 27.3, 31.1, 31.9, 32.8, 33.2, 
34.4, 42.0 (11 C, C-1Cyc, C-4Cyc, C-5Cyc, C-6Cyc, C-7Cyc, C-4Lac, C-5Lac, C-6Lac, C-7Lac, C-8Lac, C-
9Lac), 33.0 (C-2Cyc), 33.5 (C-6Cyc), 33.8 (C-3Lac), 61.5 (C-6Gal), 66.0 (C-4Gal), 67.6 (C-5Fuc), 68.6 
(C-2Fuc), 70.6 (C-2Gal), 70.8 (C-3Fuc), 72.4 (C-4Fuc), 74.8 (C-5Gal), 76.3 (C-1Fuc), 79.4 (C-2Lac), 
83.4 (C-3Gal), 85.6 (C-3Cyc), 103.8 (C-1Gal) , 183.5 (COONa); 
 
MS (2.02 eV, ES): calcd for C28H48NaO12 [M+ + H]: 599.67; found: 599.56. 
 
 
Sodium (2S)-3-cyclohexyl-2-O-{1-O-[(2R,3R,4R)-4-
hydroxy-2-methyl-3-(α-L-fucopyranosyl-methyl)-
tetrahydropyran-4-yl]-β-D-galactopyranos-3-yl} 
propanoate (82) and  
sodium (2R)-3-cyclohexyl-2-O-{1-O-[(2R,3R,4R)-4-
hydroxy-2-methyl-3-(α-L-fucopyranosyl-methyl)-tetrahydropyran-4-yl]-β-D-galacto-
pyranos-3-yl} propanoate (147):  
 
Method A (microwave oven) (II-241, cm295/296): Under argon, 141 (9.00 mg, 12.7 µmol) 
was dissolved in methanol (4 ml) in a microwave tube and a solution of NaOMe in MeOH (1 
M, 150 µl) was added. The solution was then radiated in the microwave oven at 70°C for 4 h 
OMe
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and stirred without radiation at room temperature for 15 h. The reaction was neutralized with 
amberlyste ion-exchange resin (H+ form), filtered, concentrated and dissolved in a mixture of 
dioxane and water (1:1, 2 ml). After adding LiOH (10.0 mg, 0.400 mmol), the reaction mixture 
was stirred for 3 h at room temperature, acidified to pH 4-5 with diluted acetic acid, passed 
over Dowex 50x8 ion-exchange resin (Na+ form), purified by RP-18 reversed-phase silica gel 
chromatography (gradient MeOH/H2O 0:1 → 1:0) and P2 column chromatography to yield a 
1:1 mixture of the two diastereomers 82 (F II, Rf = 0.12) and 147 (F I, Rf = 0.24) (7.00 mg, 
11.4 µmol, 89%). 
 
Method B (toluene/methanol) (II-246, cm301): Under an atmosphere of argon, 141 (6.00 
mg, 8.00 µmol) was dissolved in toluene/methanol (10 ml, 1:1) and a solution of NaOMe in 
MeOH (1M, 600 µl) was added. After stirring at room temperature for 26 h, the reaction was 
neutralized with amberlyste ion-exchange resin (H+ form), filtered through celite, 
concentrated and passed over Dowex 50x8 ion-exchange resin (Na+ form). Purification by 
RP-18 reversed-phase silica gel chromatography (gradient MeOH/H2O 0:1 → 1:0) and P2 
column chromatography yielded 82 (Rf = 0.12) (4.00 mg, 6.40 µmol, 80%). 
 
147 (F I): 
Rf = 0.24 (CH2Cl2/MeOH 2:1); 
 
1H NMR (500 MHz, D2O): δ 0.82-1.80 (m, 11 H, H-4Lac, H-5a+bLac, H-6a+bLac, H-7a+bLac, H-8a+bLac, 
H-9a+bLac), 1.17 (d, 3J5,6 = 6.6 Hz, 3 H, H-6Fuc), 1.22 (d, 3J5,6 = 5.9 Hz, 3 H, H-6Pyr), 1.37 (m, 1 
H, H-4Pyr), 1.40 (m, 1 H, H-7aPyr), 1.52 (m, 1 H, H-3aLac), 1.58 (m, 1 H, H-2aPyr), 1.63 (m, 1 H, 
H-3bLac), 2.10 (m, 1 H, H-2bPyr), 2.19 (m, 1 H, H-7bPyr), 3.37 (m, 2 H, H-3Gal, H-5Pyr), 3.48 (ddd, 
J = 1.9 Hz, 11.6 Hz, 12.3 Hz, 1 H, H-1aPyr), 3.55 (m, 2 H, H-2Gal, H-5Gal), 3.71 (m, 2 H, H-
6a+bGal), 3.75 (m, 1 H, H-4Fuc), 3.76 (m, 2 H, H-3Fuc, H-3Pyr), 3.92 (dd, 3J1,2 = 5.6 Hz, 3J2,3 = 10.1 
Hz, 1 H, H-2Fuc), 3.96 (m, 1 H, H-1bPyr), 4.03 (m, 3 H, H-4Gal, H-2Lac, H-1Fuc), 4.29 (dq, 3J4,5 = 
0.6 Hz, 3J5,6 = 6.6 Hz, 1 H, H-5Fuc), 4.48 (d, 3J1,2 = 7.8 Hz, 1 H, H-1Gal);  
 
13C NMR (125 MHz, D2O): δ 16.4 (C-6Fuc), 19.1 (C-6Pyr), 22.7 (C-7Pyr), 26.9, 27.2, 27.8, 33.4, 
34.0, 34.9 (6 C, C-4Lac, C-5Lac, C-6Lac, C-7Lac, C-8Lac, C-9Lac), 31.5 (C-2Pyr), 33.8 (C-3Lac), 44.5 
(C-4Pyr), 61.9 (C-6Gal), 65.7 (C-1Pyr), 66.4 (C-4Gal), 67.1 (C-5Fuc), 68.3 (C-2Fuc), 69.7 (C-2Gal), 
70.0 (C-3Fuc), 72.4 (C-4Fuc), 75.2 (C-5Gal), 75.4 (C-1Fuc), 76.9 (C-3Pyr), 78.3 (C-2Lac), 78.5 (C-
5Pyr), 81.6 (C-3Gal), 100.0 (C-1Gal) , 182.8 (COONa); 
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MS (API-ES, neg. mode):calcd for C28H27O13 [M - Na+]: 591.66; found: 591.30. 
 
82 (F II): 
Rf = 0.12 (CH2Cl2/MeOH 2:1); 
 
1H NMR (500 MHz, D2O): δ 0.82-1.80 (m, 11 H, H-4Lac, H-5a+bLac, H-6a+bLac, H-7a+bLac, H-8a+bLac, 
H-9a+bLac), 1.15 (d, 3J5,6 = 6.6 Hz, 3 H, H-6Fuc), 1.22 (d, 3J5,6 = 5.9 Hz, 3 H, H-6Pyr), 1.37 (m, 1 
H, H-4Pyr), 1.40 (m, 1 H, H-7aPyr), 1.52 (m, 1 H, H-3aLac), 1.58 (m, 1 H, H-2aPyr), 1.63 (m, 1 H, 
H-3bLac), 2.09 (m, 1 H, H-2bPyr), 2.17 (m, 1 H, H-7bPyr), 3.37 (m, 2 H, H-3Gal, H-5Pyr), 3.48 (ddd, 
J = 1.9 Hz, 11.6 Hz, 12.3 Hz, 1 H, H-1aPyr), 3.53 (dd, 3J1,2 = 7.8 Hz, 3J2,3 = 9.4 Hz, 1 H, H-2Gal), 
3.60 (m, 1 H, H-5Gal), 3.72 (m, 3 H, H-6a+bGal, H-3Pyr), 3.75 (m, 2 H, H-3Fuc, H-4Fuc), 3.88 (m, 1 
H, H-4Gal), 3.95 (m, 2 H, H-2Fuc, H-2Lac), 3.99 (m, 1 H, H-1bPyr), 4.02 (ddd, 3J1,2 = 5.6 Hz, 3J1,7a 
= 2.8 Hz, 3J1,7b = 11.9 Hz, 1 H, H-1Fuc), 4.29 (dq, 3J4,5 = 0.6 Hz, 3J5,6 = 6.6 Hz, 1 H, H-5Fuc), 
4.46 (d, 3J1,2 = 7.8 Hz, 1 H, H-1Gal); 
 
13C NMR (125 MHz, D2O): δ 16.4 (C-6Fuc), 19.1 (C-6Pyr), 21.8 (C-7Pyr), 26.3, 27.5, 27.8, 33.6, 
34.2, 34.4 (6 C, C-4Lac, C-5Lac, C-6Lac, C-7Lac, C-8Lac, C-9Lac), 31.5 (C-2Pyr), 33.3 (C-3Lac), 44.6 
(C-4Pyr), 61.5 (C-6Gal), 65.9 (C-1Pyr), 66.1 (C-4Gal), 66.8 (C-5Fuc), 68.4 (C-2Fuc), 69.8 (C-3Fuc), 
70.2 (C-2Gal), 72.7 (C-4Fuc), 74.8 (C-5Gal), 75.6 (C-1Fuc), 77.2 (C-3Pyr), 78.6 (C-5Pyr), 79.2 (C-
2Lac), 83.6 (C-3Gal), 100.3 (C-1Gal) , 182.9 (COONa); 
 
MS (API-ES, neg. mode):calcd for C28H27O13 [M - Na+]: 591.66; found: 591.30. 
 
 
α-Methylene cyclohexanone (83) and Diels-
Alder adduct (103) [308] (I-100, cm017):  
Under argon, 102 (254 mg, 1.00 mmol) and 
PPh3 (52.0 mg, 0.200 mmol) were dissolved in acetonitrile (20 ml). Pd2(dba)3.CHCl3 (50.0 
mg, 0.050 mmol) was added and the reaction mixture was stirred for 20 min at room 
temperature. The dark yellow solution was filtered through a short silica gel column and the 
solvent was evaporated at room temperature. The remaining colorless oil was distilled 
(Kugelrohr) under vacuum at 100-120 °C and used instantly for the radical coupling reaction.  
OO
O
CH2
+
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83:  
1H NMR (500 MHz, CDCl3): δ 1.69-1.78 (m, 2 H, CH2), 1.83-1.91 (m, 2 H, CH2), 2.30-2.48 (m, 
2 H, CH2), 2.52-2.57 (m, 2 H, CH2-CO), 5.14 (d, 2J = 1.9 Hz, 1 H, CH2-Ha), 5.83 (d, 2J = 1.9 
Hz, 1 H, CH2-Hb); 
 
13C NMR (125 MHz, CDCl3): δ  23.6, 24.8, 33.7 (3 CH2), 41.3 (CH2-CO), 119.2 (C=CH2), 
146.0 (C=CH2), 202.4 (CO). 
 
103:  
1H NMR (500 MHz, CDCl3): δ 1.40-2.06 (m, 17 H), 2.13 (m, 1 H, CH2-Ha), 2.26 (m, 1 H, CH2-
CO-Ha), 2.75 (m, 1 H, CH2-CO-Hb); 
 
13C NMR (125 MHz, CDCl3): δ 21.2, 23.2, 23.3, 23.5, 27.9, 28.2, 28.8, 29.3, 39.2 (9 CH2), 
40.0 (CH2-CO), 80.0 (Cquart.), 105.3 (C=C-O), 145.1 (C=C-O), 212.5 (CO). 
 
 
(2R)-2-Methyl-3-methylene-
tetrahydropyran-4-on (84) and dimer 115 
(II-189, cm246):  
Under an atmosphere of argon, 114 (60.0 
mg, 0.470 mmol) was dissolved in CH2Cl2 
(10 ml) containing 3Å molecular sieves. 
After 15 min, PDC (50.0 mg, 0.130 mmol) was added and the mixture was stirred for 16 h at 
room temperature. The reaction was stopped by filtration through celite and 84 (54.0 mg, 
0.420 mmol, 90%) was isolated by evaporation of the solvent and instantly used in the 
subsequent radical reaction without further purification. Upon longer storage of the product 
solution, dimer 115 is formed. 
 
84: 
1H NMR (500 MHz, CDCl3): δ 1.44 (d, 3J5,6 = 6.3 Hz, 3 H, CH3), 2.52 (ddd, 3J1ax,2eq = 3.4 Hz, 
3J1eq,2eq = 2.2 Hz, 2J2ax,2eq = 17.6 Hz, 1 H, H-2eq), 2.69 (ddd, 3J1ax,2ax = 11.3 Hz, 3J1eq,2ax = 7.2 
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Hz, 2J2ax,2eq = 17.6 Hz, 1 H, H-2ax), 3.86 (ddd, 2J1ax,1eq = 11.9 Hz, 3J1ax,2eq = 3.4 Hz, 3J1ax,2ax = 
11.3 Hz, 1 H, H-1ax), 4.20 (ddd, 2J1ax,1eq = 11.9 Hz, 3J1eq,2eq = 2.2 Hz, 3J1eq,2ax = 7.2 Hz, 1 H, H-
1eq), 4.44 (q, 3J5,6 = 6.3 Hz, H-5), 5.30 (d, 2J = 2.2 Hz, 1 H, CH2-Ha), 6.12 (d, 2J = 2.2 Hz, 1 H, 
CH2-Hb); 
 
13C NMR (125 MHz, CDCl3): δ 19.0 (C-6), 39.1 (C-2), 63.0 (C-1), 73.9 (C-5), 119.2 (C=CH2), 
145.8 (C-4), 195.9 (C-3); 
 
1H NMR (500 MHz, C6D6): δ 1.15 (d, 3J5,6 = 6.3 Hz, 3 H, CH3), 2.04 (ddd, 3J1ax,2eq = 3.4 Hz, 
3J1eq,2eq = 2.2 Hz, 2J2ax,2eq = 17.6 Hz, 1 H, H-2eq), 2.26 (ddd, 3J1ax,2ax = 11.3 Hz, 3J1eq,2ax = 7.2 
Hz, 2J2ax,2eq = 17.6 Hz, 1 H, H-2ax), 3.19 (ddd, 2J1ax,1eq = 11.9 Hz, 3J1ax,2eq = 3.4 Hz, 3J1ax,2ax = 
11.3 Hz, 1 H, H-1ax), 3.63 (ddd, 2J1ax,1eq = 11.9 Hz, 3J1eq,2eq = 2.2 Hz, 3J1eq,2ax = 7.2 Hz, 1 H, H-
1eq), 3.94 (q, 3J5,6 = 6.3 Hz, H-5), 4.78 (d, 2J = 1.8 Hz, 1 H, CH2-Ha), 6.01 (d, 2J = 1.8 Hz, 1 H, 
CH2-Hb); 
 
13C NMR (125 MHz, C6D6): δ 18.6 (C-6), 38.8 (C-2), 62.5 (C-1), 73.5 (C-5), 117.7 (C=CH2), 
148.8 (C-4), 193.9 (C-3). 
 
115: 
1H NMR (500 MHz, CDCl3): δ 1.20 (d, J = 6.5 Hz, 3 H, H-6), 1.28 (d, J = 6.3 Hz, 3 H, H-15), 
1.59 (m, 1 H, H-8a), 1.94 (m, 1 H, H-8b), 2.00 (m, 1 H, H-7a), 2.14 (m, 1 H, H-2a), 2.22 (ddd, J 
= 2.0 Hz, 5.2 Hz, 13.3 Hz, 1 H, H-7b), 2.27 (m, 1 H, H-2b), 2.45 (ddd, J = 2.3 Hz, 3.4 Hz, 13.7 
Hz, 1 H, H-11a), 2.84 (ddd, J = 7.2 Hz, 11.4 Hz, 13.7 Hz, 1 H, H-11b), 3.71 (q, J = 6.3 Hz, 1 
H, H-14), 3.73 (ddd, J = 7.9 Hz, 8.1 Hz, 11.3 Hz, 1 H, H-12a), 3.76 (ddd, J = 4.6 Hz, 7.9 Hz, 
11.2 Hz, 1 H, H-1a), 3.97 (ddd, J = 4.4 Hz, 5.6 Hz, 11.2 Hz, 1 H, H-1b), 4.10 (q, J = 6.5 Hz, 
1H, H-5), 4.18 (m, 1 H, H-12b);  
13C NMR (125 MHz, CDCl3): δ 14.4 (C-15), 17.5 (C-8), 19.6 (C-6), 22.4 (C-7), 29.7 (C-2), 
40.1 (C-11), 62.2 (C-1), 66.9 (C-12), 71.2 (C-5), 79.7 (C-14), 83.7 (C-9), 106.5 (C-4), 143.9 
(C-3), 205.1 (C-10). 
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1,2,3,4-Tetra-O-acetyl-L-fucopyranoside (91) (I-123, cm032):  
A solution of L-fucose (1.00 g, 6.10 mmol) in dry pyridine (10 ml) and 
acetic anhydride (5 ml) was stirred at room temperature for 7 h. After 
dilution with ethyl acetate (100 ml), the mixture was washed with water (50 ml), 10% HCl (2 x 
50 ml) and satd. aqueous NaHCO3 (50 ml). Evaporation of the solvent and chromatography 
on silica gel (petroleum ether/ethyl acetate 3:1) yielded 91 (1.92 g, 5.8 mmol, 95 %, α:β = 
5:1). 
 
Rf = 0.65 (petroleum ether/ethyl acetate 1:1); 
 
91-α:  
1H NMR (500 MHz, CDCl3): δ 1.17 (d, 3J5,6 = 6.3 Hz, 3 H, H-6), 2.01, 2.02, 2.14, 2.17 (4 s, 12 
H, 4 CH3CO), 4.27 (dq, 3J4,5 = 0.7 Hz, 3J5,6 = 6.3 Hz, 1 H, H-5), 5.34 (m, 3 H, H-2, H-3, H-4), 
6.35 (d, 3J1,2 = 2.8 Hz, H-1); 
 
13C NMR (125 MHz, CDCl3): δ 16.3 (C-6), 20.9, 21.0, 21.2, 21.4 (4 CH3), 66.8 (C-3), 67.6 (C-
5), 68.2 (C-4), 70.9 (C-2), 90.3 (C-1), 169.5, 169.8, 170.4, 170.9 (4 COO); 
 
91-β:  
1H NMR (500 MHz, CDCl3): δ 1.24 (d, 3J5,6 = 6.7 Hz, 3 H, H-6), 1.98, 2.04, 2.12, 2.19 (4 s, 12 
H, 4 CH3CO), 3.95 (dq, 3J4,5 = 1.1 Hz, 3J5,6 = 6.7 Hz, 1 H, H-5), 5.34 (m, 3 H, H-2, H-3, H-4), 
5.64 (d, 3J1,2 = 8.4 Hz, 1 H, H-1);  
 
13C NMR (125 MHz, CDCl3): δ 14.5 (C-6), 21.0, 21.1, 21.3, 21.4 (4 CH3), 68.3 (C-3), 70.3 (C-
5), 70.6 (C-4), 71.6 (C-2), 92.5 (C-1), 169.8, 170.3, 170.6, 170.9 (4 COO). 
 
 
2,3,4-Tri-O-acetyl-α-L-fucopyranosylbromide (92) (I-127, cm036):  
To a solution of 91 (720 mg, 2.20 mmol) in CH2Cl2 (10 ml), HBr/HOAc 
(33%, 4 ml) in CH2Cl2 (4 ml) was added dropwise at 0°C. The mixture 
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was stirred for 15 min at 0°C and further 2 h at room temperature. Dilution with CH2Cl2 (50 
ml) followed by washing of the organic layer with water (50 ml) and satd. aqueous KHCO3 (2 
x 50 ml) gave, after drying with Na2SO4 and evaporation of the solvent, 0.830 g crude 
product. Column chromatography (petroleum ether/ethyl acetate 3:1) yielded α-L-
fucosylbromide (92) (760 mg, 1.86 mmol, 86%). 
 
Rf = 0.45 (petroleum ether / ethyl acetate  3:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.21 (d, 3J5,6 = 6.5 Hz, 3 H, H-6), 2.03, 2.10, 2.18 (3 s, 9 H, 3 
CH3CO), 4.40 (dq, 3J4,5 = 1.4 Hz, 3J5,6 = 6.5 Hz, 1 H, H-5), 5.02 (dd, 3J1,2 = 4.0 Hz, 3J2,3 = 10.4 
Hz, 1 H, H-2), 5.36 (dd, 3J3,4 = 3.2 Hz, 3J4,5 = 1.4 Hz, 1 H, H-4), 5.41 (dd, 3J2,3 = 10.4 Hz, 3J3,4 
= 3.2 Hz, 1 H, H-3), 6.69 (d, 3J1,2 = 4.0 Hz, 1 H, H-1); 
 
13C NMR (125 MHz, CDCl3): δ 15.6 (C-6), 20.4, 20.6, 20.7 (3 CH3), 67.8, 68.7, 69.6, 69.9 (C-
2, C-3, C-4, C-5), 89.4 (C-1), 169.7, 169.9, 170.3 (3 CO). 
 
 
1,2,3,4-Tetra-O-benzoyl-α-L-fucopyranoside (93) (II-48, cm101):  
L-fucose (1.60 g, 9.76 mmol) was dissolved in pyridine (25 ml) under 
argon and cooled to 0°C. Benzoylchloride (6.88 g, 5.70 ml, 49.0 
mmol) was added dropwise and the reaction mixture was stirred for 3 
h at 0°C and for 1 h at room temperature. Dilution with ethyl acetate (100 ml), washing of the 
organic phase with satd. aqueous NaHCO3 (3 x 100 ml), 10% HCl (3 x 100 ml) and sat. 
CuSO4 (3 x 50 ml), drying with Na2SO4, filtration and evaporation of the solvent gave a yellow 
foam. Purification by silica gel chromatography (petroleum ether/ethyl acetate 6:1) and 
recrystallization from hot ethanol yielded 93 (5.43 g, 9.36 mmol, 96 %). 
 
Rf = 0.35 (petroleum ether/ethyl acetate 4:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.34 (d, 3J5,6 = 6.5 Hz, 3 H, CH3), 4.64 (dq, 3J4,5 = 1.2 Hz, 3J5,6 = 
6.5 Hz, 1 H, H-5), 5.90 (dd, 3J3,4 = 3.0 Hz, 3J4,5 = 1.2 Hz, 1 H, H-4), 6.00 (dd, 3J1,2 = 3.6 Hz, 
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3J2,3 = 10.7 Hz, 1 H, H-2), 6.07 (dd, 3J2,3 = 10.7 Hz, 3J3,4 = 3.0 Hz, 1 H, H-3), 6.88 (d, 3J1,2 = 
3.6 Hz, 1 H, H-1), 7.20-8.20 (m, 20 H, 4 C6H5). 
 
 
2,3,4-Tri-O-benzoyl-α-L-fucopyranosylbromide (94) (II-13, cm068):  
Under argon, 93 (3.82 g, 6.58 mmol) was dissolved in CH2Cl2 (15 ml) 
and cooled to 0°C. HBr/HOAc (7 ml, 35.0 mmol) was added dropwise 
over a period of 15 min. The ice bath was removed and the reaction 
mixture was stirred for 2 h. The mixture was diluted with CH2Cl2 (100 ml) and washed with 
water (60 ml) and satd. aqueous NaHCO3 (60 ml). After drying of the organic layer with 
Na2SO4, filtration and evaporation of the solvent, 94 (3.46 g, 6.41 mmol, 97.5 %) was 
obtained. 
 
Rf = 0.76 (petroleum ether/ethyl acetate 2:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.35 (d, 3J5,6 = 6.6 Hz, 3 H, H-6), 4.68 (dq, 3J4,5 = 2.0 Hz, 3J5,6 = 
6.6 Hz, 1 H, H-5), 5.62 (dd, 3J1,2 = 3.7 Hz, 3J2,3 = 10.7 Hz, 1 H, H-2), 5.84 (dd, 3J3,4 = 3.1 Hz, 
3J4,5 = 2.0 Hz, 1 H, H-4), 6.01 (dd, 3J2,3 = 10.1 Hz, 3J3,4 = 3.1 Hz, 1 H, H-3), 6.94 (d, 3J1,2 = 3.7 
Hz, 1 H, H-1), 7.16-8.23 (m, 15 H, 3 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 16.2 (C-6), 69.0 (C-2), 69.6 (C-3), 70.8 (C-5), 71.2 (C-4), 89.8 
(C-1), 128.2, 128.9, 129.0, 130.1, 130.3, 130.4, 131.3, 131.7, 132.1, 133.7, 134.0, 134.1 (18 
C, 3 C6H5), 164.8, 165.3, 165.6 (3 CO). 
 
 
1,2,3-Tri-O-pivaloyl-β-L-fucopyranoside (95) (II-51, cm104):  
To a solution of L-fucose (500 mg, 3.05 mmol) in pyridine (10 ml), 
pivaloylchloride (1.84 g, 1.88 ml, 15.2 mmol) was added dropwise at 
0°C. After stirring at 0°C for 2 h, at room temperature for 16 h and at 50°C for 4 h, the 
reaction was diluted with CH2Cl2 (50 ml). Washing of the organic layer with sat. aqueous 
NaHCO3 (3 x 50 ml), 10% HCl (3 x 50 ml) and sat. aqueous CuSO4 (2 x 50 ml), drying with 
Na2SO4, filtration and evaporation of the solvent lead to the crude product, which was purified 
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by silica gel chromatography (petroleum ether/ethyl acetate 4:1) to yield 95 (750 mg, 1.80 
mmol, 59%). 
 
Rf = 0.29 (petroleum ether/ethyl acetate 4:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.06, 1.12, 1.14 (3 s, 27 H, 3 CMe3), 1.28 (d, 3J5,6 = 6.4 Hz, 3 H, 
H-6), 3.79 (dq, 3J4,5 = 1.0 Hz, 3J5,6 = 6.4 Hz, 1 H, H-5), 3.82 (dd, 3J3,4 = 3.2 Hz, 3J4,5 = 1.0 Hz, 1 
H, H-4), 4.92 (dd, 3J2,3 = 10.3 Hz, 3J3,4 = 3.2 Hz, 1 H, H-3), 5.34 (dd, 3J1,2 = 8.1 Hz, 3J2,3 = 10.3 
Hz, 1 H, H-2), 5.58 (d, 3J1,2 = 8.1 Hz, 1 H, H-1). 
 
 
1,2,3,4-Tetra-O-pivaloyl-β-L-fucopyranoside (96) (II-52, cm105):  
95 (700 mg, 1.68 mmol) and DMAP (82.0 mg, 0.670 mmol) were 
dissolved in pyridine (8 ml). At room temperature pivaloylchloride (608 
mg, 620 µl, 5.04 mmol) was added slowly and the reaction was stirred at 70 °C for 24 h and 
at room temperature for 48 h. Completion of the reaction was monitored by TLC. Work-up 
was performed as in the previous reaction (→ 95). Crystallization of the crude product from 
hot ethanol yielded crystalline 96 (801 mg, 1.60 mmol, 95 %). 
 
Rf = 0.60 (petroleum ether/ethyl acetate 4:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.12, 1.13 (2 s, 18 H, 2 CMe3), 1.18 (d, 3J5,6 = 6.0 Hz, 3 H, 
CH3), 1.21, 1.30 (2 s, 18 H, 2 CMe3), 3.95 (dq, 3J4,5 = 0.6 Hz, 3J5,6 = 6.0 Hz, 1 H, H-5), 5.14 
(dd, 3J2,3 = 10.4 Hz, 3J3,4 = 3.3 Hz, 1 H, H-3), 5.26 (dd, 3J3,4 = 3.3 Hz, 3J4,5 = 0.6 Hz, 1 H, H-4), 
5.35 (dd, 3J1,2 = 8.2 Hz, 3J2,3 = 10.4 Hz, 1 H, H-2), 5.79 (d, 3J1,2 = 8.2 Hz, 1 H, H-1); 
 
13C NMR (125 MHz, CDCl3): δ 16.3 (C-6), 27.3, 27.4, 27.5, 27.6 (12 C, 4 CMe3), 39.1, 39.2, 
39.3, 39.5 (4 CMe3), 68.1 (C-3), 70.1 (C-5), 70.7 (C-4), 71.8 (C-2), 92.6 (C-1), 176.9, 177.2, 
177.6, 177.8 (4 COO). 
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2,3,4-Tri-O-pivaloyl-α-L-fucopyranosylbromide (97) (II-53, cm106):  
To a solution of 96 (430 mg, 0.870 mmol) in CH2Cl2, HBr/HOAc (33%, 
1.00 ml) in CH2Cl2 (2 ml) was added slowly at 0°C. After stirring at room 
temperature for 15 h, the mixture was diluted with CH2Cl2 (50 ml) followed by washing with 
water (50 ml) and satd. aqueous NaHCO3 (2 x 50 ml). Evaporation of the solvent delivered 
97 (417 mg, 0.870 mmol, 100%), which was used without further purification.  
 
1H NMR (500 MHz, CDCl3): δ 1.07 (s, 9 H, CMe3), 1.12 (d, 3J5,6 = 6.6 Hz, 3 H, H-6), 1.13, 
1.21 (2 s, 18 H, 2 CMe3), 4.36 (dq, 3J4,5 = 1.2 Hz, 3J5,6 = 6.6 Hz, 1 H, H-5), 4.95 (dd, 3J1,2 = 
3.7 Hz, 3J2,3 = 10.7 Hz, 1 H, H-2), 5.31 (dd, 3J3,4 = 3.1 Hz, 3J4,5 = 1.2 Hz, 1 H, H-4), 5.43 (dd, 
3J2,3 = 10.7 Hz, 3J3,4 = 3.1 Hz, 1 H, H-3), 6.62 (d, 3J1,2 = 3.7 Hz, 1 H, H-1); 
 
13C NMR (125 MHz, CDCl3): δ 15.8 (C-6), 27.1, 27.2, 27.6, 28.2 (4 CMe3), 39.0, 39.2, 39.3, 
39.7 (4 CMe3), 67.7 (C-3), 70.4 (C-5), 70.8 (C-4), 71.5 (C-2), 89.2 (C-1), 175.3, 176.2, 177.5, 
177.9 (4 COO). 
 
 
Methyl 2-oxo-cyclohexanecarboxylate 
(99) [389] (I-112, cm024):  
In a three-necked flask equipped with 
stirrer, dropping funnel and reflux 
condenser, NaH (34.9 g, 0.768 mol, 55% suspension in oil) was washed with benzene (3 X 
20 ml) under argon. Dimethylcarbonate (71.0 g, 0.537 mol) and benzene (300 ml) were 
added and the suspension was heated to reflux. Cyclohexanone (25.9 g, 0.264 mol) in 
benzene (50 ml) was added slowly within 2 h. Stirring was continued until gas evolution 
ceased. After cooling to room temperature glacial acetic acid (60 ml) was added and the 
reaction mixture was poured onto ice. The aqueous layer was extracted with benzene (3 x 50 
ml). The combined organic layers were washed with brine and dried with Na2SO4. Benzene 
was evaporated under reduced pressure and the remaining oil distilled under reduced 
pressure (bp: 70-72°C, 1 mbar) yielding 99 (38.4 g, 0.246 mol, 82%) as a colorless oil.  
 
Rf = 0.63 (petroleum ether/ethyl acetate 5:1);  
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1H NMR (500 MHz, CDCl3): δ 1.60 (m, 2 H, CH2), 1.67 (m, 2 H, CH2), 2.20 (m, 2 H, CH2), 
2.25 (m, 2 H, COCH2), 3.73 (s, 3 H, OMe), 12.14 (s, 1 H, enol-OH); 
 
13C NMR (125 MHz, CDCl3): δ 22.3, 22.7, 22.8 (3 CH2), 29.4 (CH2C(OH)=C), 57.5 (OCH3), 
97.9 (C(OH)=CR2), 172.4 (COO), 206.5 (CO). 
 
elemental analysis calcd (%) for C8H12O3 (156.18): C 61.52, H 7.74, O 30.73;  
found: C 61.50, H 7.70, O 30.39. 
 
 
Allyl 2-oxo-cyclohexanecarboxylate (100) 
[390] (I-115, cm026):  
A solution of sodium (15.0 mg, 0.023 mmol) 
and methyl cyclohexanone-2-carboxylate (99) 
(15.6 g, 0.100 mol) in benzene (10 ml) and allyl 
alcohol (150 ml) was refluxed for 48 h with continuous removal of methanol. After completion 
of the reaction, the mixture was diluted with CH2Cl2 (200 ml), washed with brine (2 x 20 ml) 
and dried with Na2SO4. Removal of the solvent followed by distillation under reduced 
pressure (bp: 90°C at 0.04 mbar) afforded the allyl ester 100 (13.3 g, 72.9 mmol, 73%).  
 
Rf = 0.68 (petroleum ether/ethyl acetate 5:1);  
 
1H NMR (500 MHz, CDCl3): δ 1.61 (m, 2 H, CH2), 1.68 (m, 2 H, CH2), 2.26 (m, 4 H, 2 CH2), 
4.65, 4.66 (m, 2 H, COOCH2), 5.24 (dd, J = 10.4 Hz, 1.3 Hz, 1 H, CH=CH2-Ha), 5.34 (dd, J = 
17.3 Hz, 1.3 Hz, 1 H, CH=CH2-Hb), 5.94 (m 1 H, CH=CH2), 12.14 (s, 1 H, enol-OH); 
 
13C NMR (125 MHz, CDCl3): δ 21.9, 22.4, 22.5 (3 CH2), 29.2 (CH2C(OH)=C), 64.7 
(COOCH2), 97.6 (C(OH)=CR2), 117.8 (CH=CH2), 132.3 (CH=CH2), 172.3 (COO), 208.5 (CO). 
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Allyl 1-hydroxymethyl-2-oxo-cyclohexanecarboxylate (101) 
[308] (I-118, cm029):  
100 (31.0 g, 0.170 mol) was dissolved in a mixture of THF (125 ml), 
water (90 ml) and allyl alcohol (125 ml). KHCO3 (20.0 g, 0.200 mol) 
and formaldehyde (36% in water, 16.7 ml, 0.200 mol) were added 
with stirring at room temperature. After 5 h, a further portion of formalin (5 ml) was added. 
After 2 h, the mixture was diluted with CH2Cl2 (200 ml). Washing with saturated NH4Cl 
solution, drying with Na2SO4 and removal of the solvent under reduced pressure yielded 101 
(36.1 g, 0.170 mol, 100 %), which was used in the next step without further purification.  
 
Rf = 0.12 (petroleum ether/ethyl acetate 5:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.60, 2.02, 2.33, 2.44, 2.62 (m, 8 H, 4 CH2), 3.69, 3.81 (AB, 2J 
= 11.4 Hz, 2 H, CH2OH), 4.65, 4.66 (m, 2 H, COOCH2), 5.23 (dd, J = 10.4 Hz, 1.3 Hz, 1 H, 
CH=CH2-Ha), 5.31 (dd, J = 17.0 Hz, 1.3 Hz, 1 H, CH=CH2-Hb), 5.88 (m, 1 H, CH=CH2); 
 
13C NMR (125 MHz, CDCl3): δ 21.8, 26.7, 32.6, 40.8 (4 CH2), 62.4 (Cquart.), 65.9 (COOCH2), 
66.1 (CH2OH), 118.8 (CH=CH2), 131.3 (CH=CH2), 170.0 (COO), 210.4 (CO). 
 
 
Allyl 1-acetoxymethyl-2-oxo-cyclohexanecarboxylate (102) [308] 
(I-119, cm030):  
A solution of 101 (36.1 g, 170 mmol) and acetic anhydride (37.0 ml, 
360 mmol) in pyridine (100 ml) was stirred at room temperature for 4 
h. The reaction mixture was diluted with ethyl acetate (150 ml) and washed with 1N HCl (3 x 
100 ml) followed by satd. NaHCO3 solution (4 x 100 ml). The organic layer was dried with 
Na2SO4, filtered and evaporated to dryness. The crude product was purified by column 
chromatography on silica gel (petrol ether/ethyl acetate 5:1) to yield 102 (36.0 g, 150 mmol, 
88%). 
 
Rf = 0.25 (petroleum ether/ethyl acetate 5:1); 
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1H NMR (500 MHz, CDCl3): δ 1.53-1.78 (m, 4 H, 2 CH2), 2.00-2.52 (m, 4 H, 2 CH2), 1.98 (s, 3 
H, CH3), 4.21, 4.46 (AB, 2J = 11.0 Hz, 2 H, CH2OH), 4.61, 4.62 (m, 2 H, COOCH2), 5.22 (dd, 
J = 10.4 Hz, 1.3 Hz, 1 H, CH=CH2-Ha), 5.29 (dd, J = 17.0 Hz, 1.3 Hz, 1 H, CH=CH2-Hb), 5.85 
(m, 1 H, CH=CH2); 
13C NMR (125 MHz, CDCl3): δ 21.1 (CH3), 22.3, 27.5, 33.9, 41.3 (4 CH2), 60.9 (Cquart.), 66.0 
(COOCH2), 66.6 (CH2-OH), 119.5 (CH=CH2), 131.6 (CH=CH2), 169.8 (COCH3), 170.8 
(COO), 205.9 (CO). 
 
 
1,5-Anhydro-2-deoxy-D-arabino-hex-1-enitol (105) (II-95, cm148):  
3,4,5-tri-O-acetyl-D-glucal (10.0 g, 36.7 mmol) was dissolved in methanol 
(60 ml). After adding NaOMe/MeOH (1 ml, 1 M), the reaction mixture was 
stirred at room temperature for 2 h and then neutralized with amberlyste 
ion-exchange resin (H+ form). Filtration through celite, evaporation of the solvent and drying 
under vacuum yielded 105 (5.40 g, 36.7 mmol, 100%), which was used without further 
purification. 
 
1H NMR (500 MHz, CDCl3): δ 3.63 (dd, 3J3,4 = 7.1 Hz, 3J4,5 = 9.7 Hz, 1 H, H-4), 3.76 (ddd, 3J4,5 
= 9.7 Hz, 3J5,6a = 4.9 Hz, 3J5,6b = 2.7 Hz, 1 H, H-5), 3.83 (dd, 3J5,6a = 4.9 Hz, 3J6a,6b = 12.1 Hz, 1 
H, H-6a), 3.90 (dd, 3J5,6b = 2.7 Hz, 3J6a,6b = 12.1 Hz, 1 H, H-6b), 4.17 (dd, 3J2,3 = 2.2 Hz, 3J3,4 = 
7.1 Hz, 1 H, H-3), 4.70 (dd, 3J1,2 = 6.0 Hz, 3J2,3 = 2.2 Hz, 1 H, H-2), 6.34 (dd, 3J1,2 = 6.0 Hz, 
4J1,3 = 1.6 Hz, 1 H, H-1); 
 
13C NMR (125 MHz, CDCl3): δ 62.8 (C-6), 71.0 (C-4), 71.4 (C-3), 79.0 (C-5), 104.8 (C-2), 
145.5 (C-1). 
 
 
1,5-Anhydro-3-O-benzoyl-2-deoxy-6-O-tert-butyldimethylsilyl-
D-arabino-hex-1-enitol (106) (II-128, cm184):  
105 (5.40 g, 37.0 mmol) was dissolved in a mixture of pyridine (75 
ml) and CH2Cl2 (15 ml) and cooled to 0°C. TBDMSCl (6.13 g, 
40.7 mmol) in CH2Cl2 (30 ml) was added dropwise over a period of 2 h. The reaction mixture 
was stirred for 2 h at 0°C and 12 h at room temperature. Since the starting material had not 
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been used completely in the reaction, an additional portion of TBDMSCl (1.67 g, 11.1 mmol) 
in CH2Cl2 (10 ml) was added at 0°C. After stirring for 1 h at 0°C and 12 h at room 
temperature, the mixture was cooled to 0°C again and benzoylchloride (4.30 ml, 37.0 mmol) 
in CH2Cl2 (15 ml) was added dropwise. The ice cooling was removed and the reaction 
mixture stirred overnight. The reaction was then diluted with CH2Cl2 (250 ml), washed with 
5% aqueous HCl (3 x 100 ml), and with satd. aqueous NaHCO3 (3 x 200 ml). The organic 
layer was dried with Na2SO4 and evaporated. The crude material was purified on a silica gel 
column (petroleum ether/ethyl acetate 9:1) and 106 was obtained as a slightly yellow oil 
(10.1 g, 27.9 mmol, 75%). 
 
Rf = 0.32 (petroleum ether/ethyl acetate 5:1); 
 
1H NMR (500 MHz, CDCl3): δ 0.02 (s, 6 H, 2 Si-CH3), 0.81 (s, 9 H, Si-CMe3), 3.43 (s, 1 H, 
OH), 3.81-3.94 (m, 3 H, H-5, H-6a+b), 4.03 (dd, 3J3,4 = 6.6 Hz, 3J4,5 = 6.7 Hz, 1 H, H-4), 4.72 
(dd, 3J1,2 = 6.0 Hz, 3J2,3 = 2.5 Hz, 1 H, H-2), 5.44 (dd, 3J2,3 = 2.5 Hz, 3J3,4 = 6.7 Hz, 1 H, H-3), 
6.38 (d, 3J1,2 = 6.0 Hz, 1 H, H-1), 7.25-7.98 (m, 5 H, C6H5); 
 
13C NMR (125 MHz, CDCl3): δ -4.9 (2 C, 2 Si-CH3), 18.8 (Si-CMe3), 26.2 (3 C, Si-CMe3), 63.2 
(C-6), 68.8 (C-4), 74.0 (C-3), 78.2 (C-5), 99.2 (C-2), 128.7, 130.2, 130.3, 133.6 (6 C, C6H5), 
146.6 (C-1), 167.9 (CO). 
 
 
1,5-Anhydro-3-O-benzoyl-4-O-benzyl-2-deoxy-6-O-tert-
butyldimethylsilyl-D-arabino-hex-1-enitol (107) (II-185, cm242):   
NaH (3.04 g, 69.6 mmol, 55% suspension in oil) was washed with 
hexane (3 x 10 ml) under argon and was suspended in DMF (100 
ml). Benzylbromide (9.14 ml, 75.4 mmol) was added. 106 (21.1 g, 58.8 mmol) was dissolved 
in DMF (100 ml) and added dropwise to the NaH suspension within 45 min. The mixture was 
stirred until TLC control showed complete consumption of the starting material (2 h). The 
reaction was quenched with MeOH (50 ml) and extracted with CH2Cl2 (3 x 50 ml). The 
organic layer was dried with Na2SO4, evaporated and purified on a silica gel column 
(petroleum ether/ethyl acetate 7:1) to obtain 107 (21.1 g, 46.4 mmol, 80%). 
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Rf = 0.58 (petroleum ether/ethyl acetate 6:1); 
 
[ ]21 D α  = -106.0 (c = 1.85, CHCl3); 
 
1H NMR (500 MHz, CDCl3): δ 0.02, 0.03 (2 s, 6 H, 2 Si-CH3), 0.82 (s, 9 H, Si-CMe3), 3.85-
4.02 (m, 4 H, H-4, H-5, H-6a+b), 4.67, 4.71 (AB, 2JA,B = 11.4 Hz, 2 H, CH2-Ph), 4.79 (dd, 3J1,2 = 
6.0 Hz, 3J2,3 = 3.1 Hz, 1 H, H-2), 5.58 (m, 1 H, H-3), 6.39 (d, 3J1,2 = 6.0 Hz, 1 H, H-1), 7.06-
7.98 (m, 10 H, 2 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ -4.9, -4.8 (2 C, 2 Si-CH3), 18.8 (Si-CMe3), 26.2 (3 C, Si-CMe3), 
61.6 (C-6), 71.0 (C-3), 73.2 (CH2-Ph), 73.9 (C-4), 78.3 (C-5), 99.0 (C-2), 128.1, 128.3, 128.7, 
128.8, 130.0, 130.5, 133.4, 138.3 (12 C, 2 C6H5), 146.4 (C-1), 166.5 (CO). 
 
elemental analysis calcd (%) for C26H34O5Si (454.64): C 68.69, H 7.54, O 17.60;  
found: C 68.43, H 7.56. 
 
 
1,5-Anhydro-3-O-benzoyl-4-O-benzyl-2-deoxy-D-arabino-hex-1-enitol 
(108) (II-187, cm244): 
To a solution of 107 (200 mg, 0.440 mmol) in THF (5 ml) TBAF (1 M in 
THF, 830 µl) was added dropwise under vigorous stirring at 0°C under 
argon. The mixture was then stirred 1 h at 0°C and 2 h at room temperature, diluted with 
CH2Cl2 (20 ml), washed with satd. aqueous NaHCO3 (50 ml), dried with Na2SO4, filtered and 
concentrated. Purification by silica gel column chromatography (petroleum ether/ethyl 
acetate 3:1) yielded 108 (127 mg, 0.370 mmol, 84%). 
 
Rf = 0.17 (petroleum ether/ethyl acetate 4:1); 
 
1H NMR (500 MHz, CDCl3): δ 2.15 (s, 1 H, OH), 3.93 (dd, 3J5,6a = 2.8 Hz, 2J6a,6b = 11.9 Hz, 1 
H, H-6a), 3.97 (dd, 3J5,6b = 3.7 Hz, 2J6a,6b = 11.9 Hz, 1 H, H-6b), 4.06 (m, 2 H, H-4, H-5), 4.72, 
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4.78 (AB, 2JA,B = 11.3 Hz, 2 H, CH2-Ph), 4.89 (dd, 3J1,2 = 5.9 Hz, 3J2,3 = 2.8 Hz, 1 H, H-2), 
5.73 (m, 1 H, H-3), 6.46 (d, 3J1,2 = 5.9 Hz, 1 H, H-1), 7.22-8.01 (m, 10 H, 2 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 61.7 (C-6), 72.3 (C-3), 73.6 (C-4), 74.1 (CH2-Ph), 78.3 (C-5), 
100.2 (C-2), 128.3, 128.4, 128.9, 129.0, 130.0, 130.4, 133.6, 138.0 (12 C, 2 C6H5), 146.0 (C-
1), 166.5 (CO). 
 
 
1,5-Anhydro-3-O-benzoyl-4-O-benzyl-2,6-dideoxy-6-iodo-D-arabino-
hex-1-enitol (109) (II-191, cm248):  
Imidazole (3.28 g, 48.2 mmol), PPh3 (11.1 g, 42.8 mmol) and 108 (8.70 g, 
25.6 mmol) were dissolved in CH2Cl2 (250 ml) under argon and cooled to 
0°C. Iodine (9.78 g, 38.5 mmol) was added and the reaction mixture was stirred for 30 min at 
0°C and 10 h at room temperature. Diluting with CH2Cl2 (250 ml), washing with satd. 
aqueous NaHCO3 (200 ml), drying with Na2SO4, evaporation of the solvent under reduced 
pressure and silica gel column chromatography (petroleum ether/ethyl acetate 7:1) yielded 
109 (9.66 g, 21.5 mmol, 84 %). 
 
Rf = 0.66 (petroleum ether/ethyl acetate 4:1); 
 
[ ]21 D α  = -41.8 (c = 1.03, CHCl3); 
 
1H NMR (500 MHz, CDCl3): δ 3.57 (dd, 3J5,6a = 4.7 Hz, 2J6a,6b = 10.7 Hz, 1 H, H-6a), 3.61 (dd, 
3J5,6b = 4.7 Hz, 2J6a,6b = 10.7 Hz, 1 H, H-6b), 3.85 (dt, 3J4,5 = 7.5 Hz, 3J5,6a = 4.7 Hz, 3J5,6b = 4.7 
Hz, 1 H, H-5), 4.07 (dd, 3J3,4 = 5.6 Hz, 3J4,5 = 7.5 Hz, 1 H, H-4), 4.77, 4.83 (AB, 2JA,B = 11.0 
Hz, 2 H, CH2-Ph), 4.95 (dd, 3J1,2 = 5.9 Hz, 3J2,3 = 2.8 Hz, 1 H, H-2), 5.71 (dd, 3J2,3 = 2.8 Hz, 
3J3,4 = 5.6 Hz, 1 H, H-3), 6.49 (d, 3J1,2 = 5.9 Hz, 1 H, H-1), 7.30-8.05 (m, 10 H, 2 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 5.89 (C-6), 71.3 (C-3), 74.3 (CH2-Ph), 75.9 (C-5), 76.5 (C-4), 
100.0 (C-2), 128.5, 128.6, 128.9, 130.6, 131.9, 132.7, 133.0, 137.8 (12 C, 2 C6H5), 145.8 (C-
1), 166.4 (CO). 
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1,5-Anhydro-3-O-benzoyl-4-O-benzyl-2,6-dideoxy-D-arabino-hex-1-
enitol (110) (II-106, cm160):   
To a solution of 109 (400 mg, 0.890 mmol) in benzene (25 ml), AIBN (15.0 
mg, 0.090 mmol) and Bu3SnH (388 mg, 353 µl, 1.33 mmol) were added and 
the reaction was stirred under reflux for 20 h. Benzene was removed under reduced 
pressure, the remaining oil dissolved in acetonitrile and washed with hexane (3 x 20 ml). 
After concentration of the acetonitrile layer, purification by silica gel column chromatography 
(petroleum ether/ethyl acetate 10:1) yielded 110 (150 mg, 0.460 mmol, 52%). 
 
Rf = 0.37 (petroleum ether/ethyl acetate 8:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.44 (d, 3J5,6 = 6.6 Hz, 3 H, CH3), 3.71 (dd, 3J3,4 = 5.6 Hz, 3J4,5 = 
7.8 Hz, 1 H, H-4), 4.15 (dq, 3J4,5 = 7.8 Hz, 3J5,6 = 6.6 Hz, 1 H, H-5), 4.70, 4.79 (AB, 2JA,B = 
11.3 Hz, 2 H, CH2-Ph), 4.89 (dd, 3J1,2 = 5.9 Hz, 3J2,3 = 3.1 Hz, 1 H, H-2), 5.66 (dd, 3J2,3 = 3.1 
Hz, 3J3,4 = 5.6 Hz, 1 H, H-3), 6.45 (d, 3J1,2 = 5.9 Hz, 1 H, H-1), 7.28-8.03 (m, 10 H, 2 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 17.2 (C-6), 71.0 (C-3), 73.5 (CH2-Ph), 73.8 (C-5), 78.0 (C-4), 
99.0 (C-2), 127.8, 128.1, 128.4, 128.5, 129.6, 130.2, 133.1, 137.8 (12 C, 2 C6H5), 146.0 (C-
1), 166.1 (CO). 
 
 
1,5-Anhydro-3-O-benzyl-2,6-dideoxy-D-arabino-hexitol 
(111) (II-176, cm233):  
Under argon, 120 (3.25 mg, 9.96 mmol) was dissolved in methanol (12 ml). 
Pd(OH)2/C (200 mg, 0.290 mmol) was added and the suspension was 
hydrogenated (4 bar H2) at room temperature for 21 h. The reaction mixture was filtered 
through celite and evaporated. Purification of the crude product by silica gel column 
chromatography yielded 111 (2.26 g, 9.56 mmol, 97 %). 
 
Rf = 0.55 (petroleum ether/ethyl acetate 2:1); 
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[ ]21 D α  = -16.6 (c = 1.00, CHCl3);  
 
1H NMR (500 MHz, CDCl3): δ 1.33 (d, 3J5,6 = 5.9 Hz, 3 H, CH3), 1.83 (dddd, 3J1ax,2ax = 11.6 
Hz, 3J1eq,2ax = 5.0 Hz, 2J2ax,2eq = 12.8 Hz, 3J2ax,3 = 11.3 Hz, 1 H, H-2ax), 2.13 (dddd, 3J1ax,2eq = 
2.0 Hz, 3J1eq,2eq = 1.6 Hz, 2J2eq,2ax = 12.8 Hz, 3J2eq,3 = 5.2 Hz, 1 H, H-2eq), 2.99 (s, 1H, OH), 
3.32 (dq, 3J4,5 = 8.9 Hz, 3J5,6 = 5.9 Hz, 1 H, H-5), 3.37 (dd, 3J3,4 = 8.7 Hz, 3J4,5 = 8.9 Hz, 1 H, 
H-4), 3.51 (ddd, 2J1ax,1eq = 11.8 Hz, 3J1ax,2ax = 11.6 Hz, 3J1ax,2eq = 2.0 Hz, 1 H, H-1ax), 3.94 
(ddd, 2J1eq,1ax = 11.8 Hz, 3J1eq,2eq = 1.6 Hz, 3J1eq,2ax = 5.0 Hz, 1 H, H-1eq), 5.00 (ddd, 3J2ax,3 = 
11.3 Hz, 3J2eq,3 = 5.2 Hz, 3J3,4 = 8.7 Hz, 1 H, H-3), 7.27-8.06 (m, 10 H, 2 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 18.5 (C-6), 31.7 (C-2), 65.5 (C-1), 75.7 (C-3), 76.7 (C-4), 77.7 
(C-5), 128.8, 130.1, 130.2, 133.6 (6 C, C6H5), 167.4 (CO); 
 
elemental analysis calcd (%) for C13H16O4 (236.27): C 66.09, H 6.83, O 27.09;  
found: C 66.10, H 6.72, O 27.18. 
 
 
1,5-Anhydro-3-O-benzyl-2,6-dideoxy-D-threo-hex-4-ulose  
(112) (II-180, cm237):  
Under argon, 111 (140 mg, 0.590 mmol) was dissolved in CH2Cl2 (5 ml) 
containing 3Å molecular sieves and cooled to 0°C. After 5 min, glacial 
acetic acid (1 drop) was added and the mixture was stirred for further 10 min before PDC 
(240 mg, 0.640 mmol) was added. After stirring for 15 min at 0°C and 8 h at room 
temperature, the reaction was stopped by filtration through celite and washing with satd. 
aqueous CuSO4 (50 ml) and satd. aqueous NaCl (20 ml). Drying of the organic layer with 
Na2SO4, filtration, evaporation of the solvents and purification by silica gel chromatography 
(petroleum ether/ethyl acetate 3:1) yielded 112 (130 mg, 0.550 mmol, 93%). 
 
Rf = 0.61 (petroleum ether/ethyl acetate 2:1); 
 
[ ]21 D α  = +34.7 (c = 1.01, CHCl3);  
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1H NMR (500 MHz, CDCl3): δ 1.33 (d, 3J5,6 = 6.4 Hz, 3 H, CH3), 2.42 (dddd, 3J1ax,2ax = 12.3 
Hz, 3J1eq,2ax = 4.9 Hz, 2J2ax,2eq = 12.7 Hz, 3J2ax,3 = 12.5 Hz, 1 H, H-2ax), 2.53 (dddd, 3J1ax,2eq = 
2.0 Hz, 3J1eq,2eq = 1.7 Hz, 2J2eq,2ax = 12.7 Hz, 3J2eq,3 = 7.0 Hz, 1 H, H-2eq), 3.97 (ddd, 2J1ax,1eq = 
12.1 Hz, 3J1ax,2ax = 12.3 Hz, 3J1ax,2eq = 2.0 Hz, 1 H, H-1ax), 4.08 (q, 3J5,6 = 6.4 Hz, 1 H, H-5), 
4.18 (ddd, 2J1eq,1ax = 12.1 Hz, 3J1eq,2eq = 1.7 Hz, 3J1eq,2ax = 4.9 Hz, 1 H, H-1eq), 5.64 (dd, 3J2ax,3 = 
12.5 Hz, 3J2eq,3  = 7.0 Hz, 1 H, H-3), 7.43-8.13 (m, 10 H, 2 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 14.6 (C-6), 35.4 (C-2), 65.6 (C-1), 74.7 (C-3), 79.1 (C-5), 
128.8, 130.3, 130.4, 133.7 (6 C, C6H5), 165.8 (COO), 200.9 (CO); 
 
elemental analysis calcd (%) for C13H14O4 (234.25): C 66.66, H 6.02, O 27.32;  
found: C 66.49, H 6.07, O 27.44. 
 
 
1,5-Anhydro-3-O-benzyl-4-methylene-2,4,6-trideoxy-D-threo-hexitol 
(113) (II-183, cm240):  
Under argon, MePPh3Br (911 mg, 2.55 mmol) was suspended in THF (5 ml) 
and cooled to -40 °C. n-BuLi (1.6 M in hexane, 1.60 ml, 2.55 mmol) was 
added dropwise by a syringe and the reaction was stirred for 2 h at -40 °C. A solution of 112 
(200 mg, 0.850 mmol) in THF (5 ml) was added carefully. The mixture was stirred for 1 h at –
40 °C and 18 h at –5°C, quenched with satd. aqueous NH4Cl (50 ml), extracted with CH2Cl2 
(2 x 100 ml), dried with Na2SO4, filtered and concentrated. Purification on a silica gel column 
(petroleum ether/ethyl acetate 2:1) yielded 113 (100 mg, 0.430 mmol, 50%) as well as 114 
(11.0 mg, 0.090 mmol, 10%). 
 
Rf = 0.77 (petroleum ether/ethyl acetate 2:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.42 (d, 3J5,6 = 6.3 Hz, 3 H, CH3), 1.94 (dddd, 3J1ax,2ax = 12.2 
Hz, 3J1eq,2ax = 4.9 Hz, 2J2ax,2eq = 12.2 Hz, 3J2ax,3 = 11.3 Hz, 1 H, H-2ax), 2.19 (dddd, 3J1ax,2eq = 
2.0 Hz, 3J1eq,2eq = 2.0 Hz, 2J2eq,2ax = 12.2 Hz, 3J2eq,3 = 5.3 Hz, 1 H, H-2eq), 3.76 (ddd, 2J1ax,1eq = 
11.8 Hz, 3J1ax,2ax = 12.2 Hz, 3J1ax,2eq = 2.0 Hz, 1 H, H-1ax), 3.98 (q, 3J5,6 = 6.3 Hz, 1 H, H-5), 
4.10 (ddd, 2J1eq,1ax = 11.8 Hz, 3J1eq,2eq = 2.0 Hz, 3J1eq,2ax = 4.9 Hz, 1 H, H-1eq), 5.01 (d, 2J = 1.9 
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Hz, 1 H, CH2-Ha), 5.10 (d, 2J = 1.9 Hz, 1 H, CH2-Hb), 5.63 (dd, 3J2ax,3 = 11.3 Hz, 3J2eq,3 = 5.3 
Hz, 1 H, H-3), 7.26-8.16 (m, 10 H, 2 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 17.8 (C-6), 34.9 (C-2), 65.6 (C-1), 72.7 (C-3), 74.4 (C-5), 
105.9 (C=CH2), 128.8, 130.0, 130.1, 133.6 (6 C, C6H5), 146.3 (C-4), 165.9 (COO). 
 
 
1,5-Anhydro-4-methylene-2,4,6-trideoxy-D-threo-hexitol (114):  
 
Method A (II-194, cm250): Under an atmosphere of argon, 113 (79.0 mg, 
0.340 mmol) was dissolved in MeOH (5 ml) and NaOMe/MeOH (1 M, 100 
µl), was added at room temperature. The mixture was stirred for 19 h, neutralized with 
amberlyste ion-exchange resin (H+ form), filtered and evaporated under reduced pressure. 
Purification by silica gel chromatography yielded 114 (32.0 mg, 0.260 mmol, 75%). 
 
Method B (II-196, cm252): Under an atmosphere of argon, 112 (200 mg, 0.850 mmol) was 
dissolved in THF (10 ml) and cooled to –40°C. Tebbe reagent (0.5 M in THF, 5 ml, 2.55 
mmol) was added dropwise by a syringe. The reaction mixture was then stirred for 2 h at –40 
°C and 3 h at –5 °C. Remaining Tebbe reagent was quenched at 0°C with satd. aqueous 
NH4Cl (100 ml) and the aqueous layer was extracted with CH2Cl2 (2 x 50 ml). After drying 
with Na2SO4, filtration and evaporation of the solvent, purification of the crude product by 
silica gel column chromatography (petroleum ether/ethyl acetate 2:1) yielded 114 (61.0 mg, 
0.510 mmol, 60%). 
 
Rf = 0.15 (petroleum ether/ethyl acetate 2:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.38 (d, 3J5,6 = 6.3 Hz, 3 H, CH3), 1.66 (dddd, 3J1ax,2ax = 12.0 
Hz, 3J1eq,2ax = 4.9 Hz, 2J2ax,2eq = 12.2 Hz, 3J2ax,3 = 11.3 Hz, 1 H, H-2ax), 2.07 (dddd, 3J1ax,2eq = 
2.2 Hz, 3J1eq,2eq = 1.7 Hz, 2J2eq,2ax = 12.2 Hz, 3J2eq,3 = 5.3 Hz, 1 H, H-2eq), 3.63 (ddd, 2J1ax,1eq = 
11.7 Hz, 3J1ax,2ax = 12.0 Hz, 3J1ax,2eq = 2.2 Hz, 1 H, H-1ax), 3.83 (q, 3J5,6 = 6.3 Hz, 1 H, H-5), 
4.01 (ddd, 2J1eq,1ax = 11.7 Hz, 3J1eq,2eq = 1.7 Hz, 3J1eq,2ax = 4.9 Hz, 1 H, H-1eq), 4.23 (dd, 3J2ax,3 = 
11.3 Hz, 3J2eq,3 = 5.2 Hz, 1 H, H-3), 4.98 (d, 2J = 1.8 Hz, 1 H, CH2-Ha), 5.16 (d, 2J = 1.8 Hz, 1 
H, CH2-Hb); 
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13C NMR (125 MHz, CDCl3): δ 17.8 (C-6), 38.2 (C-2), 66.0 (C-1), 70.9 (C-3), 74.2 (C-5), 
104.6 (C=CH2), 151.3 (C-4). 
 
 
1,5-Anhydro-3-O-benzyl-2-deoxy-6-O-tert-butyldimethylsilyl-D-
arabino-hexitol (116) (II-130, cm186):  
To a solution of 106 (4.73 g, 13.0 mmol) in methanol (10 ml), Pd/C 
(1.00 g, 0.940 mmol) was added under an atmosphere of argon. 
The reaction mixture was shaken in a hydrogenation apparatus under an atmosphere of H2 
(4 bar) for 2 h. After filtration through celite and evaporation of the solvent the crude product 
was purified by silica gel chromatography (petroleum ether/ethyl acetate 5:1). 116 was 
isolated as colorless oil (4.76 g, 13.0 mmol, 100%). 
 
Rf = 0.27 (petroleum ether/ethyl acetate 5:1); 
 
[ ]21 D α  = -33.4 (c = 1.04, CHCl3); 
 
1H NMR (500 MHz, CDCl3): δ 0.10, 0.11 (2 s, 6 H, 2 Si-CH3), 0.91 (s, 9 H, Si-CMe3), 1.82 
(dddd, 3J1ax,2ax = 12.6 Hz, 3J1eq,2ax = 5.0 Hz, 2J2ax,2eq = 12.9 Hz, 3J2ax,3 = 11.3 Hz, 1 H, H-2ax), 
2.16 (dddd, 3J1ax,2eq = 1.8 Hz, 3J1eq,2eq = 1.5 Hz, 2J2ax,2eq = 12.9 Hz, 3J2eq,3 = 5.0 Hz, 1 H, H-2eq), 
3.34 (ddd, 3J4,5 = 9.1 Hz, 3J5,6a = 5.9 Hz, 3J5,6b = 4.4 Hz, 1 H, H-5), 3.56 (ddd, 2J1ax,1eq = 11.9 Hz, 
3J1ax,2ax = 12.6 Hz, 3J1ax,2eq = 1.8 Hz, 1 H, H-1ax), 3.79 (dd, 3J3,4 = 8.8 Hz, 3J4,5 = 9.1 Hz, 1 H, H-
4), 3.84 (dd, 3J5,6a = 5.9 Hz, 2J6a,6b = 10.4 Hz, 1 H, H-6a), 3.97 (dd, 3J5,6b = 4.4 Hz, 2J6a,6b = 10.4 
Hz, 1 H, H-6b), 4.00 (ddd, 2J1eq,1ax = 11.9 Hz, 3J1eq,2ax = 5.0 Hz, 3J1eq,2eq = 1.5 Hz, 1 H, H-1eq), 
5.11 (ddd, 3J2ax,3 = 11.3 Hz, 3J2eq,3 = 5.0 Hz, 3J3,4 = 8.8 Hz, 1 H, H-3), 7.45-8.09 (m, 5 H, C6H5); 
 
13C NMR (125 MHz, CDCl3): δ -5.4 (2 C, 2 Si-CH3), 18.3 (Si-CMe3), 25.9 (3 C, Si-CMe3), 30.9 
(C-2), 65.2 (C-6), 65.3 (C-1), 72.6 (C-4), 75.9 (C-3), 78.9 (C-5), 128.4, 129.8, 130.1, 133.1 (6 
C, C6H5), 166.7 (CO). 
 
elemental analysis calcd (%) for C19H30O5Si (366.53): C 62.26, H 8.25, O 21.83;  
found: C 62.34, H 8.32. 
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1,5-Anhydro-3-O-benzyl-4-O-benzoyl-2-deoxy-6-O-tert-
butyldimethylsilyl-D-arabino-hexitol (117) (II-158, cm216):  
NaH (1.60 g, 32.8 mmol, 55% suspension in oil) was washed with 
hexane (3 x 10 ml) under argon and then suspended in DMF (170 ml). 
At room temperature benzylbromide (4.20 ml, 34.4 mmol) and 116 (9.50 g, 25.9 mmol) were 
dissolved in DMF (120 ml) and added dropwise to the NaH suspension within 45 min. The 
mixture was stirred until TLC control showed complete consumption of the starting material 
(6 h). The reaction was quenched with satd. aqueous NH4Cl (50 ml) and extracted with 
CH2Cl2 (150 ml). The organic layer was dried with Na2SO4, evaporated and purified on a 
silica gel column (petroleum ether/ethyl acetate 7:1) to obtain 117 (8.75 g, 19.2 mmol, 75%). 
 
Rf = 0.51 (petroleum ether/ethyl acetate 4:1); 
 
[ ]21 D α  = - 38.7 (c = 1.45, CHCl3); 
 
1H NMR (500 MHz, CDCl3): δ 0.16, 0.17 (2 s, 6 H, 2 Si-CH3), 1.01 (s, 9 H, Si-CMe3), 1.84 
(dddd, 3J1ax,2ax = 12.6 Hz, 3J1eq,2ax = 4.7 Hz, 2J2ax,2eq = 12.9 Hz, 3J2ax,3 = 11.3 Hz, 1H, H-2ax), 
2.27 (dddd, 3J1ax,2eq = 2.2 Hz, 3J1eq,2eq = 1.5 Hz, 2J2ax,2eq = 12.9 Hz, 3J2eq,3 = 5.0 Hz, 1H, H-2eq), 
3.37 (ddd, 3J4,5 = 9.4 Hz, 3J5,6a = 1.8 Hz, 3J5,6b = 3.7 Hz, 1 H, H-5), 3.57 (ddd, 2J1ax,1eq = 11.6 
Hz, 3J1ax,2ax = 12.6 Hz, 3J1ax,2eq = 2.2 Hz, 1 H, H-1ax), 3.81 (dd, 3J3,4 = 9.1 Hz, 3J4,5 = 9.4 Hz, 1 
H, H-4), 3.96 (ddd, 3J5,6a = 1.8 Hz, 3J5,6b = 3.7 Hz, 2J6a,6b = 11.3 Hz, 2 H, H-6a+b), 4.05 (ddd, 
2J1eq,1ax = 11.6 Hz, 3J1eq,2ax = 4.7 Hz, 3J1eq,2eq = 1.5 Hz, 1 H, H-1eq), 4.74, 4.80 (AB, 2JA,B = 12.0 
Hz, 2 H, CH2-Ph), 5.30 (ddd, 3J2ax,3 = 11.3 Hz, 3J2eq,3 = 5.0 Hz, 3J3,4 = 9.1 Hz, 1 H, H-3), 7.22-
8.14 (m, 10 H, 2 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ -4.6 (2 C, 2 Si-CH3), 18.9 (Si-CMe3), 26.6 (3 C, Si-CMe3), 32.1 
(C-2), 63.2 (C-6), 65.8 (C-1), 75.4 (CH2-Ph), 76.5 (C-3), 77.7 (C-4), 81.7 (C-5), 128.1, 128.3, 
128.8, 130.0, 130.1, 133.4, 138.6, 139.0 (12 C, 2 C6H5), 166.3 (CO). 
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1,5-Anhydro-3-O-benzyl-4-O-benzoyl-2-deoxy-D-arabino-hexitol (118) 
(II-164, cm220):  
A solution of 117 (8.31 g, 18.2 mmol) in THF (100 ml) was cooled to 0°C. 
After 15 min, TBAF (27.3 ml, 1 M in THF) was added dropwise. The 
mixture was stirred for 1 h at 0°C and 4 h at room temperature. Diluting with CH2Cl2 (300 ml), 
washing with satd. aqueous NaHCO3 (3 x 100 ml), drying with Na2SO4, evaporation and 
silica gel chromatography (petroleum ether/ethyl acetate 2:1) yielded 118 (5.97 g, 17.5 mmol, 
96%). 
 
Rf = 0.21 (petroleum ether/ethyl acetate 2:1); 
 
[ ]21 D α  = - 56.0 (c = 1.01, CHCl3);  
 
1H NMR (500 MHz, CDCl3): δ 1.79 (dddd, 3J1ax,2ax = 12.4 Hz, 3J1eq,2ax = 4.5 Hz, 2J2ax,2eq = 12.6 
Hz, 3J2ax,3 = 11.7 Hz, 1 H, H-2ax), 2.25 (dddd, 3J1ax,2eq = 2.4 Hz, 3J1eq,2eq = 1.9 Hz, 2J2ax,2eq = 
12.6 Hz, 3J2eq,3 = 4.7 Hz, 1 H, H-2eq), 3.38 (ddd, 3J4,5 = 9.4 Hz, 3J5,6a = 3.1 Hz, 3J5,6b = 1.7 Hz, 1 
H, H-5), 3.57 (ddd, 2J1ax,1eq = 11.6 Hz, 3J1ax,2ax = 12.4 Hz, 3J1ax,2eq = 2.4 Hz, 1 H, H-1ax), 3.73 
(dd, 3J3,4 = 9.2 Hz, 3J4,5 = 9.4 Hz, 1 H, H-4), 3.77 (dd, 3J5,6a = 3.1 Hz, 2J6a,6b = 11.6 Hz, 1 H, H-
6a), 3.89 (dd, 3J5,6b = 1.7 Hz, 2J6a,6b = 11.6 Hz, 1 H, H-6b), 3.99 (ddd, 2J1eq,1ax = 11.6 Hz, 3J1eq,2ax 
= 12.6 Hz, 3J1eq,2eq = 2.2 Hz, 1 H, H-1eq), 4.66, 4.76 (AB, 2JA,B = 12.0 Hz, 2 H, CH2-Ph), 5.27 
(ddd, 3J2ax,3 = 11.7 Hz, 3J2eq,3 = 4.7 Hz, 3J3,4 = 9.2 Hz, 1 H, H-3), 7.20-8.09 (m, 10 H, 2 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 31.9 (C-2), 62.6 (C-6), 65.7 (C-1), 75.4 (CH2-Ph), 76.4 (C-3), 
77.0 (C-4), 80.1 (C-5), 128.4, 128.5, 128.8, 128.9, 130.0, 130.5, 133.5, 138.2 (12 C, 2 C6H5), 
166.2 (CO); 
 
elemental analysis calcd (%) for C20H22O5 (342.39): C 70.16, H 6.48, O 23.36;  
found: C 70.22, H 6.71, O 23.07. 
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1,5-Anhydro-3-O-benzyl-4-O-benzoyl-2,6-dideoxy-6-iodo-D-arabino-
hexitol (119) (II-169, cm226):  
Imidazole (400 mg, 5.84 mmol), PPh3 (1.55 g, 5.84 mmol) and 118 (1.00 g, 
2.92 mmol) were dissolved in CH2Cl2 (50 ml) under argon. Iodine (1.50 g, 
5.84 mmol) was added and the reaction mixture was stirred for 17 h at room temperature. 
Diluting with CH2Cl2 (50 ml), washing with satd. aqueous Na2S2O3 (100 ml) and satd. 
aqueous NaHCO3 (100 ml), drying with Na2SO4, evaporation of the solvent under reduced 
pressure and silica gel column chromatography (petroleum ether/ethyl acetate 7:1) yielded 
119 (1.20 g, 2.65 mmol, 91 %). 
 
Rf = 0.75 (petroleum ether/ethyl acetate 2:1); 
 
[ ]21 D α  = -2.76 (c = 2.3, CHCl3);  
 
1H NMR (500 MHz, CDCl3): δ 1.86 (dddd, 3J1ax,2ax = 12.4 Hz, 3J1eq,2ax = 4.5 Hz, 2J2ax,2eq = 12.6 
Hz, 3J2ax,3 = 11.7 Hz, 1 H, H-2ax), 2.27 (dddd, 3J1eq,2eq = 1.4 Hz, 3J1ax,2eq = 2.3 Hz, 2J2eq,2ax = 
12.6 Hz, 3J2eq,3 = 5.1 Hz, 1 H, H-2eq), 3.03 (m, 1 H, H-5), 3.53 (m, 2 H, H-6a+b), 3.63 (ddd, 
2J1ax,1eq = 11.4 Hz, 3J1ax,2ax = 12.4 Hz, 3J1ax,2eq = 2.3 Hz, 1 H, H-1ax), 3.65 (dd, 3J3,4 = 8.9 Hz, 
3J4,5 = 8.6 Hz, 1 H, H-4), 4.06 (ddd, 2J1eq,1ax = 11.4 Hz, 3J1eq,2eq = 1.4 Hz, 3J1eq,2ax = 4.5 Hz, 1 H, 
H-1eq), 4.74, 4.82 (AB, 2JA,B = 10.7 Hz, 2 H, CH2-Ph), 5.30 (ddd, 3J2ax,3 = 11.7 Hz, 3J2eq,3 = 5.1 
Hz, 3J3,4 = 8.9 Hz, 1 H, H-3), 7.18-8.06 (m, 10 H, 2 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 9.0 (C-6), 31.9 (C-2), 60.8 (C-1), 75.8 (C-3), 76.0 (CH2-Ph), 
77.7 (C-5), 81.1 (C-4), 128.4, 128.5, 128.7, 128.8, 128.9, 130.0, 133.6, 138.0 (12 C, 2 C6H5), 
166.1 (CO); 
 
elemental analysis calcd (%) for C20H21IO4 (452.29): C 53.11, H 4.68, O 14.15;  
found: C 53.16, H 4.70. 
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1,5-Anhydro-3-O-benzyl-4-O-benzoyl-2,6-dideoxy-D-arabino-hexitol 
(120) (II-172, cm229):  
Under argon, 119 (3.40 g, 7.50 mmol) was dissolved in methanol (10 ml). 
Pd/C (200 mg, 0.190 mmol) and NaOAc (2.00 g, 24.4 mmol) were added 
and the suspension was hydrogenated (4 bar H2) at room temperature for 17 h. The reaction 
mixture was filtered through celite and the solvent was evaporated. Purification of the crude 
product by silica gel column chromatography yielded 120 (2.33 g, 7.12 mmol, 95 %). 
 
Rf = 0.65 (petroleum ether/ethyl acetate 2:1); 
 
[ ]21 D α  = -78.6 (c = 1.05, CHCl3);  
 
1H NMR (500 MHz, CDCl3): δ 1.35 (d, 3J5,6 = 6.1 Hz, 3 H, CH3), 1.80 (dddd, 3J1ax,2ax = 11.7 
Hz, 3J1eq,2ax = 4.9 Hz, 2J2ax,2eq = 12.6 Hz, 3J2ax,3 = 11.4 Hz, 1 H, H-2ax), 2.23 (dddd, 3J1ax,2eq = 
2.0 Hz, 3J1eq,2eq = 1.4 Hz, 2J2eq,2ax = 12.6 Hz, 3J2eq,3 = 5.2 Hz, 1 H, H-2eq), 3.33 (dd, 3J3,4 = 9.0 
Hz, 3J4,5 = 9.1 Hz, 1 H, H-4), 3.42 (dq, 3J4,5 = 9.1 Hz, 3J5,6 = 6.1 Hz, 1 H, H-5), 3.52 (ddd, 
2J1ax,1eq = 11.8 Hz, 3J1ax,2ax = 11.7 Hz, 3J1ax,2eq = 2.0 Hz, 1 H, H-1ax), 3.93 (ddd, 2J1eq,1ax = 11.8 
Hz, 3J1eq,2eq = 1.4 Hz, 3J1eq,2ax = 4.9 Hz, 1 H, H-1eq), 4.65, 4.76 (AB, 2JA,B = 10.9 Hz, 2 H, CH2-
Ph), 5.22 (ddd, 3J2ax,3 = 11.4 Hz, 3J2eq,3 = 5.2 Hz, 3J3,4 = 9.0 Hz, 1 H, H-3), 7.17-8.09 (m, 10 H, 
2 C6H5); 
13C NMR (125 MHz, CDCl3): δ 19.0 (C-6), 32.2 (C-2), 65.5 (C-1), 75.5 (C-3), 76.3 (CH2-Ph), 
77.4 (C-5), 83.0 (C-4), 128.0, 128.1, 128.7, 128.8, 130.0, 130.6, 133.4, 138.3 (12 C, 2 C6H5), 
166.2 (CO); 
 
elemental analysis calcd (%) for C20H22O4 (326.39): C 73.60, H 6.79, O 19.61;  
found: C 73.44, H 6.83, O 19.73. 
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(2S)-2-(2,3,4-Tri-O-acetyl-α-L-fucopyranosyl-methyl)-
cyclohexanone (122a) and (2R)-2-(2,3,4-tri-O-acetyl-α-L-
fucopyranosyl-methyl)-cyclohexanone (122b) (I-136, cm042):  
92 (700 mg, 1.98 mmol) was dissolved in dimethoxyethane (20 
ml) under argon. 83 [freshly prepared from 102 (2.00 g, 8.00 
mmol) as described previously] was instantly added to the bromide solution. After adding 
azobisisobutyronitrile (60.0 mg, 0.370 mmol) the reaction mixture was heated to 85°C and 
tributyltin hydride (900 µl, 3.40 mmol) was added dropwise over a period of 1 h. Stirring was 
continued for 15 h at 85°C. The solvent was evaporated and the crude mixture dissolved in 
acetonitrile (100 ml). Remaining tin hydride was extracted with hexane (3 x 50 ml) and the 
acetonitrile layer evaporated. The remaining oil (1.31 g) was purified by silica gel 
chromatography (petroleum ether/ethyl acetate 2:1) to yield an unseparable mixture of 
diastereomers 122a and 122b in a ratio of 1:1.3 as determined by 1H NMR (270 mg, 0.702 
mmol, 35%) as well as 2,3,4-tri-O-acetyl-1-deoxy-L-fucopyranose (162) (180 mg, 0.660 
mmol, 33%) and 1,3,4-tri-O-acetyl-2-deoxy-L-fucopyranoside (163) (90.0 mg, 0.320 mmol, 
16%). 
 
122a:  
Rf = 0.18 (petroleum ether/ethyl acetate 2:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.10 (d, 3J5,6 = 6.2 Hz, 3 H, H-6Fuc), 1.48 (m, 1 H, H-1aCyc), 2.04 
(m, 1 H, H-1bCyc), 2.00, 2.06, 2.17 (3 s, 9 H, 3 CH3CO), 1.30-2.40 (m, 9 H, H-2Cyc, H-4a+bCyc, 
H-5a+bCyc, H-6a+bCyc, H-7a+bCyc), 3.90 (dq, 3J4,5 = 1.8 Hz, 3J5,6 = 6.2 Hz, 1 H, H-5Fuc), 4.18 (ddd, 
3J1,1a-Cyc = 11.2 Hz, 3J1,1b-Cyc = 2.3 Hz, 3J1,2 = 5.6 Hz, 1 H, H-1Fuc), 5.23 (dd, 3J2,3 = 10.0 Hz, 
3J3,4 = 3.1 Hz, 1 H, H-3Fuc), 5.24 (dd, 3J3,4 = 3.1 Hz, 3J4,5 = 1.2 Hz, 1 H, H-4Fuc), 5.31 (dd, 3J1,2 
= 5.6 Hz, 3J2,3 = 10.0 Hz, 1 H, H-2Fuc); 
 
13C NMR (125 MHz, CDCl3): δ 15.9 (C-6Fuc), 20.6, 20.7, 20.8 (3 CH3CO), 23.9, 27.8, 28.2, 
35.4, 42.1 (5 C, C-1Cyc, C-4Cyc, C-5Cyc, C-6Cyc, C-7Cyc), 46.7 (C-2Cyc), 65.4 (C-5Fuc), 68.1 (C-
2Fuc), 70.1 (C-3Fuc), 70.8 (C-1Fuc), 70.9 (C-4Fuc), 170.0, 170.5, 171.1 (3 COO), 212.3 (C-3Cyc). 
 
122b:  
Rf = 0.18 (petroleum ether/ethyl acetate 2:1); 
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1H NMR (500 MHz, CDCl3): δ 1.13 (d, 3J5,6 = 6.2 Hz, 3 H, H-6Fuc), 1.25 (m, 1 H, H-1aCyc), 2.43 
(m, 1 H, H-1bCyc), 2.02, 2.05, 2.15 (3 s, 9 H, 3 CH3CO), 1.30-2.40 (m, 9 H, H-2Cyc, H-4a+bCyc, 
H-5a+bCyc, H-6a+bCyc, H-7a+bCyc), 3.95 (dq, 3J4,5 = 1.8 Hz, 3J5,6 = 6.2 Hz, 1 H, H-5Fuc), 4.27 (ddd, 
3J1,1a-Cyc = 11.2 Hz, 3J1,1b-Cyc = 2.3 Hz, 3J1,2 = 5.6 Hz, 1 H, H-1Fuc), 5.18 (dd, 3J2,3 = 10.0 Hz, 
3J3,4 = 3.1 Hz, 1 H, H-3Fuc), 5.24 (dd, 3J3,4 = 3.1 Hz, 3J4,5 = 1.2 Hz, 1 H, H-4Fuc), 5.31 (dd, 3J1,2 
= 5.6 Hz, 3J2,3 = 10.0 Hz, 1 H, H-2Fuc); 
 
13C NMR (125 MHz, CDCl3): δ 14.2 (C-6Fuc), 20.7, 20.8, 20.9 (3 CH3CO), 25.5, 28.2, 33.2, 
35.4, 42.3 (5 C, C-1Cyc, C-4Cyc, C-5Cyc, C-6Cyc, C-7Cyc), 47.0 (C-2Cyc), 65.6 (C-5Fuc), 67.9 (C-
2Fuc), 68.3 (C-3Fuc), 71.3 (C-1Fuc), 72.6 (C-4Fuc), 169.9, 170.2, 170.5 (3 COO), 212.1 (C-3Cyc). 
 
162: 
Rf = 0.29 (petroleum ether/ethyl acetate 2:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.19 (d, 3J5,6 = 6.4 Hz, 3 H, H-6), 2.01, 2.13, 2.18 (3 s, 9 H, 3 
CH3CO), 3.27 (dd, 2J1ax,1eq = 10.7 Hz, 3J1ax,2 = 10.2 Hz, 1 H, H-1ax), 3.73 (dq, 3J4,5 = 1.2 Hz, 
3J5,6 = 6.4 Hz, 1 H, H-5), 4.14 (dd, 2J1ax,1eq = 10.7 Hz, 3J1eq,2 = 5.7 Hz, 1 H, H-1eq), 5.03 (dd, 
3J2,3 = 10.1 Hz, 3J3,4 = 3.5 Hz, 1 H, H-3), 5.22 (ddd, 3J1ax,2 = 10.2 Hz, 3J1eq,2 = 5.7 Hz, 3J2,3 = 
10.1 Hz, 1 H, H-2), 5.29 (dd, 3J3,4 = 3.5 Hz, 3J4,5 = 1.2 Hz, 1 H, H-4); 
 
13C NMR (125 MHz, CDCl3): δ 16.4 (C-6), 20.7, 20.8, 21.1 (3 CH3CO), 66.2 (C-1),66.5 (C-2), 
70.8 (C-4), 72.0 (C-3), 73.4 (C-5), 170.0, 170.3, 170.6 (3 COO). 
 
163: 
Rf = 0.29 (petroleum ether/ethyl acetate 2:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.18 (d, 3J5,6 = 6.6 Hz, 3 H, H-6), 1.85 (ddd, 3J1,2eq = 1.4 Hz, 
2J2ax,2eq = 13.1 Hz, 3J2eq,3 = 4.7 Hz, 1 H, H-2eq), 2.01, 2.12, 2.16 (3 s, 9 H, 3 CH3CO), 2.16 
(ddd, 3J1,2ax = 4.0 Hz, 2J2ax,2eq = 13.1 Hz, 3J2ax,3 = 12.4 Hz, 1 H, H-2ax), 4.18 (dq, 3J4,5 = 1.7 Hz, 
3J5,6 = 6.6 Hz, 1 H, H-5), 5.22 (dd, 3J3,4 = 2.4 Hz, 3J4,5 = 1.7 Hz, 1 H, H-4), 5.30 (ddd, 3J2ax,3 = 
12.4 Hz, 3J2eq,3 = 4.7 Hz, 3J3,4 = 2.4 Hz, 1 H, H-3), 6.29 (dd, 3J1,2ax = 1.4 Hz, 3J1,2eq = 4.0 Hz, 1 
H, H-1); 
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13C NMR (125 MHz, CDCl3): δ 16.5 (C-6), 20.6, 20.7, 20.8 (3 CH3CO), 28.7 (C-2), 66.5 (C-3), 
67.3 (C-5), 70.8 (C-4), 91.9 (C-1), 169.3, 170.0, 170.6 (3 COO). 
 
 
(2S)-2-(2,3,4-Tri-O-benzoyl-α-L-fucopyranosyl-methyl)-
cyclohexanone (123a) and (2R)-2-(2,3,4-tri-O-benzoyl-α-L-
fucopyranosyl-methyl)-cyclohexanone (123b) (II-14, cm069):  
94 (1.00 g, 1.84 mmol) was dissolved in dimethoxyethane (20 ml) 
under argon. 83 [freshly prepared from 102 (2.00 g, 8.00 mmol) as described previously] was 
instantly added to the bromide solution. After adding azobisisobutyronitrile (60 mg, 0.370 
mmol) the reaction mixture was heated to 85°C and tributyltin hydride (900 µl, 3.40 mmol) 
was added dropwise over a period of 4 h. Stirring was continued for 15 h at 85°C. The 
solvent was evaporated and the crude mixture dissolved in acetonitrile (100 ml). Remaining 
tin hydride was extracted with hexane (3 x 50 ml) and the acetonitrile layer evaporated. The 
remaining oil was purified by silica gel chromatography (petroleum ether/ethyl acetate 6:1) to 
yield an unseparable mixture of diastereomers 123a and 123b in a ratio of 1 : 1.9 as 
determined by 1H NMR (290 mg, 0.508 mmol, 26%) as well as 2,3,4-tri-O-benzoyl-1-deoxy-L-
fucopyranose (164) (246 mg, 0.530 mmol, 27%) and 1,3,4-tri-O-benzoyl-2-deoxy-L-
fucopyranoside (165) (160 mg, 0.350 mmol, 17%). 
 
123a:  
Rf = 0.55 (petroleum ether/ethyl acetate 2:1); 
1H NMR (500 MHz, CDCl3): δ 1.25 (d, 3J5,6 = 6.2 Hz, 3 H, H-6Fuc), 1.20-2.50 (m, 9 H, H-2Cyc, 
H-4a+bCyc, H-5a+bCyc, H-6a+bCyc, H-7a+bCyc), 1.40 (m, 1 H, H-1aCyc), 2.72 (ddd, J = 12.6 Hz, 12.5 
Hz, 3.3 Hz, 1 H, H-1bCyc), 4.28 (dq, 3J4,5 = 1.8 Hz, 3J5,6 = 6.2 Hz, 1 H, H-5Fuc), 4.46 (ddd, 3J1,1a-
Cyc = 12.5 Hz, 3J1,1b-Cyc = 3.5 Hz, 3J1,2 = 4.7 Hz, 1 H, H-1Fuc), 5.72 (m, 1 H, H-4Fuc), 5.84 (m, 2 
H, H-2Fuc, H-3Fuc), 7.21-8.16 (m, 15 H, 3 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 16.4 (C-6Fuc), 24.8, 27.7, 32.2, 34.5, 41.9 (5 C, C-1Cyc, C-4Cyc, 
C-5Cyc, C-6Cyc, C-7Cyc), 46.9 (C-2Cyc), 65.8 (C-5Fuc), 66.4 (C-2Fuc), 70.2 (C-1Fuc), 71.3 (C-3Fuc), 
71.5 (C-4Fuc), 128.2, 128.3, 128.4, 128.5, 129.2, 129.4, 129.6, 129.9, 130.4, 133.1, 133.3, 
133.4 (18 C, 3 C6H5), 165.6, 165.7, 165.9 (3 COO), 212.3 (C-3Cyc); 
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MS (2.02 eV, ES): calcd for C34H34O8 [M+ + H]: 571.24; found: 571.43. 
 
123b:  
Rf = 0.55 (petroleum ether/ethyl acetate 2:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.30 (d, 3J5,6 = 6.2 Hz, 3 H, H-6Fuc), 1.20-2.60 (m, 9 H, H-2Cyc, 
H-4a+bCyc, H-5a+bCyc, H-6a+bCyc, H-7a+bCyc), 1.73 (m, 1 H, H-1aCyc), 2.25 (m, 1 H, H-1bCyc), 4.28 
(dq, 3J4,5 = 2.0 Hz, 3J5,6 = 6.2 Hz, 1 H, H-5Fuc), 4.62 (ddd, 3J1,1a-Cyc = 11.3 Hz, 3J1,1b-Cyc = 2.5 
Hz, 3J1,2 = 5.3 Hz, 1 H, H-1Fuc), 5.72 (dd, 3J3,4 = 3.4 Hz, 3J4,5 = 2.0 Hz, 1 H, H-4Fuc), 5.75 (dd, 
3J2,3 = 9.4 Hz, 3J3,4 = 3.4 Hz, 1 H, H-3Fuc), 5.84 (m, 1 H, H-2Fuc), 7.21-8.16 (m, 15 H, 3 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 16.2 (C-6Fuc), 25.2, 28.1, 32.2, 35.3, 41.2 (5 C, C-1Cyc, C-4Cyc, 
C-5Cyc, C-6Cyc, C-7Cyc), 47.0 (C-2Cyc), 65.9 (C-5Fuc), 66.3 (C-2Fuc), 69.1 (C-1Fuc), 71.4 (C-3Fuc), 
71.7 (C-4Fuc), 128.2, 128.3, 128.5, 129.1, 129.2, 129.4, 129.7, 129.9, 130.4, 133.2, 133.3, 
133.4 (18 C, 3 C6H5), 165.6, 165.7, 165.9 (3 COO), 211.9 (C-3Cyc); 
 
164: 
Rf = 0.65 (petroleum ether/ethyl acetate 2:1);  
 
1H NMR (500 MHz, CDCl3): δ 1.29 (d, 3J5,6 = 6.3 Hz, 3 H, H-6), 3.57 (dd, 2J1ax,1eq = 11.0 Hz, 
3J1ax,2 = 10.1 Hz, 1 H, H-1ax), 3.98 (dd, 3J4,5 = 0.9 Hz, 3J5,6 = 6.3 Hz, 1 H, H-5), 4.44 (dd, 
2J1ax,1eq = 11.0 Hz, 3J1eq,2 = 5.4 Hz, 1 H, H-1eq), 5.65 (dd, 3J2,3 = 10.1 Hz, 3J3,4 = 3.5 Hz, 1 H, H-
3), 5.72 (ddd, 3J1ax,2 = 10.1 Hz, 3J1eq,2 = 5.4 Hz, 3J2,3 = 10.1 Hz, 1 H, H-2), 5.76 (dd, 3J3,4 = 3.5 
Hz, 3J4,5 = 0.9 Hz, 1 H, H-4), 7.25-8.24 (m, 15 H, 3 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 17.2 (C-6), 67.4 (C-1), 67.7 (C-2), 71.6 (C-3), 72.6 (C-4), 74.0 
(C-5), 128.2, 128.4, 128.6, 129.1, 129.2, 129.4, 129.6, 129.7, 129.9, 133.2, 133.3, 133.4 (18 
C, 3 C6H5), 165.7, 165.9, 166.0 (3 COO). 
 
165: 
Rf = 0.74 (petroleum ether/ethyl acetate 2:1); 
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1H NMR (500 MHz, CDCl3): δ 1.28 (d, 3J5,6 = 6.3 Hz, 3 H, H-6), 2.33 (ddd, 3J1,2eq = 1.3 Hz, 
3J2ax,2eq = 13.2 Hz, 3J2eq,3 = 5.0 Hz, 1 H, H-2eq), 2.56 (ddd, 3J1,2ax = 3.5 Hz, 3J2ax,2eq = 13.2 Hz, 
3J2ax,3 = 12.9 Hz, 1 H, H-2ax), 4.49 (dq, 3J4,5 = 0.5 Hz, 3J5,6 = 6.3 Hz, 1 H, H-5), 5.70 (dd, 3J3,4 = 
2.8 Hz, 3J4,5 = 0.5 Hz, 1 H, H-4), 5.81 (ddd, 3J2ax,3 = 12.9 Hz, 3J2eq,3 = 5.0 Hz, 3J3,4 = 2.8 Hz, 1 
H, H-3), 6.71 (dd, 3J1,2eq = 1.3 Hz, 3J1,2ax = 3.5 Hz, 1 H, H-1), 7.34-8.22 (m, 15 H, 3 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 16.8 (C-6), 29.4 (C-2), 67.3 (C-4), 68.0 (C-5), 69.9 (C-3), 92.5 
(C-1), 128.3, 128.5, 128.6, 129.5, 129.6, 129.6, 129.8, 129.9, 130.1, 133.2, 133.4, 133.5 (18 
C, 3 C6H5), 164.8, 165.6, 165.9 (3 COO). 
 
 
(2S)-2-(2,3,4-Tri-O-pivaloyl-α-L-fucopyranosyl-methyl)-
cyclohexanone (124a) and (2R)-2-(2,3,4-tri-O-pivaloyl-α-L-
fucopyranosyl-methyl)-cyclohexanone (124b) (II-56, cm108):  
97 (400 mg, 0.830 mmol) was dissolved in dimethoxyethane (20 
ml) under argon. 83 [freshly prepared from 102 (2 g, 8 mmol) as described previously] was 
instantly added to the bromide solution. After adding azobisisobutyronitrile (60.0 mg, 0.370 
mmol) the reaction mixture was heated to 85°C and tributyltin hydride (900 µl, 3.40 mmol) 
was added dropwise over a period of 4 h. Stirring was continued for 17 h at 85°C and 1 h at 
room temperature. The solvent was evaporated and the crude mixture dissolved in 
acetonitrile (100 ml). Remaining tin hydride was extracted with hexane (3 x 50 ml) and the 
acetonitrile layer evaporated. The remaining oil was purified by chromatography to yield the 
diastereomers 124a (43.0 mg, 0.084 mmol, 10%) and 124b (85.0 mg, 0.166 mmol, 20%) as 
well as 2,3,4-tri-O-pivaloyl-1-deoxy-L-fucopyranose (166) (105 mg, 0.260 mmol, 31%). 
 
124a:  
Rf = 0.29 (petroleum ether/ethyl acetate 5:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.09 (d, 3J5,6 = 6.4 Hz, 3 H, H-6Fuc), 1.16, 1.18, 1.29 (3 s, 27 H, 
3 CMe3), 1.20 (m, 1 H, H-1aCyc), 1.61-2.53 (m, 9 H, H-2Cyc, H-4a+bCyc, H-5a+bCyc, H-6a+bCyc, H-
7a+bCyc), 2.51 (ddd, J = 4.3 Hz, 12.8 Hz, 15.3 Hz, 1 H, H-1bCyc), 4.00 (dq, 3J4,5 = 1.2 Hz, 3J5,6 = 
6.4 Hz, 1 H, H-5Fuc), 4.23 (ddd, 3J1,1a-Cyc = 2.7 Hz, 3J1,1b-Cyc = 12.5 Hz, 3J1,2 = 5.7 Hz, 1 H, H-
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1Fuc), 5.26 (dd, 3J3,4 = 3.1 Hz, 3J4,5 = 1.2 Hz, 1 H, H-4Fuc), 5.30 (dd, 3J2,3 = 10.8 Hz, 3J3,4 = 3.1 
Hz, 1 H, H-3Fuc), 5.35 (dd, 3J1,2 = 5.7 Hz, 3J2,3 = 10.8 Hz, 1 H, H-2Fuc); 
13C NMR (125 MHz, CDCl3): δ 17.0 (C-6Fuc), 26.5, 26.8, 27.1, (3 CMe3), 23.7, 26.1, 32.4, 
34.6, 41.3, 46.7 (6 C, C-1Cyc, C-2Cyc, C-4Cyc, C-5Cyc, C-6Cyc, C-7Cyc), 38.6, 39.4, 39.7 (3 CMe3), 
66.3 (C-5Fuc), 69.5 (C-2Fuc), 69.9 (C-3Fuc), 70.0(C-4Fuc), 70.2 (C-1Fuc), 176.3, 176.8, 177.4, (3 
COO), 211.7 (C-3Cyc). 
 
124b:  
Rf = 0.35 (petroleum ether/ethyl acetate 5:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.13 (d, 3J5,6 = 6.5 Hz, 3 H, H-6Fuc), 1.16, 1.22, 1.27 (3 s, 27 H, 
3 CMe3), 1.50 (m, 1 H, H-1aCyc), 2.05 (m, 1 H, H-1bCyc), 1.61-2.53 (m, 9 H, H-2Cyc, H-4a+bCyc, H-
5a+bCyc, H-6a+bCyc, H-7a+bCyc), 3.96 (dq, 3J4,5 = 1.5 Hz, 3J5,6 = 6.5 Hz, 1 H, H-5Fuc), 4.25 (ddd, 
3J1,1a-Cyc = 11.9 Hz, 3J1,1b-Cyc = 2.4 Hz, 3J1,2 = 5.8 Hz, 1 H, H-1Fuc), 5.22 (dd, 3J2,3 =10.2 Hz, 3J3,4 
= 3.3 Hz, 1 H, H-3Fuc), 5.25 (dd, 3J3,4= 3.3 Hz, 3J4,5 = 1.5 Hz, 1 H, H-4Fuc), 5.36 (dd, 3J1,2 = 5.8 
Hz, 3J2,3 = 10.2 Hz, 1 H, H-2Fuc); 
 
13C NMR (125 MHz, CDCl3): δ 16.3 (C-6Fuc), 27.2, 27.5, 27.7 (3 CMe3), 24.3, 27.6, 33.9, 35.5, 
40.9, 47.1 (6 C, C-1Cyc, C-2Cyc, C-4Cyc, C-5Cyc, C-6Cyc, C-7Cyc), 39.3, 39.6, 39.8 (3 CMe3), 67.1 
(C-5Fuc), 67.5 (C-2Fuc), 67.8 (C-3Fuc), 70.2 (C-4Fuc), 72.9 (C-1Fuc), 175.3, 175.8, 176.4, (3 
COO), 212.6 (C-3Cyc). 
 
166:  
Rf = 0.54 (petroleum ether/ethyl acetate 5:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.18, 1.19, 1.31 (3 s, 27 H, 3 CMe3), 1.18 (d, 3J5,6 = 6.2 Hz, 3 
H, H-6), 3.30 (dd, 2J1ax,1eq = 11.7 Hz, 3J1ax,2 = 11.2 Hz, 1 H, H-1ax), 3.74 (dq, 3J4,5 = 1.0 Hz, 
3J5,6 = 6.2 Hz, 1 H, H-5), 4.11 (dd, 2J1ax,1eq = 11.7 Hz, 3J1eq,2 = 4.6 Hz, 1 H, H-1eq), 5.09 (dd, 
3J2,3 = 10.4 Hz, 3J3,4 = 3.1 Hz, 1 H, H-3), 5.20 (dd, 3J1ax,2 = 11.2 Hz, 3J1eq,2 = 4.6 Hz, 3J2,3 = 
10.4 Hz,1 H, H-2), 5.31 (dd, 3J3,4 = 3.1 Hz, 3J4,5 = 1.0 Hz, 1 H, H-4). 
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(2R,3R)-2-Methyl-3-(2,3,4-tri-O-benzoyl-α-L-fucopyranosyl-
methyl)-tetrahydropyran-4-on (125) (II-207, cm263):  
To a solution of 2,3,4-tri-O-benzoyl-α-L-fucopyranosylbromide 
(94) (270 mg, 0.468 mmol) and freshly prepared 84 (50.0 mg, 
0.396 mmol) in dimethoxyethane (10 ml), AIBN (8.00 mg, 0.040 
mmol) was added and the solution was heated to 85°C. Bu3SnH (80.0 mg, 55.0 µl, 0.280 
mmol) was added. After stirring for 2 h, another portion of Bu3SnH (80.0 mg, 55.0 µl, 0.280 
mmol) was added and the reaction mixture was stirred at 85°C for 18 h. The solvent was 
then evaporated, the crude reaction mixture dissolved in acetonitrile (50 ml) and washed with 
n-hexane (3 x 20 ml). Evaporation of the acetonitrile lead to a crude oil, which was purified by 
silica gel chromatography (petroleum ether/ethyl acetate 2:1) to yield 125 (25.0 mg, 0.042 
mmol, 11%) together with 2,3,4-tri-O-benzoyl-1-deoxy-α-L-fucopyranose 164 and 1,3,4-tri-O-
benzoyl-2-deoxy-α-L-fucopyranoside 165 (177 mg, 0.384 mmol, 82%). 
 
Rf = 0.32 (petroleum ether/ethyl acetate 2:1); 
 
[ ]22 D α  = -162.8 (c = 1.25, CHCl3); 
 
1H NMR (500 MHz, CDCl3): δ 1.14 (d, 3J5,6 = 6.3 Hz, 3 H, H-6Fuc), 1.19 (d, 3J5,6 = 6.0 Hz, 3 H, 
H-6Pyr), 1.33 (ddd, 3J = 2.9 Hz, 4.6 Hz, 15.7 Hz, 1 H, H-7aPyr), 2.34 (m, 2 H, H-2aPyr, H-4Pyr), 
2.62 (ddd, 3J1ax,2b = 12.5 Hz, 3J1eq,2b = 7.1 Hz, 2J2a,2b = 14.2 Hz, 1 H, H-2bPyr), 2.72 (ddd, 3J = 
3.9 Hz, 11.9 Hz, 15.7 Hz, 1 H, H-7bPyr), 3.44 (dq, 3J4,5 = 9.9 Hz, 3J5,6 = 6.0 Hz, 1 H, H-5Pyr), 
3.61 (ddd, 2J1ax,1eq = 11.4 Hz, 3J1ax,2a = 2.5 Hz, 3J1ax,2b = 12.5 Hz, 1 H, H-1axPyr), 4.18 (ddd, 
2J1eq,1ax = 11.4 Hz, 3J1eq,2a = 1.6 Hz, 3J1eq,2b = 7.1 Hz, 1 H, H-1eqPyr), 4.32 (dq, 3J4,5 = 1.6 Hz, 
3J5,6 = 6.3 Hz, 1 H, H-5Fuc), 4.47 (ddd, 3J1,2 = 5.5 Hz, 3J1,7a = 2.9 Hz, 3J1,7b = 11.9 Hz, 1 H, H-
1Fuc), 5.65 (dd, 3J3,4 = 3.3 Hz, 3J4,5 = 1.6 Hz, 1 H, H-4Fuc), 5.71 (dd, 3J1,2 = 5.5 Hz, 3J2,3 = 10.2 
Hz, 1 H, H-2Fuc), 5.76 (dd, 3J2,3 = 10.2 Hz, 3J3,4 = 3.3 Hz, 1 H, H- 3Fuc), 7.18-8.04 (m, 15 H, 3 
C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 16.7 (C-6Fuc), 19.9 (C-7Pyr), 20.8 (C-6Pyr), 42.7 (C-2Pyr), 55.4 
(C-4Pyr), 66.6 (C-5Fuc), 67.2 (C-1Pyr), 69.4 (C-3Fuc), 70.0 (C-2Fuc), 72.1 (C-4Fuc), 73.3 (C-1Fuc), 
79.4 (C-5Pyr), 128.7, 128.8, 128.9, 129.5, 129.6, 129.8, 130.1, 130.2, 130.3, 133.6, 133.8, 
133.9 (18 C, 3 C6H5), 166.1, 166.2, 166.3 (3 COO), 207.7 (C-3Pyr); 
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elemental analysis calcd (%) for C34H34O9 (586.65): C 69.61, H 5.84, O 24.55;  
found: C 69.31, H 6.16, O 24.53. 
 
 
(1R,2S)-2-(2,3,4-Tri-O-acetyl-α-L-fucopyranosyl-methyl)-
cyclohexanol (127a),  
(1S,2R)-2-(2,3,4-Tri-O-acetyl-α-L-fucopyranosyl-methyl)-
cyclohexanol (127b), 
(1S,2S)-2-(2,3,4-Tri-O-acetyl-α-L-fucopyranosyl-methyl)-
cyclohexanol (127c) and  
(1R,2R)-2-(2,3,4-Tri-O-acetyl-α-L-fucopyranosyl-methyl)-cyclohexanol (127d): 
Reduction with NaBH4 in MeOH (II-147, cm052): 
An unseparable mixture of the ketone diastereomers 122a and 122b (100 mg, 0.260 mmol) 
was dissolved in methanol (5 ml) under argon and cooled to –20°C. NaBH4 (7.00 mg, 0.170 
mmol) was added and the reaction mixture was stirred at –20°C for 1 h. Quenching of the 
remaining reducing agent with 5% aqueous HCl (10 ml), extraction of the organic layer with 
CH2Cl2 (3 x 20 ml), drying with Na2SO4 and evaporation of the solvents lead to a crude 
mixture (110 mg) of the four alcohols 127a, 127b, 127c and 127d in a ratio of 1 : 1.3 : 1 : 1.3 
as determined by 1H NMR-spectroscopy. Purification of the crude mixture by silica gel 
chromatography (petroleum ether/ethyl acetate 2:1) yielded 127a (23.0 mg, 0.060 mmol, 
21%), 127b (31.0 mg, 0.080 mmol, 28%), 127c (23.0 mg, 0.060 mmol, 21%) and 127d (31.0 
mg, 0.080 mmol, 28%). 
 
Reduction with Li(tBuO)3AlH in THF (II-10, cm065): 
An unseparable mixture of the ketone diastereomers 122a and 122b (50.0 mg, 0.130 mmol) 
was dissolved in THF (3 ml) under argon and cooled to -5°C. Li[(tBuO)3AlH] (49.0 mg, 0.195 
mmol) was added and the reaction mixture was stirred at –5°C for 4 h and at 0°C for 3 h. 
Quenching of the remaining reducing agent with 5% aqueous HCl (10 ml), extraction of the 
organic layer with CH2Cl2 (3 x 20 ml), drying with Na2SO4 and evaporation of the solvent lead 
to a crude mixture (60 mg) of the four alcohols 127a, 127b, 127c and 127d in a ratio of 4 : 
5.2 : 1 : 1.3 as determined by 1H NMR-spectroscopy. Purification of the crude mixture by 
silica gel chromatography (petroleum ether/ethyl acetate 2:1) yielded 127a (17.0 mg, 0.044 
mmol, 35%), 127b (23.0 mg, 0.059 mmol, 45%), 127c (4.00 mg, 0.01 mmol, 9%) and 127d 
(6.00 mg, 0.016 mmol, 11%). 
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Reduction with L-Selectride in THF (II-8, cm063): 
An unseparable mixture of the ketone diastereomers 122a and 122b (20.0 mg, 0.052 mmol) 
was dissolved in THF (3 ml) under argon and cooled to 0°C. L-selectride (1.0 M in THF, 57.0 
µl, 0.057 mmol) was added slowly by a syringe and the reaction mixture was stirred at 0°C 
for 1.5 h. Quenching of the remaining reducing agent with water (10 ml), extraction of the 
organic layer with CH2Cl2 (3 x 20 ml), drying with Na2SO4 and evaporation of the solvent lead 
to a crude mixture (27 mg) of the two axial alcohols 127c and 127d in a ratio of 1:1.3 as 
determined by 1H NMR spectroscopy. Purification of the crude mixture by silica gel 
chromatography (petroleum ether/ethyl acetate 2:1) yielded 127c (8.00 mg, 0.021 mmol, 
40%) and 127d (10.0 mg, 0.027 mmol, 52%). 
 
127a:  
Rf = 0.38 (petroleum ether/ethyl acetate 1:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.14 (m, 1 H, H-1aCyc), 1.15 (d, 3J5,6 = 6.4 Hz, 3 H, H-6Fuc), 1.61-
2.53 (m, 9 H, H-2Cyc, H-4a+bCyc, H-5a+bCyc, H-6a+bCyc, H-7a+bCyc), 2.02, 2.08, 2.14 (3 s, 9 H, 3 
CH3), 2.16 (m, 1 H, H-1bCyc), 3.20 (ddd, 3J2,3 = 9.8 Hz, 3J3,4a = 4.3 Hz, 3J3,4b = 10.2 Hz, 1 H, H-
3Cyc), 4.06 (dq, 3J4,5 = 1.7 Hz, 3J5,6 = 6.4 Hz, 1 H, H-5Fuc), 4.35 (ddd, 3J1,1a-Cyc = 2.7 Hz, 3J1,1b-
Cyc = 12.2 Hz, 3J1,2 = 5.5 Hz, 1 H, H-1Fuc), 5.17 (dd, 3J2,3 = 8.6 Hz, 3J3,4 = 3.5 Hz, 1 H, H-3Fuc), 
5.26 (dd, 3J3,4 = 3.5 Hz, 3J4,5 = 1.7 Hz, 1 H, H-4Fuc), 5.30 (dd, 3J1,2 = 5.5 Hz, 3J2,3 = 8.6 Hz, 1 
H, H-2Fuc); 
 
13C NMR (125 MHz, CDCl3): δ 15.5 (C-6Fuc), 21.0, 21.2, 21.5 (3 CH3CO), 25.8 (C-1Cyc), 26.0, 
28.6, 29.4, 33.2, 35.4 (5 C, C-2Cyc, C-4Cyc, C-5Cyc, C-6Cyc, C-7Cyc), 66.1 (C-5Fuc), 68.7 (C-3Fuc), 
68.9 (C-2Fuc), 70.8 (C-1Fuc), 71.0 (C-4Fuc), 75.0 (C-3Cyc), 168.0, 169.3, 170.0 (3 COO). 
 
127b: 
Rf = 0.38 (petroleum ether/ethyl acetate 1:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.15 (d, 3J5,6 = 6.6 Hz, 3 H, H-6Fuc), 1.61-2.53 (m, 9 H, H-2Cyc, 
H-4a+bCyc, H-5a+bCyc, H-6a+bCyc, H-7a+bCyc), 1.74 (m, 2 H, H-1a+bCyc), 2.00, 2.09, 2.16 (3 s, 9 H, 3 
CH3), 3.29 (ddd, 3J2,3 = 9.8 Hz, 3J3,4a = 3.9 Hz, 3J3,4b = 10.3 Hz, 1 H, H-3Cyc), 4.06 (dq, 3J4,5 = 
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1.6 Hz, 3J5,6 = 6.6 Hz, 1 H, H-5Fuc), 4.45 (ddd, 3J1,1a-Cyc = 4.7 Hz, 3J1,1b-Cyc = 8.2 Hz, 3J1,2 = 5.1 
Hz, 1 H, H-1Fuc), 5.17 (dd, 3J2,3 = 8.4 Hz, 3J3,4 = 3.1 Hz, 1 H, H-3Fuc), 5.26 (m, 2 H, H-2Fuc, H-
4Fuc); 
 
13C NMR (125 MHz, CDCl3): δ 15.4 (C-6Fuc), 21.0, 21.2, 21.5 (3 CH3), 31.2 (C-1Cyc), 27.8, 
29.0, 31.7, 33.2, 35.4 (5 C, C-2Cyc, C-4Cyc, C-5Cyc, C-6Cyc, C-7Cyc), 66.1 (C-5Fuc), 68.7 (C-3Fuc), 
68.9 (C-2Fuc), 71.0 (C-4Fuc), 71.9 (C-1Fuc), 75.0 (C-3Cyc), 168.0, 169.2, 170.2 (3 COO). 
 
127c: 
Rf = 0.42 (petroleum ether/ethyl acetate 1:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.12 (d, 3J5,6 = 6.3 Hz, 3 H, H-6Fuc), 1.39 (m, 1 H, H-1aCyc), 1.61-
2.53 (m, 9 H, H-2Cyc, H-4a+bCyc, H-5a+bCyc, H-6a+bCyc, H-7a+bCyc), 1.85 (m, 1 H, H-1bCyc), 1.98, 
2.05, 2.12 (3 s, 9 H, 3 CH3), 3.88 (ddd, 3J2,3 = 2.3 Hz, 3J3,4a = 4.3 Hz, 3J3,4b = 3.8 Hz, 1 H, H-
3Cyc), 4.06 (dq, 3J4,5 = 1.6 Hz, 3J5,6 = 6.3 Hz, 1 H, H-5Fuc), 4.28 (ddd, 3J1,1a-Cyc = 3.1 Hz, 3J1,1b-
Cyc = 11.8 Hz, 3J1,2 = 5.5 Hz, 1 H, H-1Fuc), 5.17 (dd, 3J2,3 = 8.4 Hz, 3J3,4 = 3.2 Hz, 1 H, H-3Fuc), 
5.26 (dd, 3J3,4 = 3.2 Hz, 3J4,5 = 1.6 Hz,1 H, H-4Fuc), 5.27 (dd, 3J1,2 = 5.5 Hz, 3J2,3 = 8.4 Hz, 1 H, 
H-2Fuc); 
 
13C NMR (125 MHz, CDCl3): δ 15.8 (C-6Fuc), 20.4 (C-1Cyc), 21.0, 21.2, 21.5 (3 CH3), 23.6, 
26.9, 27.4, 29.8, 33.1 (5 C, C-2Cyc, C-4Cyc, C-5Cyc, C-6Cyc, C-7Cyc), 66.1 (C-5Fuc), 68.3 (C-3Cyc), 
68.7 (C-3Fuc), 68.9 (C-2Fuc), 71.0 (C-4Fuc), 71.6 (C-1Fuc), 168.3, 169.1, 169.7 (3 COO). 
 
127d:  
Rf = 0.42 (petroleum ether/ethyl acetate 1:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.10 (d, 3J5,6 = 6.6 Hz, 3 H, H-6Fuc), 1.61-2.53 (m, 9 H, H-2Cyc, 
H-4a+bCyc, H-5a+bCyc, H-6a+bCyc, H-7a+bCyc), 1.63 (m, 2 H, H-1a+bCyc), 2.01, 2.06, 2.10 (3 s, 9 H, 3 
CH3), 3.94 (ddd, 3J = 1.5 Hz, 2.7 Hz, 3.9 Hz, 1 H, H-3Cyc), 3.98 (dq, 3J4.5 = 1.9 Hz, 3J5,6 = 6.6 
Hz, 1 H, H-5Fuc), 4.40 (ddd, 3J1,1a-Cyc = 4.8 Hz, 3J1,1b-Cyc = 7.9 Hz, 3J1,2 = 4.9 Hz, 1 H, H-1Fuc), 
5.17 (dd, 3J2,3 = 8.5 Hz, 3J3,4 = 3.3 Hz, 1 H, H-3Fuc), 5.26 (dd, 3J3,4 = 3.3 Hz, 3J4,5 = 1.9 Hz,1 H, 
H-4Fuc), 5.28 (dd, 3J1,2 = 4.9 Hz, 3J2,3 = 8.5 Hz, 1 H, H-2Fuc); 
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13C NMR (125 MHz, CDCl3): δ 15.6 (C-6Fuc), 21.0, 21.2, 21.5 (3 CH3), 25.4 (C-1Cyc), 26.7, 
27.5, 30.1, 31.8, 33.2 (5 C, C-2Cyc, C-4Cyc, C-5Cyc, C-6Cyc, C-7Cyc), 65.8 (C-5Fuc), 67.7 (C-3Cyc), 
68.7 (C-3Fuc), 68.9 (C-2Fuc), 70.6 (C-1Fuc), 71.0 (C-4Fuc), 168.4, 168.9, 169.9 (3 COO). 
 
 
(1R,2S)-2-(2,3,4-Tri-O-benzoyl-α-L-fucopyranosyl-methyl)-
cyclohexanol (128a), 
(1S,2R)-2-(2,3,4-Tri-O-benzoyl-α-L-fucopyranosyl-methyl)-
cyclohexanol (128b), 
(1S,2S)-2-(2,3,4-Tri-O-benzoyl-α-L-fucopyranosyl-methyl)-
cyclohexanol (128c) and 
(1R,2R)-2-(2,3,4-Tri-O-benzoyl-α-L-fucopyranosyl-methyl)-cyclohexanol (128d) (II-57, 
cm109):  
To a solution of the diastereomeric mixture of 123a and 123b (570 mg, 1.00 mmol) in THF 
(30 ml), Li[(tBuO)3AlH] (393 mg, 1.50 mmol) was added at 0°C and the suspension was 
stirred at 0°C for 5 h. Quenching of the remaining reducing agent with water (50 ml), 
extraction of the organic layer with CH2Cl2 (3 x 50 ml), drying with Na2SO4, evaporation of the 
solvent and purification of the crude mixture by silica gel chromatography (petroleum 
ether/ethyl acetate  5:1) yielded 128a (130 mg, 0.230 mmol, 23%), 128b (243 mg, 0.420 
mmol, 42%), 128c (41.0 mg, 0.070 mmol, 7%) and 128d (80.0 mg, 0.140 mmol, 14%) in an 
overall yield of 86%. 
 
128a: 
Rf = 0.42 (petroleum ether/ethyl acetate 2:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.25 (d, 3J5,6 = 6.5 Hz, 3 H, H-6Fuc), 1.28-2.04 (m, 9 H, H-2Cyc, 
H-4a+bCyc, H-5a+bCyc, H-6a+bCyc, H-7a+bCyc), 1.25 (m, 1 H, H-1aCyc), 2.44 (m, 1 H, H-1bCyc), 3.17 
(dt, 3J = 9.6 Hz, 9.6 Hz, 3.7 Hz, 1 H, H-3Cyc), 4.29 (dq, 3J4,5 = 1.8 Hz, 3J5,6 = 6.2 Hz, 1 H, H-
5Fuc), 4.59 (ddd, 3J1,1a-Cyc = 2.0 Hz, 3J1,1b-Cyc = 12.5 Hz, 3J1,2 = 5.0 Hz, 1 H, H-1Fuc), 5.66 (m, 1H, 
H-4Fuc), 5,75 (m, 2 H, H-2Fuc, H-3Fuc), 7.18-8.02 (m, 15 H, 3 C6H5); 
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13C NMR (125 MHz, CDCl3): δ 16.3 (C-6Fuc), 25.0, 26.3, 29.4, 32.6, 36.8 (5 C, C-2Cyc, C-4Cyc, 
C-5Cyc, C-6Cyc, C-7Cyc), 32.2 (C-1Cyc), 67.0 (C-5Fuc), 70.5 (C-2Fuc), 70.6 (C-3Fuc), 71.0 (C-1Fuc), 
71.7 (C-4Fuc), 75.3 (C-3Cyc), 128.8, 128.9, 130.0, 130.2, 130.4, 130.8, 132.3, 132.5, 132.6, 
133.7, 133.9, 134.0 (18 C, 3 C6H5), 164.7, 165.3, 166.6 (3 COO). 
 
elemental analysis calcd (%) for C34H36O8 (572.65): C 71.31, H 6.34, O 22.35;  
found: C 70.90, H 6.365, O 22.74. 
 
128b: 
Rf = 0.50 (petroleum ether/ethyl acetate 2:1);  
 
1H NMR (500 MHz, CDCl3): δ 1.25 (d, 3J5,6 = 6.4 Hz, 3 H, H-6Fuc), 1.21-1.80 (m, 9 H, H-2Cyc, 
H-4a+bCyc, H-5a+bCyc, H-6a+bCyc, H-7a+bCyc), 1.86 (m, 2 H, H-1a+bCyc), 3.26 (ddd, 3J2,3 = 9.5 Hz, 
3J3,4a = 9.5 Hz, 3J3,4b = 4.3 Hz, 1 H, H-3Cyc), 4.26 (dq, 3J4,5 = 1.7 Hz, 3J5,6 = 6.4 Hz, 1 H, H-5Fuc), 
4.70 (ddd, 3J1,1a-Cyc = 2.5 Hz, 3J1,1b-Cyc = 8.5 Hz, 3J1,2 = 4.7 Hz, 1 H, H-1Fuc), 5.65 (dd, 3J3,4 = 3.0 
Hz, 3J4,5 = 1.7 Hz, 1 H, H-4Fuc), 5,70 (dd, 3J2,3 = 7.9 Hz, 3J3,4 = 3.0 Hz, 1 H, H-3Fuc), 5.70 (m, 1 
H, H-2Fuc), 7.18-8.02 (m, 15 H, 3 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 16.0 (C-6Fuc), 25.0, 26.3, 29.4, 32.6, 36.8 (5 C, C-2Cyc, C-4Cyc, 
C-5Cyc, C-6Cyc, C-7Cyc), 37.0 (C-1Cyc), 67.1 (C-5Fuc), 70.7 (C-2Fuc), 70.8 (C-3Fuc), 71.8 (C-4Fuc), 
72.0 (C-1Fuc), 75.0 (C-3Cyc), 128.2, 128.4, 128.8, 129.1, 129.2, 129.4, 129.5, 129.7, 129.9, 
133.2, 133.4, 133.7 (18 C, 3 C6H5), 166.1, 166.8, 167.4 (3 CO); 
 
128c: 
Rf = 0.50 (petroleum ether/ethyl acetate 2:1);  
 
1H NMR (500 MHz, CDCl3): δ 1.23 (d, 3J5,6 = 6.2 Hz, 3 H, H-6Fuc), 1.21-.80 (m, 9 H, H-2Cyc, H-
4a+bCyc, H-5a+bCyc, H-6a+bCyc, H-7a+bCyc),1.49 (m, 1 H, H-1aCyc), 2.02 (m, 1 H, H-1bCyc), 3.88 (ddd, 
3J = 5.3 Hz, 4.7 Hz, 2.8 Hz, 1 H, H-3Cyc), 4.27 (dq, 3J5,4 = 1.8 Hz, 3J5,6 = 6.2 Hz, 1 H, H-5Fuc), 
4.52 (ddd, 3J1,1a-Cyc = 2.5 Hz, 3J1,1b-Cyc = 11.6 Hz, 3J1,2 = 4.7 Hz, 1 H, H-1Fuc), 5.70 (m, 3 H, H-
2Fuc, H-3Fuc, H-4Fuc), 7.18-8.02 (m, 15 H, 3 C6H5); 
5. Experimental Section                                                                                                                       143 
 
 
13C NMR (125 MHz, CDCl3): δ 16.5 (C-6Fuc), 25.2, 26.6, 29.7, 32.2, 35.4 (5 C, C-2Cyc, C-4Cyc, 
C-5Cyc, C-6Cyc, C-7Cyc), 30.6 (C-1Cyc), 68.4 (C-5Fuc), 69.8 (C-3Cyc), 70.4 (C-2Fuc), 71.8 (C-1Fuc), 
72.4 (C-4Fuc), 75.3 (C-3Cyc), 128.6, 128.8, 130.2, 130.3, 130.4, 131.6, 132.0, 132.4, 132.6, 
133.5, 133.7, 134.6 (18 C, 3 C6H5), 165.3, 165.5, 166.2 (3 COO). 
 
128d: 
Rf = 0.58 (petroleum ether/ethyl acetate 2:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.23 (d, 3J5,6 = 6.5 Hz, 3 H, H-6Fuc), 1.25-1.78 (m, 9 H, H-2Cyc, 
H-4a+bCyc, H-5a+bCyc, H-6a+bCyc, H-7a+bCyc), 1.80 (m, 2 H, H-1a+bCyc), 3.92 (ddd, 3J = 1.1 Hz, 2.3 
Hz, 2.9 Hz, 1 H, H-3Cyc), 4.18 (dq, 3J4,5 = 1.3 Hz, 3J5,6 = 6.5 Hz, 1 H, H-5Fuc), 4.61 (ddd, 3J1,1a-
Cyc = 2.9 Hz, 3J1,1b-Cyc = 10.8 Hz, 3J1,2 = 5.1 Hz, 1 H, H-1Fuc), 5.64 (dd, 3J3,4 = 3.2 Hz, 3J4,5 = 1.3 
Hz, 1 H, H-4Fuc), 5.74 (dd, 3J2,3 = 9.1 Hz, 3J3,4 = 3.2 Hz, 1 H, H-3Fuc), 5.74 (m, 1 H, H-2Fuc), 
7.18-8.02 (m, 15 H, 3 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 16.8 (C-6Fuc), 25.0, 26.3, 29.4, 32.6, 36.8 (5C, C-2Cyc, C-4Cyc, 
C-5Cyc, C-6Cyc, C-7Cyc), 32.8 (C-1Cyc), 66.9 (C-5Fuc), 68.6 (C-3Cyc), 70.1 (C-2Fuc), 70.3 (C-3Fuc), 
71.2 (C-1Fuc), 71.5 (C-4Fuc), 128.0, 128.4, 128.6, 129.1, 129.3, 129.4, 129.6, 129.8, 129.9, 
132.7, 133.1, 133.4 (18 C, 3 C6H5), 165.6, 165.8, 166.3 (3 COO). 
 
 
(1R,2S)-2-(2,3,4-Tri-O-pivaloyl-α-L-fucopyranosyl-methyl)-
cyclohexanol (129a),  
(1S,2R)-2-(2,3,4-Tri-O-pivaloyl-α-L-fucopyranosyl-methyl)-
cyclohexanol (129b), 
(1S,2S)-2-(2,3,4-Tri-O-pivaloyl-α-L-fucopyranosyl-methyl)-
cyclohexanol (129c), and 
(1R,2R)-2-(2,3,4-tri-O-pivaloyl-α-L-fucopyranosyl-methyl)-cyclohexanol (129d) (II-58, 
cm110):  
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A diastereomeric (1:1)-mixture of 124a and 124b (200 mg, 0.390 mmol), was dissolved in 
THF (10 ml) and cooled to 0°C. After addition of Li[(tBuO)3AlH] (231 mg, 0.910 mmol) the 
reaction was stirred for 3 h at 0°C and 20 h at room temperature. Quenching of the remaining 
reducing agent with water (50 ml), extraction of the organic layer with CH2Cl2 (3 x 50 ml), 
drying with Na2SO4, evaporation of the solvent and purification of the crude mixture (129a : 
129b : 129c : 129d = 1.4 : 1.4 : 0.7 : 0.8 as determined by 1H NMR spectroscopy) by silica 
gel chromatography (toluene/ethyl acetate 6:1) yielded 129a (60.0 mg, 0.120 mmol, 37%), 
129b (47.0 mg, 0.090 mmol, 29%), 129c (13.0 mg, 0.025 mmol, 9%) and 129d (40.0 mg, 
0.080 mmol, 25 %) in an overall yield of 81%. 
 
129a:  
Rf = 0.24 (petroleum ether/ethyl acetate 3:1); 
1H NMR (500 MHz, CDCl3): δ 1.14 (d, 3J5,6 = 6.2 Hz, 3 H, H-6Fuc), 1.14, 1.18, 1.28 (3 s, 27 H, 
3 CMe3), 1.16 (m, 1 H, H-1aCyc), 1.20-1.81 (m, 9 H, H-2Cyc, H-4a+bCyc, H-5a+bCyc, H-6a+bCyc, H-
7a+bCyc), 2.28 (m, 1 H, H-1bCyc), 3.20 (ddd, 3J2,3 = 7.0 Hz, 3J3,4a = 7.0 Hz, 3J3,4b = 4.4 Hz, 1 H, 
H-3Cyc), 4.12 (dq, 3J4,5 = 1.3 Hz, 3J5,6 = 6.2 Hz, 1 H, H-5Fuc), 4.33 (ddd, 3J1,1a-Cyc = 2.2 Hz, 3J1,1b-
Cyc = 12.2 Hz, 3J1,2 = 5.5 Hz, 1 H, H-1Fuc), 5.26 (m, 2 H, H-3Fuc, H-4Fuc), 5.31 (m, 1 H, H-2Fuc); 
 
13C NMR (125 MHz, CDCl3): δ 16.2 (C-6Fuc), 22.3, 24.6, 28.1, 31.4, 35.8 (5 C, C-2Cyc, C-4Cyc, 
C-5Cyc, C-6Cyc, C-7Cyc), 27.4, 27.6, 27.9 (3 CMe3), 34.8 (C-1Cyc), 38.2, 39.6, 42.3 (3 CMe3), 
66.2 (C-5Fuc), 68.6 (C-2Fuc), 69.4 (C-3Fuc), 71.0 (C-4Fuc), 71.6 (C-1Fuc), 73.6 (C-3Cyc), 177.4, 
177.6, 177.9 (3 COO). 
 
129b:  
Rf = 0.31 (petroleum ether/ethyl acetate 3:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.15 (d, 3J5,6 = 6.3 Hz, 3 H, H-6Fuc), 1.14, 1.20, 1.29 (3 s, 27 H, 
3 CMe3), 1.21 (m, 2 H, H-1a+bCyc), 1.22-1.74 (m, 9 H, H-2Cyc, H-4a+bCyc, H-5a+bCyc, H-6a+bCyc, H-
7a+bCyc), 3.29 (ddd, 3J2,3 = 8.1 Hz, 3J3,4a = 8.2 Hz, 3J3,4b = 3.8 Hz, 1 H, H-3Cyc), 4.09 (dq, 3J4,5 = 
1.6 Hz, 3J5,6 = 6.3 Hz, 1 H, H-5Fuc), 4.44 (ddd, 3J1,1a-Cyc = 3.6 Hz, 3J1,1b-Cyc = 8.1 Hz, 3J1,2 = 5.3 
Hz, 1 H, H-1Fuc), 5.20 (m, 1 H, H-3Fuc), 5.23 (m, 1 H, H-4Fuc), 5.26 (m, 1 H, H-2Fuc); 
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13C NMR (125 MHz, CDCl3): δ 16.2 (C-6Fuc), 24.6, 25.9, 27.5, 31.9, 36.2 (5 C, C-2Cyc, C-4Cyc, 
C-5Cyc, C-6Cyc, C-7Cyc), 27.2, 27.5, 28.1 (3 CMe3), 28.5 (C-1Cyc), 39.2, 39.4, 43.5 (3 CMe3), 
65.8 (C-5Fuc), 67.6 (C-2Fuc), 68.2 (C-3Fuc), 71.2 (C-4Fuc), 73.4 (C-1Fuc), 74.8 (C-3Cyc), 177.1, 
177.4, 177.8 (3 COO). 
 
129c:  
Rf = 0.27 (petroleum ether/ethyl acetate 3:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.16 (d, 3J5,6 = 6.4 Hz, 3 H, H-6Fuc), 1.15, 1.19, 1.29 (3 s, 27 H, 
3 CMe3), 1.26-1.76 (m, 9 H, H-2Cyc, H-4a+bCyc, H-5a+bCyc, H-6a+bCyc, H-7a+bCyc), 1.37 (m, 1 H, H-
1aCyc), 1.91 (m, 1 H, H-1bCyc), 3.87 (ddd, 3J = 2.1 Hz, 4.3 Hz, 5.4 Hz, 1 H, H-3Cyc), 4.09 (dq, 
3J4,5 = 1.9 Hz, 3J5,6 = 6.4 Hz, 1 H, H-5Fuc), 4.27 (ddd, 3J1,1a-Cyc = 2.3 Hz, 3J1,1b-Cyc = 11.6 Hz, 
3J1,2 = 4.9 Hz, 1 H, H-1Fuc), 5.20 (dd, 3J2,3 = 10.1 Hz, 3J3,4 = 2.8 Hz, 1 H, H-3Fuc), 5.24 (dd, 3J3,4 
= 2.8 Hz, 3J4,5 = 1.9 Hz, 1 H, H-4Fuc), 5.29 (dd, 3J1,2 = 4.9 Hz, 3J2,3 = 10.1 Hz, 1 H, H-2Fuc);  
 
13C NMR (125 MHz, CDCl3): δ 16.3 (C-6Fuc), 25.2, 26.0, 27.4, 32.2, 37.6 (5 C, C-2Cyc, C-4Cyc, 
C-5Cyc, C-6Cyc, C-7Cyc), 27.1, 27.5, 27.9 (3 CMe3), 36.3 (C-1Cyc), 38.7, 39.3, 43.1 (3 CMe3), 
66.0 (C-5Fuc), 68.6 (C-2Fuc), 69.2 (C-3Fuc), 70.9 (C-3Cyc), 72.4 (2 C, C-4Fuc, C-1Fuc), 177.2, 
177.4, 177.7 (3 COO). 
 
129d:  
Rf = 0.39 (petroleum ether/ethyl acetate 3:1); 
 
1H NMR (500 MHz, CDCl3): δ 1.14 (d, 3J5,6 = 6.4 Hz, 3 H, H-6Fuc), 1.14, 1.18, 1.28 (3 s, 27 H, 
3 CMe3), 1.26-1.76 (m, 9 H, H-2Cyc, H-4a+bCyc, H-5a+bCyc, H-6a+bCyc, H-7a+bCyc), 1.65 (m, 2 H, H-
1a+bCyc), 3.93 (ddd, 3J = 1.6 Hz, 3.3 Hz, 4.4 Hz, 1 H, H-3Cyc), 4.01 (dq, 3J4,5 = 1.3 Hz, 3J5,6 = 
6.4 Hz, 1 H, H-5Fuc), 4.39 (ddd, 3J1,1a-Cyc = 3.9 Hz, 3J1,1b-Cyc = 8.9 Hz, 3J1,2 = 6.1 Hz, 1 H, H-
1Fuc), 5.25 (d, 3J3,4 = 3.3 Hz, 3J4,5 = 1.3 Hz, 1 H, H-4Fuc), 5.30 (m, 2 H, H-2Fuc, H-3Fuc);  
 
13C NMR (125 MHz, CDCl3): δ 16.3 (C-6Fuc), 20.2, 25.5, 26.8, 27.4, 29.7 (5 C, C-2Cyc, C-4Cyc, 
C-5Cyc, C-6Cyc, C-7Cyc), 27.1, 27.3, 27.6 (3 CMe3), 33.3 (C-1Cyc), 38.5, 38.7, 39.2 (3 CMe3), 
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66.3 (C-5Fuc), 68.7 (C-3Cyc), 69.4 (C-2Fuc), 69.8 (C-3Fuc), 71.5 (C-4Fuc), 72.0 (C-1Fuc), 177.2, 
177.5, 177.6 (3 COO). 
 
 
 
(2R,3R,4R)-4-Hydroxy-2-methyl-3-(2,3,4-tri-O-benzoyl-α-L-
fucopyranosyl-methyl)-tetrahydropyran (130a) (II-227, 
cm281): 
A solution of 125 (41.0 mg, 0.068 mmol) in THF (10 ml) was 
cooled to 0°C, Li[(tBuO)3AlH] (52.0 mg, 0.204 mmol) was added 
and the mixture was stirred for 20 h, being allowed to warm to room temperature. The 
reaction was then quenched at 0°C with satd. aqueous NH4Cl (50 ml), extracted with CH2Cl2 
(100 ml), dried with Na2SO4, filtered and concentrated under reduced pressure. Purification 
by silica gel column chromatography (petroleum ether/ethyl acetate 2:1) yielded 130a (37.0 
mg, 0.063 mmol, 93%). 
 
Rf = 0.28 (petroleum ether/ethyl acetate 1:1); 
 
[ ]22 D α  = -142.8 (c = 0.5, CHCl3); 
 
1H NMR (500 MHz, CDCl3): δ 1.10 (d, 3J5,6 = 6.1 Hz, 3 H, H-6Pyr), 1.28 (d, 3J5,6 = 6.4 Hz, 3 H, 
H-6Fuc), 1.28 (m, 1 H, H-4Pyr), 1.57 (m, 1 H, H-2aPyr), 1.61 (m, 1 H, H-7aPyr), 1.86 (m, 1 H, H-
2bPyr), 1.96 (m, 1 H, H-7bPyr), 3.09 (dq, 3J4,5 = 9.6 Hz, 3J5,6 = 6.1 Hz, 1 H, H-5Pyr), 3.34 (ddd, 
2J1ax,1eq = 11.7 Hz, 3J1ax,2eq = 1.8 Hz, 3J1ax,2ax = 11.4 Hz, 1 H, H-1axPyr), 3.40 (ddd, 3J = 4.2 Hz, 
9.7 Hz, 10.6 Hz, 1 H, H-3Pyr), 3.88 (ddd, 3J = 2.0 Hz, 4.8 Hz,11.7 Hz, 1 H, H-1eqPyr), 4.47 (dq, 
3J4,5 = 2.0 Hz, 3J5,6 = 6.4 Hz, 1 H, H-5Fuc), 4.57 (ddd, 3J1,2 = 4.5 Hz, 3J1,7a = 2.1 Hz, 3J1,7b = 
11.4 Hz, 1 H, H-1Fuc), 5.68 (m, 3 H, H-2Fuc, H-3Fuc, H-4Fuc), 7.18-8.05 (m, 15 H, 3 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 16.5 (C-6Fuc), 20.2 (C-6Pyr), 26.8 (C-7Pyr), 34.4 (C-2Pyr), 48.3 
(C-4Pyr), 65.9 (C-1Pyr), 68.0 (C-5Fuc), 69.9 (2 C, C-2Fuc, C-3Fuc), 72.0 (C-4Fuc), 71.3 (C-1Fuc), 
71.4 (C-3Pyr), 76.0 (C-5Pyr), 127.4, 127.6, 128.0, 128.3, 128.7, 128.8, 129.8, 130.3, 130.6, 
132.3, 132.4, 132.5 (18 C, 3 C6H5), 164.6, 164.7, 164.8 (3 COO). 
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Benzyl (2S)-3-cyclohexyl-2-O-{2,4,6-tri-O-benzoyl-1-O-
[(1R,2S)-2-(2,3,4-tri-O-benzoyl-α-L-fucopyranosyl-
methyl)-cyclohexyl]-β-D-galactopyranos-3-
yl}propanoate (135a) (II-86, cm138):  
A solution of 128a (50.0 mg, 0.087 mmol), benzyl (2S)-3-
cyclohexyl-2-O-[1-S-ethyl-2,4,6-tri-O-benzoyl-β-D-thio-galactopyranos-3-yl] propanoate (90) 
(102 mg, 0.131 mmol) and 3Å molecular sieves (0.5g) in CH2Cl2 (10 ml) was cooled to -20°C. 
After stirring for 30 min at –20°C, NIS (59.0 mg, 0.262 mmol) was added and stirring was 
continued for 30 min. Trifluoromethanesulfonic acid (70 µl) was added and the dark-purple 
solution was stirred at –20°C for 4 h. Filtration of molecular sieves, washing of the organic 
layer with satd. aqueous Na2S2O3 (50 ml) and satd. aqueous NaHCO3 (50 ml), drying with 
Na2SO4, evaporation of the solvent and purification of the crude product mixture by silica gel 
chromatography (toluene/ethyl acetate 25:1) yielded 135a (92.0 mg, 0.071 mmol, 82%). 
 
Rf = 0.58 (toluene/ethyl acetate 5:1); 
 
[ ]21 D α  = -50.9 (c = 0.55, CHCl3); 
 
1H NMR (500 MHz, CDCl3): δ 0.42-1.96 (m, 20 H, H-2Cyc, H-4a+bCyc, H-5a+bCyc, H-6a+bCyc, H-
7a+bCyc, H-4Lac, H-5a+bLac, H-6a+bLac, H-7a+bLac, H-8a+bLac, H-9a+bLac), 1.08 (m, 1 H, H-1aCyc), 1.18 
(d, 3J5,6 = 6.4 Hz, 3 H, H-6Fuc), 1.26 (m, 1 H, H-3aLac), 1.34 (m, 1 H, H-3bLac), 2.84 (m, 1 H, H-
1bCyc), 3.31 (ddd, 3J2,3 = 9.8 Hz, 3J3,4a = 4.2 Hz, 3J3,4b = 9.8 Hz, 1 H, H-3Cyc), 3.90 (dd, 3J2,3 = 
9.8 Hz, 3J3,4 = 3.6 Hz, 1 H, H-3Gal), 3.98 (ddd, 3J4,5 = 1.1 Hz, 3J5,6a = 6.6 Hz, 3J5,6b = 6.8 Hz, 1 
H, H-5Gal), 4.18 (dd, 3J2,3a = 4.4 Hz, 3J2,3b = 7.8 Hz, 1 H, H-2Lac), 4.31 (dq, 3J4,5 = 0.8 Hz, 3J5,6 = 
6.4 Hz, 1 H, H-5Fuc), 4.56 (ddd, 3J1,1a-Cyc = 3.4 Hz, 3J1,1b-Cyc = 12.9 Hz, 3J1,2 = 5.9 Hz, 1 H, H-
1Fuc), 4.60 (m, 1 H, H-6aGal), 4.65 (d, 3J1,2 = 8.0 Hz, 1 H, H-1Gal), 4.67 (m, 1 H, H-6bGal), 5.10, 
5.13 (AB, 2JA,B = 12.8 Hz, 2 H, CH2-Ph), 5.66 (dd, 3J1,2 = 8.0 Hz, 3J2,3 = 9.8 Hz, 1 H, H-2Gal), 
5.73 (dd, 3J3,4 = 3.4 Hz, 3J4,5 = 0.8 Hz, 1 H, H-4Fuc), 5.78 (dd, 3J1,2 = 5.9 Hz, 3J2,3 = 10.5 Hz, 1 
H, H-2Fuc), 5.95 (dd, 3J2,3 = 10.5 Hz, 3J3,4 = 3.4 Hz, 1 H, H-3Fuc), 5.97 (dd, 3J3,4 = 3.6 Hz, 3J4,5 = 
1.1 Hz, 1 H, H-4Gal), 7.22-8.20 (m, 35 H, 7 C6H5);  
 
13C NMR (125 MHz, CDCl3): δ 16.5 (C-6Fuc), 24.3, 24.9, 25.5, 25.8, 26.1, 29.7, 30.3, 30.8, 
32.7, 33.3, 33.4, 37.9, 40.5 (13 C, C-1Cyc, C-2Cyc, C-4Cyc, C-5Cyc, C-6Cyc, C-7Cyc, C-3Lac, C-4Lac, 
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C-5Lac, C-6Lac, C-7Lac, C-8Lac, C-9Lac), 62.7 (C-6Gal), 65.5 (C-5Fuc), 66.6 (CH2-Ph), 69.0 (C-3Fuc), 
69.8 (C-4Gal), 69.4 (C-2Fuc), 70.4 (C-1Fuc), 71.9 (C-5Gal), 72.6 (C-2Gal), 72.7 (C-4Fuc), 77.2 (C-
3Gal), 78.3 (C-2Lac), 79.9 (C-3Cyc), 98.5 (C-1Gal), 128.0, 128.2, 128.3, 128.5, 128.6, 128.6, 
128.9, 129.3, 129.4, 129.4, 129.6, 129.7, 129.9, 130.1, 130.1, 130.2, 130.5, 130.6, 130.7, 
130.8, 130.9, 132.7, 133.1, 133.2, 133.4, 133.8, 134.4, 135.6 (42 C, 7 C6H5), 164.8, 165.1, 
165.8, 165.9, 166.0, 166.1, 172.5 (7 COO). 
 
elemental analysis calcd (%) for C77H78O18 (1291.47): C 71.61, H 6.09, O 22.30;  
found: C 71.29, H 6.12, O 22.59. 
 
 
Benzyl (2S)-3-cyclohexyl-2-O-{2,4,6-tri-O-benzoyl-1-O-
[(1S,2R)-2-(2,3,4-tri-O-benzoyl-α-L-fucopyranosyl-
methyl)-cyclohexyl]-β-D-galactopyranos-3-yl} 
propanoate (135b) (II-67, cm119):  
A solution of 128b (100 mg, 0.175 mmol), benzyl (2S)-3-
cyclohexyl-2-O-[1-S-ethyl-2,4,6-tri-O-benzoyl-β-D-thio-
galactopyranos-3-yl] propanoate (90) (205 mg, 0.262 mmol) and activated 3Å molecular 
sieves (1g) in CH2Cl2 (20 ml) was cooled to -20°C. After stirring for 30 min at -20°C, NIS 
(78.0 mg, 0.345 mmol) was added and stirring was continued for 30 min. 
Trifluoromethanesulfonic acid (70.0 µl) was added and the dark-purple solution was stirred at 
-20°C for 4 h. Filtration of molecular sieves, washing of the organic layer with satd. aqueous 
Na2S2O3 (50 ml) and satd. aqueous NaHCO3 (50 ml), drying with Na2SO4, evaporation of the 
solvent under reduced pressure and purification of the crude product mixture by silica gel 
chromatography (toluene/ethyl acetate 25:1) yielded 135b (170 mg, 0.132 mmol, 80%). 
 
Rf = 0.65 (toluene/ethyl acetate 5:1); 
 
[ ]21 D α  = -33.0 (c = 0.25, CHCl3); 
 
1H NMR (500 MHz, CDCl3): δ 0.50-1.80 (m, 17 H, H-5a+bCyc, H-6a+bCyc, H-7a+bCyc, H-4Lac, H-
5a+bLac, H-6a+bLac, H-7a+bLac, H-8a+bLac, H-9a+bLac), 1.02 (d, 3J5,6 = 6.8 Hz, 3 H, H-6Fuc), 1.16 (m, 1 
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H, H-1aCyc), 1.32 (m, 2 H, H-3aLac, H-4aCyc), 1.39 (m, 1 H, H-3bLac), 1.48 (m, 1 H, H-2Cyc), 1.92 
(m, 1 H, H-4bCyc), 2.26 (m, 1 H, H-1bCyc), 3.22 (ddd, 3J2,3 = 8.5 Hz, 3J3,4a = 3.5 Hz, 3J3,4b = 8.5 
Hz, 1 H, H-3Cyc), 3.49 (dq, 3J4,5 = 1.2 Hz, 3J5,6 = 6.8 Hz, 1 H, H-5Fuc), 3.90 (dd, 3J2,3 = 8.9 Hz, 
3J3,4 = 3.5 Hz, 1 H, H-3Gal), 3.92 (dd, 3J4,5 = 0.8 Hz, 3J5,6 = 7.3 Hz, 1 H, H-5Gal), 4.16 (dd, 3J2,3a 
= 4.5 Hz, 3J2,3b = 7.7 Hz, 1 H, H-2Lac), 4.31 (m, 1 H, H-1Fuc), 4.42 (m, 2 H, H-6a+bGal), 4.62 (d, 
3J1,2 = 7.8 Hz, 1 H, H-1Gal), 5.10, 5.12 (AB, 2JA,B = 12.6 Hz, 2 H, CH2-Ph), 5.52 (dd, 3J3,4 = 3.5 
Hz, 3J4,5 = 1.7 Hz, 1 H, H-4Fuc), 5.58 (dd, 3J2,3 = 9.7 Hz, 3J3,4 = 3.5 Hz, 1 H, H-3Fuc), 5.63 (dd, 
3J1,2 = 7.8 Hz, 3J2,3 = 8.9 Hz, 1 H, H-2Gal), 5.77 (dd, 3J1,2 = 5.7 Hz, 3J2,3 = 9.7 Hz, 1 H, H-2Fuc), 
5.84 (dd, 3J3,4 = 3.5 Hz, 3J4,5 = 0.7 Hz, 1 H, H-4Gal), 7.22-8.20 (m, 35 H, 7 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 15.9 (C-6Fuc), 24.3, 24.5, 26.4, 26.5, 26.7, 29.7, 30.1, 32.5, 
33.0, 33.7, 34.8, 40.8, 41.0 (13 C, C-1Cyc, C-2Cyc, C-4Cyc, C-5Cyc, C-6Cyc, C-7Cyc, C-3Lac, C-4Lac, 
C-5Lac, C-6Lac, C-7Lac, C-8Lac, C-9Lac), 63.3 (C-6Gal), 66.4 (C-5Fuc), 66.6 (CH2-Ph), 69.4 (C-2Fuc), 
70.0 (C-3Fuc), 70.2 (C-4Gal), 71.5 (C-4Fuc), 71.8 (C-1Fuc), 72.3 (C-5Gal), 73.7 (C-2Gal), 78.2 (C-
3Gal), 78.8 (C-2Lac), 84.3 (C-3Cyc), 101.0 (C-1Gal), 128.5, 128.6, 128.7, 128.8, 129.1, 129.2, 
129.2, 130.1, 130,2, 130.3, 130.4, 130.5, 130.7, 130.7, 130.8, 130.9, 131.1, 131.2, 131.2, 
131.3, 131.3, 133.2, 133.3, 133.4, 133.4, 133.5, 133.7, 133.8 (42 C, 7 C6H5), 164.5, 165.2, 
166.0, 166.1, 166.8, 167.2, 173.2 (7 COO); 
 
elemental analysis calcd (%) for C77H78O18 (1291.47): C 71.61, H 6.09, O 22.30;  
found: C 71.27, H 6.05, O 22.68. 
 
 
Benzyl (2S)-3-cyclohexyl-2-O-{2,4,6-tri-O-benzoyl-1-
O-[(2R,3R,4R)-4-hydroxy-2-methyl-3-(2,3,4-tri-O-
benzoyl-α-L-fucopyranosyl-methyl)-tetrahydropyran-
4-yl]-β-D-galactopyranos-3-yl} propanoate (136):  
 
Method A (II-230, cm284): 130a (20.0 mg, 0.034 mmol) and benzyl (2S)-3-cyclohexyl-2-O-
[1-S-ethyl-2,4,6-tri-O-benzoyl-β-D-thio-galactopyranos-3-yl] propanoate (90) (80.0 mg, 0.102 
mmol) were dissolved in CH2Cl2 (10ml) containing 3Å MS and cooled to –20°C. After 30 min, 
NIS (24.0 mg, 0.102 mmol) was added and the mixture was stirred for further 30 min. TfOH 
(15.0 µl) was added and the reaction was stirred for 6 h at –20°C. The dark-red suspension 
was then filtered through celite, diluted with CH2Cl2 (50 ml), washed with satd. aqueous 
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Na2S2O3 (50 ml) and satd. aqueous NaHCO3 (2 x 50 ml), dried with Na2SO4, filtered and 
concentrated. Purification by silica gel chromatography (petroleum ether/ethyl acetate 3:1) 
yielded 136 (31.0 mg, 0.023 mmol, 69%). 
Method B (II-216, cm270): 130a (10.0 mg, 0.017 mmol) and benzyl (2S)-3-cyclohexyl-2-O-
[1-S-ethyl-2,4,6-tri-O-benzoyl-β-D-thio-galactopyranos-3-yl] propanoate (90) (40.0 mg, 0.034 
mmol) were dissolved in CH2Cl2 (10ml) containing 3Å MS and cooled to –5°C. After 30 min of 
stirring, DMTST (20.0 mg, 0.068 mmol) was added and the reaction was stirred for 24 h at –
5°C. The mixture was then filtered through celite, washed with satd. aqueous NaHCO3 (2 x 
50 ml), dried with Na2SO4, filtered and concentrated. Purification by silica gel 
chromatography (petroleum ether/ethyl acetate 3:1) yielded 136 (18.0 mg, 0.014 mmol, 
80%). 
 
Rf = 0.27 (petroleum ether/ethyl acetate 2:1); 
 
[ ]22 D α  = -53.4 (c = 0.5, CHCl3); 
 
1H NMR (500 MHz, CDCl3): δ 0.38-1.24 (m, 11 H, H-4Lac, H-5a+bLac, H-6a+bLac, H-7a+bLac, H-
8a+bLac, H-9a+bLac), 1.03 (m, 1 H, H-7aPyr), 1.06 (d, 3J5,6 = 6.1 Hz, 3 H, H-6Pyr), 1.24 (m, 2 H, H-
2aPyr, H-3aLac), 1.32 (m, 1 H, H-3bLac), 1.34 (d, 3J5,6 = 5.9 Hz, 3 H, H-6Fuc), 1.44 (m, 1 H, H-4Pyr), 
1.68 (m, 1 H, H-2bPyr), 2.56 (ddd, 3J1,7b = 3.4 Hz, 3J4,7b = 11.5 Hz, 2J7a,7b = 13.8 Hz, 1 H, H-
7bPyr), 2.78 (dq, 3J4,5 = 9.7 Hz, 3J5,6 = 6.1 Hz, 1 H, H-5Pyr), 3.12 (ddd, 3J1ax,1eq = 11.6 Hz, 
3J1ax,2eq = 2.1 Hz, 3J1ax,2ax = 12.0 Hz, 1 H, H-1axPyr), 3.25 (ddd, 3J = 4.8 Hz, 9.8 Hz, 10.7 Hz, 1 
H, H-3Pyr), 3.72 (ddd, 3J = 1.8 Hz, 4.8 Hz, 11,6 Hz, 1 H, H-1eqPyr), 3.84 (dd, 3J2,3 = 9.9 Hz, 3J3,4 
= 3.4 Hz, 1 H, H-3Gal), 3.98 (ddd, 3J4,5 = 1.6 Hz, 3J5,6a = 5.8 Hz, 3J5,6b = 7.4 Hz, 1 H, H-5Gal), 
4.11 (dd, 3J = 4.5, 7.9 Hz, 1 H, H-2Lac), 4.53 (d, 3J1,2 = 7.8 Hz, 1 H, H-1Gal), 4.56 (ddd, 3J1,2 = 
5.9 Hz, 3J1,7a-Pyr = 13.8 Hz, 3J1,7b-Pyr = 3.4 Hz, 1 H, H-1Fuc), 4.65 (m, 2 H, H-6aGal, H-5Fuc), 4.87 
(dd, 3J5,6b = 7.4 Hz, 3J6a,6b = 11.6 Hz, 1 H, H-6bGal), 5.01, 5.09 (AB, 2JA,B = 12.0 Hz, CH2-Ph), 
5.55 (dd, 3J1,2 = 7.8 Hz, 3J2,3 = 9.9 Hz, 1 H, H-2Gal), 5.65 (m, 2 H, H-2Fuc, H-4Fuc), 5.92 (m, 2 H, 
H-3Fuc, H-4Gal), 7.03-8.14 (m, 35 H, 7 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 17.0 (C-6Fuc), 20.2 (C-6Pyr), 24.0 (C-7Pyr), 25.9, 26.1, 26.6, 
30.1, 32.3, 33.7 (6 C, C-4Lac, C-5Lac, C-6Lac, C-7Lac, C-8Lac, C-9Lac) 33.0 (C-2Pyr), 40.8 (C-3Lac), 
43.1 (C-4Pyr), 63.1 (C-6Gal), 65.8 (C-1Pyr), 67.0 (C-5Fuc), 67.2 (CH2-Ph), 69.1 (C-3Fuc), 70.1 (C-
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4Gal), 71.1 (C-2Fuc), 72.6 (C-1Fuc), 72.8 (C-5Gal), 72.9 (C-2Gal), 73.4 (C-4Fuc), 78.0 (C-3Gal), 78.7 
(C-2Lac), 78.8 (C-5Pyr), 80.2 (C-3Pyr), 100.0 (C-1Gal), 128.3, 128.4, 128.5, 128.6, 128.6, 128.9, 
129.3, 129.4, 129.4, 129.6, 129.7, 129.9, 130.1, 130.1, 130.2, 130.5, 130.6, 130.7, 130.8, 
130.9, 132.7, 133.1, 133.2, 133.4, 133.8, 134.4, 135.6, 135.9 (42 C, 7 C6H5), 165.2, 165.5, 
165.8, 166.3, 166.4, 166.6, 172.9 (7 COO). 
 
elemental analysis calcd (%) for C77H78O19 (1307.44): C 70.74, H 6.01, O 23.25;  
found: C 70.79, H 6.28, O 22.95. 
 
 
Methyl (2S)-3-cyclohexyl-2-O-{2-O-benzoyl-1-O-
[(1R,2S)-2-(α-L-fucopyranosyl-methyl)-cyclohexyl]-β-
D-galactopyranos-3-yl} propanoate (137a) (II-136, 
cm192):  
To a solution of 135a (64.0 mg, 0.049 mmol) in MeOH (5 ml), NaOMe/MeOH (1M, 100 µl) 
was added and the reaction was stirred at room temperature for 1 h and at 40°C for 2 h. The 
mixture was then neutralized with amberlyste ion-exchange resin (H+ form), filtered through 
celite, concentrated and the remaining crude product was purified by silica gel column 
chromatography (CH2Cl2/MeOH 3:1) to yield 137a (30.0 mg, 0.044 mmol, 89%). 
 
Rf = 0.16 (CH2Cl2/MeOH 2:1); 
 
1H NMR (500 MHz, CDCl3): δ 0.60-1.90 (m, 17 H, H-5a+bCyc, H-6a+bCyc, H-7a+bCyc, H-4Lac, H-
5a+bLac, H-6a+bLac, H-7a+bLac, H-8a+bLac, H-9a+bLac), 0.98 (m, 1 H, H-2Cyc), 1.27 (d, 3J5,6 = 6.1 Hz, 1 
H, H-6Fuc), 1.34 (m,1 H, H-3aLac), 1.46 (m, 2 H, H-1aCyc, H-4aCyc), 1.55 (m, 1 H, H-3bLac), 1.91 
(m, 1 H, H-4bCyc), 2.26 (m, 1 H, H-1bCyc), 3.34 (ddd, 3J = 4.2 Hz, 3J = 8.5 Hz, 3J = 8.6 Hz, 1 H, 
H-3Cyc), 3.53 (dd, 3J2,3 = 9.6 Hz, 3J3,4 = 4.8 Hz, 1 H, H-3Gal), 3.59 (m, 1 H, H-5Gal), 3.82 (dd, 
3J3,4 = 2.1 Hz, 3J4,5 = 1.0 Hz, 1 H, H-4Fuc), 3.86 (m, 2 H, H-3Fuc, H-4Gal), 3.89 (dq, 3J4,5 = 1.0 
Hz, 3J5,6 = 6.1 Hz, 1 H, H-5Fuc), 3.97 (m, 2 H, H-2Lac, H-6aGal), 4.04 (m, 2 H, H-2Fuc, H-6bGal), 
4.21 (ddd, 3J1,1a-Cyc = 10.6 Hz, 3J1,1b-Cyc = 2.1 Hz, 3J1,2 = 5.3 Hz, 1 H, H-1Fuc), 4.61 (d, 3J1,2 = 
8.0 Hz, 1 H, H-1Gal), 5.44 (dd, 3J1,2 = 8.0 Hz, 3J2,3 = 9.6 Hz, 1 H, H-2Gal), 7.40-8.12 (m, 5 H, 
C6H5); 
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Methyl (2S)-3-cyclohexyl-2-O-{2-O-benzoyl-1-O-
[(1S,2R)-2-(α-L-fucopyranosyl-methyl)-cyclohexyl]-β-D-
galactopyranos-3-yl} propanoate (138b) (II-25, cm079): 
Under argon, 135b (155 mg, 0.120 mmol) was dissolved in 
methanol (5 ml). A solution of NaOMe in MeOH (0.1 M, 5 
ml) was added and the reaction mixture was stirred at 
room temperature for 2 h. After neutralization with 
amberlyste ion-exchange resin (H+ form), the suspension was filtered through celite, 
concentrated and the remaining crude product was purified by silica gel column 
chromatography (CH2Cl2/MeOH 6:1) to yield 138b (73.0 mg, 0.105 mmol, 88%). 
 
Rf = 0.71 (CH2Cl2/MeOH 4:1); 
 
1H NMR (500 MHz, CDCl3): δ 0.52-1.95 (m, 20 H, H-2Cyc, H-4a+bCyc, H-5a+bCyc, H-6a+bCyc, H-
7a+bCyc, H-4Lac, H-5a+bLac, H-6a+bLac, H-7a+bLac, H-8a+bLac, H-9a+bLac), 1.05 (m, 1 H, H-1aCyc), 1.13 
(d, 3J5,6 = 6.3 Hz, 3 H, H-6Fuc), 1.32 (m, 1 H, H-3aLac), 1.56 (m, 1 H, H-3bLac), 2.19 (m, 1 H, H-
1bCyc), 3.39 (m, 2 H, H-5Fuc, H-3Cyc), 3.55 (dd, 3J2,3 = 9.4 Hz, 3J3,4 = 2.5 Hz, 1 H, H-3Gal), 3.62 
(m, 2 H, H-3Fuc, H-5Gal), 3.66 (dd, 1 H, H-4Fuc), 3.74 (s, 3 H, OMe), 3.80 (dd, 3J1,2 = 3.7 Hz, 
3J2,3 = 11.3 Hz, 1 H, H-2Fuc), 3.91 (m, 1 H, H-4Gal), 3.95-4.05 (m, 4 H, H-1Fuc, H-2Lac, H-6a+bGal), 
4.70 (d, 3J1,2 = 8.5 Hz, 1 H, H-1Gal), 5.51 (dd, 3J1,2 = 8.5 Hz, 3J2,3 = 9.4 Hz, 1 H, H-2Gal), 7.47, 
7.59, 8.08 (m, 5 H, C6H5). 
 
 
(2S)-3-cyclohexyl-2-O-{1-O-[(1S,2R)-2-(α-L-fuco-
pyranosyl-methyl)-cyclohexyl]-β-D-galactopyranos-3-yl} 
propanoic acid (139b) (II-68, cm120): 
Under argon, 135b (140 mg, 0.110 mmol) was dissolved in 
methanol (5 ml) and a solution of NaOMe in MeOH (23.0 
mg Na dissolved in 5 ml MeOH) was added. The mixture 
was then stirred at 55°C for 42 h, neutralized with amberlyste ion-exchange resin (H+ form), 
filtered through celite, concentrated and the remaining crude product was purified by silica 
gel column chromatography (CH2Cl2/MeOH/H2O 10:4:0.8) to yield 139b (60.0 mg, 0.104 
mmol, 94%). 
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Rf = 0.27 (CH2Cl2/MeOH/H2O 10:4:0.8); 
 
1H NMR (500 MHz, CDCl3/CD3OD): δ 0.90-2.17 (m, 20 H, H-2Cyc, H-4a+bCyc, H-5a+bCyc, H-
6a+bCyc, H-7a+bCyc, H-4Lac, H-5a+bLac, H-6a+bLac, H-7a+bLac, H-8a+bLac, H-9a+bLac), 1.24 (d, 3J5,6 = 6.6 
Hz, 3 H, H-6Fuc), 1.38 (m, 1 H, H-1aCyc), 1.66 (m, 1 H, H-3aLac), 1.69 (m, 1 H, H-3bLac), 2.17 (m, 
1 H, H-1bCyc), 3.24 (dd, 3J2,3 = 9.2 Hz, 3J3,4 = 3.4 Hz, 1 H, H-3Gal), 3.29 (ddd, 3J = 3.7 Hz, 10.0 
Hz, 10.1 Hz, H-3Cyc), 3.47 (m, 1 H, H-5Gal), 3.67 (m, 2 H, H-2Gal, H-3Fuc), 3.71 (dd, 3J3,4 = 3.1 
Hz, 3J4,5 = 1.8 Hz, 1 H, H-4Fuc), 3.75 (m, 2 H, H-6a+bGal), 3.85 (dq, 3J4,5 = 1.8 Hz, 3J5,6 = 6.6 Hz, 
1 H, H-5Fuc), 3.85 (dd, 3J1,2 = 5.3 Hz, 3J2,3 = 9.2 Hz, 1 H, H-2Fuc), 3.93 (m, 2 H, H-2Lac, H-4Gal), 
4.16 (ddd, 3J1,1a-Cyc = 4.0 Hz, 3J1,1b-Cyc = 9.1 Hz, 3J1,2 = 5.3 Hz, 1 H, H-1Fuc), 4.30 (d, 3J1,2 = 7.5 
Hz, 1 H, H-1Gal); 
 
13C NMR (125 MHz, CDCl3/CD3OD): δ 16.2 (C-6Fuc), 25.1, 25.9, 26.7, 27.1, 28.4, 32.7, 34.0, 
34.3, 34.6, 42.1, 42.4 (12 C, C-1Cyc, C-2Cyc, C-4Cyc, C-5Cyc, C-6Cyc, C-7Cyc, C-4Lac, C-5Lac, C-
6Lac, C-7Lac, C-8Lac, C-9Lac), 26.5 (C-3Lac), 61.8 (C-6Gal), 66.6 (C-4Gal), 68.1 (C-5Fuc), 69.7 (C-
2Fuc), 71.2 (C-3Fuc), 71.3 (C-2Gal), 71.8 (C-4Fuc), 74.7 (C-5Gal), 75.2 (C-1Fuc), 78.4 (C-2Lac), 84.5 
(C-3Gal), 86.5 (C-3Cyc), 105.0 (C-1Gal) , 183.7 (COONa). 
 
 
Methyl (2S)-3-cyclohexyl-2-O-{2-O-benzoyl-1-O-
[(2R,3R,4R)-4-hydroxy-2-methyl-3-(α-L-fuco-
pyranosyl)-methyl-tetrahydropyran-4-yl]-β-D-galacto-
pyranos-3-yl} propanoate (140) (II-234, cm288):  
To a solution of 136 (35.0 mg, 0.027 mmol) in methanol (5 ml), NaOMe/MeOH (1 M, 100µl) 
was added and the reaction was stirred for 11 h at room temperature. The mixture was then 
neutralized with amberlyste ion-exchange resin (H+ form), filtered through celite and 
concentrated. Purification by silica gel chromatography (CH2Cl2/MeOH 5:1) yielded 140 (16.5 
mg, 0.023 mmol, 87%). 
 
Rf = 0.43 (CH2Cl2/MeOH 4:1); 
 
[ ]22 D α  = -57.2 (c = 0.9, MeOH); 
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1H NMR (500 MHz, CD3OD): δ 0.60-1.61 (m, 11 H, H-4Lac, H-5a+bLac, H-6a+bLac, H-7a+bLac, H-
8a+bLac, H-9a+bLac), 1.15 (m, 1 H, H-2axPyr), 1.20 (d, 3J5,6 = 5.9 Hz, 3 H, H-6Pyr), 1.27 (d, 3J5,6 = 
6.3 Hz, 3 H, H-6Fuc), 1.31 (m, 1 H, H-4Pyr), 1.36 (m, 2 H, H-3aLac, H-7aPyr), 1.53 (m, 1 H, H-
3bLac), 1.95 (m, 1 H, H-2eqPyr), 2.24 (ddd, J = 11.9 Hz, 12.2 Hz, 3.0 Hz, 1 H, H-7bPyr), 3.19 (dq, 
3J4,5 = 9.7 Hz, 3J5,6 = 5.9 Hz, 1 H, H-5Pyr), 3.38 (ddd, J = 12.6 Hz, 12.3 Hz, 1.5 Hz, 1 H, H-
1axPyr), 3.56 (ddd, J = 10.7 Hz, 10.4 Hz, 4.4 Hz, 1 H, H-3Pyr), 3.62 (ddd, 3J4,5 = 2.5 Hz, 3J5,6a = 
6.6 Hz, 3J5,6b = 6.0 Hz, 1 H, H-5Gal), 3.72 (m, 2 H, H-3Gal, H-3Fuc), 3.76 (s, 3 H, OMe), 3.77 (m, 
1 H, H-4Fuc), 3.81 (m, 3 H, H-6a+bGal, H-1eqPyr), 3.95 (m, 2 H, H-1Fuc, H-2Fuc), 4.02 (dd, 3J3,4 = 
1.8 Hz, 3J4,5 = 2.5 Hz, 1 H, H-4Gal), 4.17 (dd, 3J2,3a = 3.1 Hz, 3J2,3b = 9.7 Hz, 1 H, H-2Lac), 4.31 
(dq, 3J4,5 = 1.5 Hz, 3J5,6 = 6.3 Hz, 1 H, H-5Fuc), 4.73 (d, 3J1,2 = 7.8 Hz, 1 H, H-1Gal), 5.47 (dd, 
3J1,2 = 7.8 Hz, 3J2,3 = 6.6 Hz, 1 H, H-2Gal), 7.52-8.11 (m, 5 H, C6H5); 
 
13C NMR (125 MHz, CD3OD): δ 17.3 (C-6Fuc), 20.7 (C-6Pyr), 24.3 (C-7Pyr), 24.9, 26.9, 27.2, 
27.6, 31.1, 33.6 (6 C, C-4Lac, C-5Lac, C-6Lac, C-7Lac, C-8Lac, C-9Lac), 34.0 (C-2Pyr), 42.9 (C-3Lac), 
45.8 (C-4Pyr), 53.2 (OCH3), 62.9 (C-6Gal), 66.8 (C-1Pyr), 68.6 (C-4Gal), 68.7 (C-5Fuc), 70.5 (C-
2Fuc), 72.3 (C-3Fuc), 73.6 (C-2Gal), 73.8 (C-4Fuc), 76.2 (C-1Fuc), 76.4 (C-5Gal), 78.7 (C-2Lac), 79.9 
(C-3Pyr), 80.0 (C-5Pyr), 83.5 (C-3Gal), 100.6 (C-1Gal), 131.3, 131.9, 132.3, 133.6, 135.0 (6 C, 
C6H5). 
 
 
Sodium (2S)-3-cyclohexyl-2-O-{2-O-benzoyl-1-O-
[(2R,3R,4R)-4-hydroxy-2-methyl-3-(α-L-fuco-
pyranosyl-methyl)-tetrahydropyran-4-yl]-β-D-galacto-
pyranos-3-yl} propanoate (141) (II-240, cm294):  
To a solution of 140 (5.00 mg, 7.03 µmol) in a mixture of dioxane and water (1:1, 4 ml), LiOH 
(16.0 mg, 0.700 mmol) was added and the reaction was stirred at room temperature for 3 h. 
The mixture was then acidified to pH 4 (diluted HCl), freeze-dried, passed over Dowex 50x8 
ion-exchange resin (Na+ form), purified by RP-18 reversed-phase silica gel column 
chromatography (gradient MeOH/H2O 0:1 → 1:0) and P2 column chromatography to yield 
141 (3.00 mg, 4.17 µmol, 60 %). 
 
Rf = 0.24 (CH2Cl2/MeOH 2:1); 
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1H NMR (500 MHz, D2O): δ 0.51-1.63 (m, 11 H, H-4Lac, H-5a+bLac, H-6a+bLac, H-7a+bLac, H-8a+bLac, 
H-9a+bLac), 1.17 (m, 1 H, H-2aPyr), 1.18 (d, 3J5,6 = 6.3 Hz, 3 H, H-6Pyr), 1.23 (d, 3J5,6 = 6.3 Hz, 3 
H, H-6Fuc), 1.29 (m, 1 H, H-4Pyr), 1.37 (m, 1 H, H-7aPyr), 1.41 (m, 1 H, H-3aLac), 1.50 (ddd, J = 
9.7 Hz, 6.6 Hz, 3.4 Hz, 1 H, H-3bLac), 1.97 (m, 1 H, H-2bPyr), 2.22 (ddd, J = 15.1 Hz, 12.9 Hz, 
1.5 Hz, H-7bPyr), 3.19 (dq, 3J5,6 = 6.3 Hz, 3J5,4 = 9.4 Hz, 1 H, H-5Pyr), 3.39 (ddd, J = 12.9 Hz, 
11.6 Hz, 1.5 Hz, 1 H, H-1aPyr), 3.57 (ddd, J = 11.3 Hz, 10.4 Hz, 4.4 Hz, 1 H, H-3Pyr), 3.61 (dd, 
3J2,3 = 9.7 Hz, 3J3,4 = 2.5 Hz, 1 H, H-3Gal), 3.63 (ddd, J = 0.6 Hz, 5.3 Hz, 5.9 Hz, 1 H, H-5Gal), 
3.72 (m, 1 H, H-3Fuc), 3.75 (m, 1 H, H-4Fuc), 3.77-3.85 (m, 3 H, H-1bPyr, H-6a+bGal), 3.79 (m, 1 
H, H-2Lac), 3.92 (dd, 3J1,2 = 5.3 Hz, 3J2,3 = 9.8 Hz,1 H, H-2Fuc), 3.94 (m, 1 H, H-1Fuc), 3.98 (m, 1 
H, H-4Gal), 4.27 (dq, 3J4,5 = 1.2 Hz, 3J5,6 = 6.3 Hz, 1 H, H-5Fuc), 4.73 (d, 3J1,2 = 7.8 Hz, 1 H, H-
1Gal), 5.36 (dd, 3J1,2 = 7.8 Hz, 3J2,3 = 9.7 Hz, 1 H, H-2Gal), 7.50-8.10 (m, 5 H, C6H5); 
 
13C NMR (125 MHz, D2O): δ 16.1 (C-6Fuc), 19.1 (C-6Pyr), 22.7 (C-7Pyr), 26.9, 27.2, 27.8, 33.4, 
34.0, 34.9 (6 C, C-4Lac, C-5Lac, C-6Lac, C-7Lac, C-8Lac, C-9Lac), 32.5 (C-2Pyr), 42.6 (C-3Lac), 61.9 
(C-6Gal), 65.4 (C-1Pyr), 66.8 (C-4Gal), 67.3 (C-5Fuc), 68.9 (C-2Fuc), 70.0 (C-3Fuc), 72.0 (C-2Gal), 
72.3 (C-4Fuc), 74.6 (C-1Fuc), 74.9 (C-5Gal), 78.1 (C-3Pyr), 78.7 (C-5Pyr), 79.5 (C-2Lac), 82.6 (C-
3Gal), 99.2 (C-1Gal), 128.4, 129.8, 133.0, 134.7 (6 C, C6H5) , 183.1 (COONa). 
 
 
Benzyl (2S)-3-cyclohexyl-2-O-{2,4,6-tri-O-benzoyl-1-O-
isopropyl-β-D-galactopyranos-3-yl} propanoate (142) 
(II-161, cm217):  
Under argon, benzyl (2S)-3-cyclohexyl-2-O-[1-S-ethyl-
2,4,6-tri-O-benzoyl-β-D-thio-galactopyranos-3-yl] 
propanoate (90) (300 mg, 0.380 mmol) was dissolved in CH2Cl2 (10 ml) containing freshly 
activated 3Å molecular sieves (600 mg) and cooled to -5°C. After stirring for 1 h at –5°C, 
isopropanol (90.0 µl, 0.770 mmol) was added and stirring was continued for an additional 
hour, before DMTST (200 mg, 0.510 mmol) was added. The reaction mixture was then 
stirred for 24 h at –5°C, molecular sieves were filtered off, the reaction was quenched with 
satd. aqueous NaHCO3 (50 ml) and extracted with CH2Cl2 (3 x 50 ml). The combined organic 
layers were dried with Na2SO4, filtered, evaporated and dried under high vacuum. The crude 
product was purified by silica gel column chromatography (petroleum ether/ethyl acetate 6:1) 
to yield 142 (292 mg, 0.370 mmol, 98%). 
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Rf = 0.41 (petroleum ether/ethyl acetate 3:1); 
 
[ ]22 D α  = +17.7 (c = 1.03, CHCl3); 
 
1H NMR (500 MHz, CDCl3): δ 0.49-1.29 (m, 11 H, H-4Lac, H-5a+bLac, H-6a+bLac, H-7a+bLac, H-
8a+bLac, H-9a+bLac), 1.38 (m, 2 H, H-3a+bLac), 1.00 (d, 3J1,Me-1 = 6.1 Hz, 3 H, CHMe2), 1.18 (d, 
3J1,Me-2 = 6.2 Hz, 3 H, CHMe2), 3.87 (dq, 3J1,Me-1 = 6.1 Hz, 3J1,Me-2 = 6.2 Hz, 1 H, CHMe2), 3.91 
(dd, 3J2,3 = 9.9 Hz, 3J3,4 = 3.4 Hz, 1 H, H-3Gal), 3.98 (ddd, 3J4,5= 0.5 Hz, 3J5,6a = 5.3 Hz, 3J5,6b = 
7.4 Hz, 1 H, H-5Gal), 4.18 (dd, 3J2,3a = 4.5 Hz, 3J2,3b = 8.2 Hz, 1 H, H-2Lac), 4.43 (dd, 3J5,6a = 5.3 
Hz, 2J6a,6b = 11.5 Hz, 1 H, H-6aGal), 4.48 (dd 3J5,6b = 7.4 Hz, 2J6a,6b = 11.5 Hz, 1 H, H-6bGal), 
4.60 (d, 3J1,2 = 7.9 Hz, 1 H, H-1Gal), 5.04, 5.16 (AB, 2JA,B = 12.1 Hz, 2 H, CH2-Ph), 5.59 (dd, 
3J1,2= 7.9 Hz, 3J2,3= 9.9 Hz, 1 H, H-2Gal), 5.91 (dd, 3J3,4= 3.4 Hz, 3J4,5= 0.5 Hz, 1 H, H-4Gal), 
7.20-8.20 (m, 20 H, 4 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 22.0, 23.2 (4 C, 2 CHMe2), 25.5, 25.8, 26.1, 32.6, 33.3, 33.4, 
40.4 (7 C, C-3Lac, C-4Lac, C-5Lac, C-6Lac, C-7Lac, C-8Lac, C-9Lac), 62.9 (C-6Gal), 66.6 (CH2-Ph), 
69.9 (C-4Gal), 71.7 (C-5Gal), 72.9 (C-2Gal), 73.3 (CHMe2), 77.4 (C-3Gal), 78.0 (C-2Lac), 100.6 (C-
1Gal), 128.3, 128.4, 128.4, 128.5, 128.6, 128.7, 128.9, 129.6, 129.7, 129.7, 129.8, 129.9, 
130.2, 133.1, 133.2, 135.5 (24 C, 4 C6H5), 164.9, 165.9, 166.1, 172.5 (4 COO); 
 
elemental analysis calcd (%) for C46H50O11 (778.89): C 70.94, H 6.47, O 22.59;  
found: C 70.71, H 6.54, O 22.75. 
 
 
Methyl (2S)-3-cyclohexyl-2-O-{2-O-benzoyl-1-O-
isopropyl-β-D-galactopyranos-3-yl} propanoate 
(143) (II-162, cm218): 
Under argon, 142 (150 mg, 0.190 mmol) was dissolved in 
methanol (5 ml) and a freshly prepared solution of 
NaOMe/MeOH (1 M, 100 µl) was added slowly. The reaction mixture was stirred for 20 h at 
room temperature. The mixture was then neutralized with amberlyste ion-exchange resin (H+ 
form), filtered through celite, evaporated and dried at high vacuum. The crude product was 
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purified by silica gel chromatography (toluene/ethyl acetate 5:1) to yield 143 (80.0 mg, 0.160 
mmol, 85%). 
 
Rf = 0.55 (CH2Cl2/MeOH 6:1); 
 
[ ]22 D α  = -22.3 (c = 1.03, CHCl3); 
 
1H NMR (500 MHz, CDCl3): δ 0.60-1.60 (m, 11 H, H-4Lac, H-5a+bLac, H-6a+bLac, H-7a+bLac, H-
8a+bLac, H-9a+bLac), 1.01 (d, 3J1,Me-1 = 6.1 Hz, 3 H, CHMe2), 1.18 (d, 3J1,Me-2 = 6.3 Hz, 3 H, 
CHMe2), 1.50 (m, 1 H, H-3aLac), 1.60 (m, 1 H, H-3bLac), 3.58 (ddd, 3J4,5 = 1.0 Hz, 3J5,6a = 5.6 Hz, 
3J5,6b = 11.4 Hz, 1H, H-5Gal), 3.60 (dd, 3J2,3 = 9.5 Hz, 3J3,4 = 3.0 Hz, 1 H, H-3Gal), 3.76 (s, 3 H, 
OMe), 3.84 (ddd, 3J5,6a = 5.6 Hz, 3J5,6b = 11.4 Hz, 2J6a,6b = 14.0 Hz, 2 H, H-6a+bGal), 3.96 (dq, 
3J1,Me-1 = 6.1 Hz, 3J1, Me-2 = 6.3 Hz, 1 H, CHMe2), 3.98 (dd, 3J3,4 = 3.0 Hz, 3J4,5 = 1.0 Hz, 1 H, H-
4Gal), 4.06 (dd, 3J2,3a = 3.0 Hz, 3J2,3b = 12.7 Hz, 1 H, H-2Lac), 4.62 (d, 3J1,2 = 8.0 Hz, 1 H, H-1Gal), 
5.42 (dd, 3J1,2 = 8.0 Hz, 3J2,3 = 9.5 Hz, 1 H, H-2Gal), 7.3-8.05 (m, 5 H, C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 22.6, 23.8 (4 C, 2 CHMe2), 26.2, 26.4, 27.0, 32.9, 33.8, 34.6 
(6 C, C-4Lac, C-5Lac, C-6Lac, C-7Lac, C-8Lac, C-9Lac), 42.2 (C-3Lac), 53.2 (OMe), 62.0 (C-6Gal), 
67.7 (C-4Gal), 72.8 (C-2Gal), 73.3 (CHMe2), 75.6 (C-5Gal), 78.1 (C-2Lac), 83.0 (C-3Lac), 101.0 (C-
1Gal), 129.1, 129.4, 129.7, 129.8, 130.6, 130.9, 131.2, 134.2 (12 C, 2 C6H5), 166.7, 176.7 (2 
COO). 
 
 
Sodium (2S)-3-cyclohexyl-2-O-{1-O-isopropyl-β-D-
galactopyranos-3-yl} propanoic acid (144) and 
Sodium (2R)-3-cyclohexyl-2-O-{1-O-isopropyl-β-D-
galactopyranos-3-yl} propanoic acid (145): 
 
Method A (microwave oven) (II-237, cm297): Under argon, 142 (25.0 mg, 0.032 mmol) was 
dissolved in methanol (3 ml) in a microwave tube and a solution of NaOMe/MeOH (1 M, 100 
µl) was added. The solution was radiated in a microwave oven at 70°C for 2 h and stirred 
without radiation at room temperature for 20 h. The reaction was then neutralized with 
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amberlyste ion-exchange resin (H+ form), filtered, concentrated and dissolved again in a 
mixture of dioxane and water (1:1, 2 ml). After adding LiOH (10.0 mg, 0.396 mmol), the 
reaction mixture was stirred for 3 h at room temperature, acidified to pH 4-5 with diluted 
acetic acid, passed over Dowex 50x8 ion-exchange resin (Na+ form), purified by RP-18 
reversed-phase silica gel column chromatography (gradient MeOH/H2O 0:1 → 1:0) and P2 
column chromatography to yield a 1:1 mixture of the two diastereomers 144 and 145 (12.0 
mg, 0.030 mmol, 94%). 
 
Method B (toluene/methanol) (II-244, cm299): Under argon, 143 (20.0 mg, 0.040 mmol) 
was dissolved in toluene/methanol (1:1, 20 ml) and a freshly prepared solution of NaOMe in 
MeOH (1 M, 750 µl) was added. The reaction was stirred for 26 h at room temperature, 
neutralized with amberlyste ion-exchange resin (H+ form), filtered through celite, evaporated 
and dried under high vacuum. The crude mixture was purified by RP-18 reversed-phase 
silica gel column chromatography (gradient MeOH/H2O 1:1 → 1:0) and passed over a basic 
Na-ionexchange column to yield 144 (8.00 mg, 0.020 mmol, 51%). Starting material 143 
(10.0 mg, 0.019 mmol, 49%) could be recovered. 
 
145 (F I): 
Rf = 0.48 (CH2Cl2/MeOH 2:1); 
 
1H NMR (500 MHz, D2O): δ 0.88-1.81 (m, 11 H, H-4Lac, H-5a+bLac, H-6a+bLac, H-7a+bLac, H-8a+bLac, 
H-9a+bLac), 1.19 (d, 3J = 5.9 Hz, 3 H, CHMe2), 1.22 (d, 3J = 5.9 Hz, 3 H, CHMe2), 1.54 (m, 2 H, 
H-3a+bLac), 3.40 (dd, 3J2,3 = 9.7 Hz, 3J3,4 = 3.4 Hz, 1 H, H-3Gal), 3.54 (dd, 3J1,2 = 7.8 Hz, 3J2,3 = 
9.7 Hz, 1 H, H-2Gal), 3.60 (m, 1 H, H-5Gal), 3.72 (m, 2 H, H-6a+bGal), 3.41 (dd, 3J3,4 = 3.4 Hz, 
3J4,5 = 0.9 Hz, 1 H, H-4Gal), 4.05 (dd, J = 4.4 Hz, 8.8 Hz, 1 H, H-2Lac), 4.10 (m, 1 H, CHMe2), 
4.47 (d, 3J1,2 = 7.8 Hz, 1 H, H-1Gal); 
 
13C NMR (125 MHz, D2O): δ 21.4, 22.8 (4 C, 2 CHMe2), 26.3, 26.5, 26.9, 30.4, 32.5, 33.3, 
41.0 (7 C, C-3Lac, C-4Lac, C-5Lac, C-6Lac, C-7Lac, C-8Lac, C-9Lac), 61.1 (C-6Gal), 66.4 (C-4Gal), 
69.8 (C-2Gal), 73.1 (CHMe2), 75.6 (C-5Gal), 78.5 (C-2Lac), 81.4 (C-3Gal), 101.6 (C-1Gal); 
 
1H NMR (500 MHz, CD3OD): δ 0.78-1.91 (m, 11 H, H-4Lac, H-5a+bLac, H-6a+bLac, H-7a+bLac, H-
8a+bLac, H-9a+bLac), 1.18 (d, 3J = 6.0 Hz, 3 H, CHMe2), 1.22 (d, 3J = 6.0 Hz, 3 H, CHMe2), 1.56 
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(m, 1 H, H-3aLac), 1.64 (m, 1 H, H-3bLac), 3.19 (dd, 3J2,3 = 9.2 Hz, 3J3,4 = 3.5 Hz, 1 H, H-3Gal), 
3.48 (ddd, 3J4,5 = 1.5 Hz, 3J5,6a = 4.9 Hz, 3J5,6b = 4.6 Hz, 1 H, H-5Gal), 3.58 (dd, 3J1,2 = 7.4 Hz, 
3J2,3 = 9.2 Hz, 1 H, H-2Gal), 3.75 (m, 2 H, H-6a+bGal), 3.87 (dd, J = 3.7 Hz, 9.7 Hz, 1 H, H-2Lac), 
3.89 (dd, 3J3,4 = 3.5 Hz, 3J4,5 = 1.5 Hz, 1 H, H-4Gal), 4.04 (m, 1 H, CHMe2), (d, 3J1,2 = 7.4 Hz, 1 
H, H-1Gal); 
 
13C NMR (125 MHz, CD3OD): δ 21.6, 23.2 (4 C, 2 CHMe2), 62.1 (C-6Gal), 67.2 (C-4Gal), 70.9 
(C-2Gal), 72.0 (CHMe2), 75.5 (C-5Gal), 80.3 (C-2Lac), 85.1 (C-3Gal), 102.6 (C-1Gal), 182.9 
(COONa). 
 
144 (F II): 
Rf = 0.45 (CH2Cl2/MeOH 2:1); 
 
1H NMR (500 MHz, D2O): δ 0.88-1.79 (m, 11 H, H-4Lac, H-5a+bLac, H-6a+bLac, H-7a+bLac, H-8a+bLac, 
H-9a+bLac), 1.19 (d, 3J = 5.9 Hz, 3 H, CHMe2), 1.22 (d, 3J = 5.9 Hz, 3 H, CHMe2), 1.54 (m, 1 H, 
H-3aLac), 1.59 (m, 1 H, H-3bLac), 3.39 (dd, 3J2,3 = 9.4 Hz, 3J3,4 = 3.1 Hz, 1 H, H-3Gal), 3.52 (dd, 
3J1,2 = 8.2 Hz, 3J2,3 = 9.4 Hz, 1 H, H-2Gal), 3.65 (m, 1 H, H-5Gal), 3.72 (m, 2 H, H-6a+bGal), 3.41 
(dd, 3J3,4 = 3.1 Hz, 3J4.5 = 0.7 Hz, 1 H, H-4Gal), 3.90 (dd, J = 3.4 Hz, 10.0 Hz, 1 H, H-2Lac), 3.95 
(m, 1 H, CHMe2), 4.46 (d, 3J1,2 = 8.2 Hz, 1 H, H-1Gal);  
 
13C NMR (125 MHz, D2O): δ 21.2, 22.6 (4 C, 2 CHMe2), 26.1, 26.3, 26.5, 30.6, 32.2, 33.6, 
41.6 (7 C, C-3Lac, C-4Lac, C-5Lac, C-6Lac, C-7Lac, C-8Lac, C-9Lac), 41.6 (C-3Lac), 61.0 (C-6Gal), 
66.4 (C-4Gal), 70.2 (C-2Gal), 73.6 (CHMe2), 75.1 (C-5Gal), 79.4 (C-2Lac), 83.6 (C-3Gal), 101.3 (C-
1Gal) , 183.1 (COONa). 
 
 
Sodium (2S)-3-cyclohexyl-2-O-{2-O-benzyl-1-O-
isopropyl-β-D-galactopyranos-3-yl} propanoate 
(146) (II-244, cm299):  
Under argon, 143 (20 mg, 0.04 mmol) was dissolved in 
toluene/methanol (1:1, 20 ml) and a freshly prepared 
solution of NaOMe in MeOH (1 M, 750 µl) was added. The reaction was stirred for 26 h at 
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room temperature, neutralized with amberlyste ion-exchange resin (H+ form), filtered through 
celite, evaporated and dried under high vacuum. The crude mixture was purified by RP-18 
reversed-phase silica gel column chromatography (gradient MeOH/H2O 1:1 → 1:0) and 
passed over Dowex 50x8 ion-exchange resin (Na+ form) to yield 146 (10.0 mg, 0.019 mmol, 
49%) together with 144 (8.00 mg, 0.021 mmol, 51%). 
 
146: 
Rf = 0.67 (CH2Cl2/MeOH 2:1); 
 
1H NMR (500 MHz, CD3OD): δ 0.51-1.66 (m, 11 H, H-4Lac, H-5a+bLac, H-6a+bLac, H-7a+bLac, H-
8a+bLac, H-9a+bLac), 1.01 (d, 3J = 5.9 Hz, 3 H, CHMe2), 1.15 (d, 3J = 5.9 Hz, 3 H, CHMe2), 1.42 
(m, 1 H, H-3aLac), 1.49 (m, 1 H, H-3bLac), 3.64 (m, 2 H, H-5Gal, H-3Gal), 3.78 (m, 2 H, H-6a+bGal), 
3.79 (dd, 3J2,3a = 6.6 Hz, 3J2,3b = 2.5 Hz, 1 H, H-2Lac), 3.98 (m, 1 H, CHMe2), 4.02 (dd, 3J3,4 = 
4.1 Hz, 3J4,5 = 1.2 Hz, 1 H, H-4Gal), 4.71 (d, 3J1,2 = 7.8 Hz, 1 H, H-1Gal), 5.34 (dd, 3J1,2 = 7.8 
Hz, 3J2,3 = 9.7 Hz, 1 H, H-2Gal), 7.49-8.10 (m, 5 H, C6H5); 
 
13C NMR (125 MHz, CD3OD): δ 21.9, 23.4 (4 C, 2 CHMe2), 27.0, 27.3, 27.8, 33.5, 33.9, 35.8 
(6 C, C-4Lac, C-5Lac, C-6Lac, C-7Lac, C-8Lac, C-9Lac), 43.9 (C-3Lac), 61.9 (C-6Gal), 67.3 (C-4Gal), 
72.0 (C-2Gal), 72.8 (CHMe2), 75.2 (C-5Gal), 80.3 (C-2Lac), 83.1 (C-3Gal), 100.8 (C-1Gal), 129.2, 
130.4, 131.1, 133.9 (6 C, C6H5), 166.8, 183.0 (2 COO). 
 
 
Sodium (2S)-3-cyclohexyl-2-O-{1-O-[(1S,2S)-2-O-(α-L-
fucopyranosyl)cyclohexyl]-β-D-galactopyranos-3-
yl}propanoate (148) (II-236, cm290):  
A solution of 154 (30.0 mg, 33.8 µmol) in methanol (3 ml) 
and NaOMe/MeOH (1 M, 100 µl) was stirred in a 
microwave oven at 70°C for 2 h. The solution was 
neutralized with amberlyste ion-exchange resin (H+ form), filtered through celite and 
concentrated. The obtained syrup was purified by RP-18 reversed-phase silica gel 
chromatography (gradient MeOH/H2O 0:1 → 1:0), passed over Dowex 50x8 ion-exchange 
resin (Na+ form) and chromatographed on a P2 gel column to yield 148 (16.0 mg, 26.6 µmol, 
71%). 
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Rf = 0.23 (CH2Cl2/MeOH/H2O 10:4:0.8); 
 
[ ]21 D α  = -57.4 (c = 0.75, MeOH); 
 
1H NMR (500 MHz, D2O): δ 0.82-2.10 (m, 15 H, H-4a+bCyc, H-5a+bCyc, H-4Lac, H-5a+bLac, H-
6a+bLac, H-7a+bLac, H-8a+bLac, H-9a+bLac), 1.16 (d, 3J5,6 = 6.6 Hz, 3 H, H-6Fuc), 1.32 (m, 1 H, H-
3aCyc), 1.36 (m, 1 H, H-6aCyc), 1.50 (m, 1 H, H-3aLac), 1.56 (m, 1 H, H-3bLac), 1.96 (m, 1 H, H-
6bCyc), 2.09 (m, 1 H, H-3bCyc), 3.35 (dd, 3J2,3 = 9.7 Hz, 3J3,4 = 3.1 Hz, 1 H, H-3Gal), 3.49 (m, 1 H, 
H-1Cyc), 3.54 (dd, 3J1,2 = 8.2 Hz, 3J2,3 = 9.7 Hz, 1 H, H-2Gal), 3.61 (m, 1 H, H-5Gal), 3.66 (m, 1 
H, H-2Cyc), 3.69-3.78 (m, 4 H, H-6a+bGal, H-2Fuc, H-4Fuc), 3.80 (dd, 3J2,3 = 10.7 Hz, 3J3,4 = 3.1 
Hz, 1 H, H-3Fuc), 3.87 (dd, 3J3,4 = 3.1 Hz 3J4,5 = 0.6 Hz, 1 H, H-4Gal), 3.98 (dd, 3J = 3.7, 8.8 Hz, 
1 H, H-2Lac), 4.12 (dq, 3J4,5 = 0.9 Hz, 3J5,6 = 6.6 Hz, 1 H, H-5Fuc), 4.59 (d, 3J1,2 = 8.2 Hz, 1 H, 
H-1Gal), 5.14 (d, 3J1,2 = 4.1 Hz, 1 H, H-1Fuc); 
 
1H NMR (500 MHz, CD3OD): δ 0.76-1.80 (m, 15 H, H-4a+bCyc, H-5a+bCyc, H-4Lac, H-5a+bLac, H-
6a+bLac, H-7a+bLac, H-8a+bLac, H-9a+bLac), 1.08 (d, 3J5,6 = 6.6 Hz, 3 H, H-6Fuc), 1.16 (m, 1 H, H-
3aCyc), 1.19 (m, 1 H, H-6aCyc), 1.47 (m, 1 H, H-3aLac), 1.56 (m, 1 H, H-3bLac), 1.92 (m, 1 H, H-
6bCyc), 2.06 (m, 1 H, H-3bCyc), 3.18 (dd, 3J2,3 = 9.7 Hz, 3J3,4 = 2.8 Hz, 1 H, H-3Gal), 3.36 (ddd, J 
= 5.0 Hz, 8.8 Hz, 10.4 Hz, 1 H, H-1Cyc), 3.40 (m, 1 H, H-5Gal), 3.48 (ddd, J = 5.0 Hz, 9.1 Hz, 
10.4 Hz, 1 H, H-2Cyc), 3.55 (m, 2 H, H-2Gal, H-4Fuc), 3.62 (m, 2 H, H-6a+bGal), 3.65 (m, 1 H, H-
3Fuc), 3.68 (dd, 3J1,2 = 3.7 Hz, 3J2,3 = 10.4 Hz, 1 H, H-2Fuc), 3.82 (m, 1 H, H-4Gal), 3.83 (dd, 3J = 
4.7 Hz, 9.4 Hz, 1 H, H-2Lac), 3.94 (dq, 3J5,6 = 6.6 Hz, 3J4,5 = 1.2 Hz, 1 H, H-5Fuc), 4.53 (d, 3J1,2 
= 8.1 Hz, 1H, H-1Gal), 5.02 (d, 3J1,2 = 3.7 Hz, 1 H, H-1Fuc); 
 
13C NMR (125 MHz, CD3OD): δ 16.9 (C-6Fuc), 25.5, 25.7, 27.7, 27.9, 28.2, 30.9, 31.1, 34.0, 
34.2 (9 C, C-4Cyc, C-5Cyc, C-6Cyc, C-4Lac, C-5Lac, C-6Lac, C-7Lac, C-8Lac, C-9Lac), 33.5 (C-3Cyc), 
43.2 (C-3Lac), 63.0 (C-6Gal), 67.9 (C-5Fuc), 68.2 (C-4Gal), 70.7 (C-3Fuc), 71.9 (C-2Gal), 72.4 (C-
4Fuc), 74.0 (C-5Gal), 81.3 (C-2Lac), 83.8 (C-1Cyc), 84.2 (C-2Cyc), 85.4 (C-3Gal), 102.3 (C-1Fuc), 
105.7 (C-1Gal) , 183.5 (COONa); 
 
MS (40.0 eV, ES): calcd for C27H46NaO13 [M+ + H]: 601.64; found: 601.24. 
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2,3,4-Tri-O-benzyl-1-O-[(1S,2S)-cyclohexanol-2-yl]-α-L-
fucopyranoside (151) (II-134, cm190):  
2,3,4-tri-O-benzyl-1-S-ethyl-L-thio-fucopyranoside (617 mg, 1.29 
mmol) was dissolved in CH2Cl2 (5 ml) and cooled to 0°C. After 
adding bromine (232 mg, 28.6 µl, 1.46 mmol) with a syringe at 
0°C, the orange solution was stirred at room temperature for 30 min. Remaining bromine was 
quenched with cyclohexene. (1S,2S)-cyclohexanediol (100 mg, 0.860 mmol), NEt4Br (361 
mg, 1.72 mmol) and 4Å molecular sieves (500 mg) were stirred at room temperature for 1 h. 
The freshly prepared 2,3,4-tri-O-benzylfucosylbromide (94) was added and the mixture was 
stirred at room temperature. TLC control (petroleum ether/ethyl acetate 2:1) showed 
complete consumption of the diol after 17 h. The crude mixture was diluted with CH2Cl2 (50 
ml), filtered through celite, washed with satd. aqueous NaHCO3 (2 x 20 ml), dried with 
Na2SO4, filtered and concentrated. Purification by silica gel chromatography (petroleum 
ether/ethyl acetate 4:1) yielded 151 (360 mg, 0.680 mmol, 74%). 
 
Rf = 0.61 (petroleum ether/ethyl acetate 2:1); 
 
[ ]22 D α  = -48.4 (c = 1.75, CHCl3); 
 
1H NMR (500 MHz, CDCl3): δ 1.02 (d, 3J5,6 = 6.4 Hz, 3 H, H-6Fuc), 1.10-1.95 (m, 8 H, H-
3a+bCyc, H-4a+bCyc, H-5a+bCyc, H-6a+bCyc), 3.12 (ddd, 3J = 3.9 Hz, 8.6 Hz, 9.9 Hz, 1 H, H-1Cyc), 
3.35 (ddd, 3J = 3.9 Hz, 8.6 Hz, 10.6 Hz, 1 H, H-2Cyc), 3.60 (dd, 3J3,4 = 2.6 Hz, 3J4,5 = 0.5 Hz, 1 
H, H-4Fuc), 3.89 (dd, 3J2,3 = 9.6 Hz, 3J3,4 = 2.6 Hz, 1 H, H-3Fuc), 3.92 (dd, 3J4,5 = 0.5 Hz, 3J5,6 = 
6.4 Hz, 1 H, H-5Fuc), 3.97 (dd, 3J1,2 = 3.5 Hz, 3J2,3 = 9.6 Hz, 1 H, H-2Fuc), 4.54-4.86 (m, 6 H, 3 
CH2-Ph), 4.86 (d, 3J1,2 = 3.5 Hz, 1 H, H-1Fuc), 7.10-7.30 (m, 15 H, 3 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 17.1 (C-6Fuc), 24.3, 24.9, 32.2, 32.4 (4 C, C-3Cyc, C-4Cyc, C-
5Cyc, C-6Cyc), 67.0 (C-5Fuc), 73.0, 74.0, 74.9 (3 CH2-Ph), 75.2 (C-1Cyc), 76.7 (C-2Fuc), 77.9 (C-
4Fuc), 80.4 (C-3Fuc), 87.5 (C-2Cyc), 101.4 (C-1Fuc), 127.8, 127.9, 128.0, 128.3, 128.6, 128.7, 
128.8, 128.9, 128.9, 138.4, 138.9, 139.0 (18 C, 3 C6H5). 
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Benzyl (2S)-3-cyclohexyl-2-O-{2,4,6-tri-O-benzoyl-1-O-
[(1S,2S)-2-O-(2,3,4-tri-O-benzyl-α-L-fucopyr-
anosyl)cyclohexyl]-β-D-galactopyranos-3-yl} 
propanoate (152) (II-144, cm200):  
151 (92.0 mg, 0.170 mmol) and benzyl (2S)-3-cyclohexyl-
2-O-[1-S-ethyl-2,4,6-tri-O-benzoyl-β-D-thio-
galactopyranos-3-yl] propanoate (90) (203 mg, 0.260 mmol) were dissolved in CH2Cl2 (15 ml) 
containing 3Å molecular sieves and stirred at -2°C for 1 h. DMTST (90.0 mg, 0.346 mmol) 
was added and the reaction mixture was stirred at -2°C for 18 h. The mixture was diluted with 
CH2Cl2 (50 ml), filtered through celite, washed with satd. aqueous NaHCO3 (20 ml), dried 
with Na2SO4, filtered and concentrated. Purification by silica gel chromatography (petroleum 
ether/ethyl acetate 5:1) yielded 152 (200 mg, 0.160 mmol, 92%). 
 
Rf = 0.45 (petroleum ether/ethyl acetate 3:1); 
 
[ ]21 D α  = -7.11 (c = 0.58, CHCl3); 
 
1H NMR (500 MHz, CDCl3): δ 0.44-1.64 (m, 15 H, H-4a+bCyc, H-5a+bCyc, H-4Lac, H-5a+bLac, H-
6a+bLac, H-7a+bLac, H-8a+bLac, H-9a+bLac), 1.02 (d, 3J5,6 = 6.1 Hz, 3 H, H-6Fuc), 1.22 (m, 1 H, H-
6aCyc), 1.27 (m, 1 H, H-3aLac), 1.36 (m, 1 H, H-3bLac), 1.54 (m, 1 H, H-3aCyc), 1.65 (m, 1 H, H-
6bCyc), 1.87 (m, 1 H, H-3bCyc), 3.45 (ddd, 3J = 3.9 Hz, 5.8 Hz, 5.9 Hz, 1 H, H-1Cyc), 3.59 (dd, 
3J3,4 = 1.8 Hz, 3J4,5 = 0.3 Hz, 1 H, H-4Fuc), 3.68 (dd, 3J2,3 = 10.1 Hz, 3J3,4 = 3.6 Hz, 1 H, H-3Gal), 
3.74 (ddd, 3J = 3.6 Hz, 6.5 Hz, 6.6 Hz, 1 H, H-2Cyc), 3.80 (m, 2 H, H-5Gal, H-5Fuc), 3.89 (m, 2 
H, H-2Fuc, H-3Fuc), 4.08 (dd, 3J2,3a = 4.3 Hz, 3J2,3b = 7.6 Hz, 1 H, H-2Lac), 4.37 (dd, 3J5,6a = 6.1 
Hz, 2J6a,6b = 10.8 Hz, 1 H, H-6aGal), 4.46 (dd, 3J5,6b = 7.2 Hz, 2J6a,6b = 10.8 Hz, 1 H, H-6bGal), 
4.58-5.11 (m, 8 H, 4 CH2-Ph), 4.82 (d, 3J1,2 = 4.4 Hz, 1 H, H-1Fuc), 4.86 (d, 3J1,2 = 7.9 Hz, 1 H, 
H-1Gal), 5.57 (dd, 3J1,2 = 7.9 Hz, 3J2,3 = 10.1 Hz, 1 H, H-2Gal), 5.80 (dd, 3J3,4 = 3.6 Hz, 3J4,5 = 
0.8 Hz, 1 H, H-4Gal), 7.21-8.16 (m, 35 H, 7 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 16.5 (C-6Fuc), 21.8, 21.9, 22.3, 25.5, 25.8, 26.1, 29.4, 29.7, 
32.7, 33.4 (10 C, C-3Cyc, C-4Cyc, C-5Cyc, C-6Cyc, C-4Lac, C-5Lac, C-6Lac, C-7Lac, C-8Lac, C-9Lac), 
40.4 (C-3Lac), 62.8 (C-6Gal), 66.4 (C-5Gal), 66.5 (CH2-Ph), 70.0 (C-4Gal), 71.5 (C-5Fuc), 72.7, 
72.9, (2 CH2-Ph), 73.1 (C-2Gal), 74.7 (CH2-Ph), 76.0 (C-2Fuc), 77.0 (C-1Cyc), 77.2 (C-2Cyc), 77.4 
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(C-3Gal), 77.6 (C-4Fuc), 78.2 (C-2Lac), 79.6 (C-3Fuc), 97.7 (C-1Fuc), 100.3 (C-1Gal), 127.3, 127.4, 
127.4, 127.5, 128.1, 128.2, 128.2, 128.3, 128.4, 128.4, 128.5, 128.5, 128.6, 128.7, 128.7, 
128.8, 128.9, 130.2, 130.4, 130.6, 133.1, 133.2, 133.3, 135.5, 135.6, 138.7, 138.8, 138.9 (42 
C, 7 C6H5), 165.0, 165.2, 165.3, 165.9, 165.9, 166.0, 172.4 (7 COO); 
 
elemental analysis calcd (%) for C76H82O16 (1251.49): C 72.94, H 6.60, O 20.46;  
found: C 72.85, H 6.54, O 20.61. 
 
 
Methyl (2S)-3-cyclohexyl-2-O-{2-O-benzoyl-1-O-
[(1S,2S)-2-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-
cyclohexyl]-β-D-galactopyranos-3-yl} propanoate 
(153) (II-239, cm293):  
To a solution of 152 (40.0 mg, 0.032 mmol) in methanol 
(5 ml), NaOMe/MeOH (1 M, 100 µl) was added and the 
mixture was stirred for 15 h at room temperature. After 
neutralization with amberlyste ion-exchange resin (H+ form), filtration, evaporation of solvents 
and purification by silica gel chromatography (CH2Cl2/MeOH 30:1), 153 (22.0 mg, 0.031 
mmol, 98%) was isolated. 
 
Rf = 0.49 (CH2Cl2/MeOH 10:1); 
 
[ ]21 D α  = -24.3 (c = 1.2, CHCl3);  
 
1H NMR (500 MHz, CDCl3): δ 0.40-1.60 (m, 15 H, H-4a+bCyc, H-5a+bCyc, H-4Lac, H-5a+bLac, H-
6a+bLac, H-7a+bLac, H-8a+bLac, H-9a+bLac), 1.04 (d, 3J5,6 = 6.4 Hz, 3 H, H-6Fuc), 1.23 (m, 1 H, H-
6aCyc), 1.33 (m, 1 H, H-3aLac), 1.52 (m, 2 H, H-3a+bLac), 1.59 (m, 1 H, H-6bCyc), 1.84 (m, 1 H, H-
3bCyc), 3.19 (dd, 3J2,3 = 9.5 Hz, 3J3,4 = 3.0 Hz, 1 H, H-3Gal), 3.42 (m, 1 H, H-5Gal), 3.50 (m, 1 H, 
H-1Cyc), 3.64 (dd, 3J3,4 = 3.4 Hz, 3J4,5 = 0.7 Hz, 1 H, H-4Fuc), 3.69 (dd, 3J3,4 = 3.0 Hz, 3J4,5 = 0.9 
Hz, 1 H, H-4Gal), 3.73 (s, 3 H, OMe), 3.78 (m, 3 H, H-2Cyc, H-2Lac, H-6aGal), 3.87 (dq, 3J4,5 = 0.7 
Hz, 3J5,6 = 6.4 Hz, 1 H, H-5Fuc), 3.95 (dd, 3J2,3 = 10.2 Hz, 3J3,4 = 3.4 Hz, 1 H, H-3Fuc), 4.00 (m, 
1 H, H-6bGal), 4.01 (dd, 3J1,2 = 3.0 Hz, 2J2,3 = 10.2 Hz, 1 H, H-2Fuc), 4.60-4.98 (m, 6 H, 3 CH2-
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Ph), 4.89 (d, 3J1,2 = 7.6 Hz, 1 H, H-1Gal), 4.97 (d, 3J1,2 = 3.0 Hz, 1 H, H-1Fuc), 5.43 (dd, 3J1,2 = 
7.6 Hz, 3J2,3 = 9.5 Hz, 1 H, H-2Gal), 7.21-8.02 (m, 20 H, 4 C6H5); 
13C NMR (125 MHz, CDCl3): δ 16.9 (C-6Fuc), 22.2 (C-6Cyc), 25.6, 25.7, 26.5, 29.8, 29.9, 32.5, 
33.1, 34.0 (8 C, C-4Lac, C-5Lac, C-6Lac, C-7Lac, C-8Lac, C-9Lac, C-4Cyc, C-5Cyc), 32.4 (C-3Cyc), 
41.7 (C-3Lac), 52.8 (OCH3), 62.9 (C-6Gal), 66.9 (C-5Fuc), 67.7 (C-4Fuc), 71.9 (C-2Gal), 73.2, 73.6, 
74.3 (3 CH2-Ph), 75.1 (C-5Gal), 76.8 (C-2Fuc), 77.4 (C-2Cyc), 77.7 (C-1Cyc), 78.0 (C-2Lac), 79.9 
(C-3Fuc), 82.7 (C-3Gal), 98.2 (C-1Fuc), 100.4 (C-1Gal), 127.8, 127.9, 127.9, 128.5, 128.6, 128.7, 
128.7, 128.8, 129.0, 130.0, 130.5, 130.7, 133.4, 139.1, 139.2, 139.6 (24 C, 4 C6H5), 165.5, 
175.9 (2 COO).  
 
 
(2S)-3-cyclohexyl-2-O-{2,4,6-tri-O-benzoyl-1-O-
[(1S,2S)-2-O-(α-L-fucopyranosyl)cyclohexyl]-β-D-
galactopyranos-3-yl} propanoic acid (154) (II-153, 
cm209):  
A solution of 152 (130 mg, 0.104 mmol) and Pd/C (100 
mg, 0.080 mmol) in dioxane (5 ml) was shaken for 24 h 
under an atmosphere of 4 bar H2 in a hydrogenation 
apparatus. After filtration through celite, evaporation of the solvent and purification by silica 
gel chromatography (CH2Cl2/MeOH 8:1), 154 was isolated (87.0 mg, 0.098 mmol, 94%). 
 
Rf = 0.24 (CH2Cl2/MeOH 6:1); 
 
[ ]21 D α  = -23.8 (c = 1.07, CHCl3); 
 
1H NMR (500 MHz, CDCl3): δ 0.36-2.01 (m, 19 H, H-3a+bCyc, H-4a+bCyc, H-5a+bCyc, H-6a+bCyc, H-
4Lac, H-5a+bLac, H-6a+bLac, H-7a+bLac, H-8a+bLac, H-9a+bLac), 1.14 (d, 3J5,6 = 6.6 Hz, 3 H, H-6Fuc), 
1.28 (m, 2 H, H-3a+bLac), 3.40 (m, 1 H, H-1Cyc), 3.61-3.79 (m, 4 H, H-2Cyc, H-2Fuc, H-3Fuc, H-
4Fuc), 3.84 (dq, 3J5,6 = 6.6 Hz, 3J4,5 = 1.4 Hz, 1 H, H-5Fuc), 4.03 (dd, 3J2,3 = 8.5 Hz, 3J3,4 = 2.8 
Hz, 1 H, H-3Gal), 4.22 (m, 2 H, H-2Lac, H-5Gal), 4.46 (dd, 3J5,6a = 5.6 Hz, 2J6a,6b = 11.3 Hz, 1 H, 
H-6aGal), 4.60 (dd, 3J5,6b = 7.2 Hz, 2J6a,6b = 11.3 Hz, 1 H, H-6bGal), 4.88 (d, 3J1,2 = 3.4 Hz, 1 H, 
H-1Fuc), 5.17 (d, 3J1,2 = 7.5 Hz, 1 H, H-1Gal), 5.53 (dd, 3J1,2 = 7.5 Hz, 3J2,3 = 8.5 Hz, 1 H, H-
2Gal), 5.82 (dd, 3J3,4 = 2.8 Hz, 3J4,5 = 1.0 Hz, 1 H, H-4Gal), 7.40-8.20 (m, 15 H, 3 C6H5); 
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13C NMR (125 MHz, CDCl3): δ 16.0 (C-6Fuc), 23.6, 23.7, 25.5, 25.7, 25.9, 26.0, 31.4, 32.1, 
32.9, 33.2 (10 C, C-3Cyc, C-4Cyc, C-5Cyc, C-6Cyc, C-4Lac, C-5Lac, C-6Lac, C-7Lac, C-8Lac, C-9Lac), 
40.6 (C-3Lac), 62.2 (C-4Fuc), 62.5 (C-6Gal), 66.2 (C-3Fuc), 67.1 (C-5Fuc), 69.4 (C-2Fuc), 70.1 (C-
4Gal), 70.2 (C-5Gal), 73.1 (C-2Gal), 84.9 (C-1Cyc), 78.0 (C-2Cyc), 79.9 (C-2Lac), 83.0 (C-3Gal), 99.8 
(C-1Fuc), 100.1 (C-1Gal), 128.5, 128.9, 130.1, 130.3, 130.5, 130.7, 130.9, 131.2, 131.5, 133.2, 
133.6, 133.9 (18 C, 3 C6H5), 165.8, 166.2, 167.9 (3 COO). 
 
 
Sodium (2S)-3-cyclohexyl-2-O-{2-O-benzoyl-1-O-
[(1S,2S)-2-O-(α-L-fucopyranosyl)cyclohexyl]-β-D-
galactopyranos-3-yl} propanoate (155) (II-247, cm302):  
To a solution of 152 (10.0 mg, 0.008 mmol) in 
toluene/methanol (1:1, 20 ml) NaOMe/MeOH (1 M, 750 
µl) was added and the reaction was stirred at room 
temperature for 24 h. The mixture was neutralized with amberlyste ion-exchange resin (H+ 
form), filtered through celite, concentrated and dissolved again in dioxane/methanol (1:1, 5 
ml). After addition of  Pd(OH)2/C (10 mg), the mixture was hydrogenated (5 bar H2) for 19 h 
at room temperature, filtered through celite, concentrated and passed over Dowex 50x8 ion-
exchange resin (Na+ form). Purification of the isolated crude product by RP-18 reversed-
phase column chromatography (gradient MeOH/H2O 0:1 → 1:0) and P2-gel column chroma-
tography yielded 155 (4.00 mg, 0.006 mmol, 76%). 
 
Rf = 0.14 (CH2Cl2/MeOH 2:1); 
 
1H NMR (500 MHz, D2O): δ 0.38-1.47 (m, 15 H, H-4a+bCyc, H-5a+bCyc, H-4Lac, H-5a+bLac, H-
6a+bLac, H-7a+bLac, H-8a+bLac, H-9a+bLac), 1.02 (d, 3J5,6 = 6.6 Hz, 3 H, H-6Fuc), 1.15 (m, 1 H, H-
6aCyc), 1.30 (m, 1 H, H-3aLac), 1.35 (m, 1 H, H-3bLac), 1.42 (m, 1 H, H-3aCyc), 1.57 (m, 1 H, H-
6bCyc), 1.89 (m, 1 H, H-3bCyc), 3.45 (m, 1 H, H-1Cyc), 3.57 (dd, 3J3,4 = 3.4 Hz, 3J4,5 = 1.1 Hz, 1 
H, H-4Fuc), 3.58 (dd, 3J1,2 = 3.1 Hz, 3J2,3 = 10.0 Hz, 1 H, H-2Fuc), 3.67 (dd, 3J2,3 = 10.0 Hz, 3J3,4 
= 3.4 Hz, 1 H, H-3Fuc), 3.76 (m, 4 H, H-3Gal, H-5Gal, H-6a+bGal), 3.81 (m, 2 H, H-2Cyc, H-5Fuc), 
3.87 (dd, J = 2.5 Hz, 9.4 Hz, 1 H, H-2Lac), 3.98 (dd, 3J3,4 = 2.5 Hz, 3J4,5 = 0.6 Hz, 1 H, H-4Gal), 
4.81 (d, 3J1,2 = 3.1 Hz, 1 H, H-1Fuc), 5.02 (d, 3J1,2 = 8.1 Hz, 1 H, H-1Gal), 5.21 (dd, 3J1,2 = 8.1 
Hz, 3J2,3 = 8.8 Hz, 1 H, H-2Gal), 7.56-8.13 (m, 5 H, C6H5); 
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13C NMR (125 MHz, D2O): δ 15.0 (C-6Fuc), 61.2 (C-6Gal), 66.6 (C-4Gal), 66.8 (C-5Fuc), 68.7 (C-
2Fuc), 70.0 (C-3Fuc), 71.8 (C-4Fuc), 72.7 (C-2Gal), 75.2 (C-5Gal), 78.3 (C-1Cyc), 79.3 (C-2Cyc), 81.2 
(C-3Gal), 98.7 (C-1Fuc), 99.9 (C-1Gal), 129.4, 130.7, 131.3, 134.7 (6 C, C6H5), 165.3 (COO). 
 
 
(3S)-3-(2,3,4-tri-O-benzoyl-α-L-fucopyranosyl-methyl)-
cyclohexene (156) (II-83, cm135):  
Under argon, 128a (140 mg, 0.266 mmol) and DMAP (20.0 mg, 
0.160 mmol) were dissolved in a mixture of pyridine and CH2Cl2 
(10 ml, 1:1) and cooled to 0°C. Triflic acid anhydride (90.0 µl, 154 
mg, 0.570 mmol) was added slowly with a syringe and the reaction was stirred for 3 h at 0°C. 
The mixture was then poured onto ice water, extracted with CH2Cl2 (50 ml), washed with 7% 
aqueous HCl (2 x 50 ml) and satd. aqueous NaHCO3 (2 x 50 ml), dried with Na2SO4, filtered, 
concentrated and dried under high vacuum. Purification by silica gel chromatography 
(toluene/ethyl acetate 30:1) yielded 156 (73.0 mg, 0.131 mmol, 54%). 
 
Rf = 0.15 (petroleum ether/ethyl acetate 10:1); 
 
[ ] 21 D α  = -162.9 (c = 0.80, CHCl3); 
 
1H NMR (500 MHz, CDCl3): δ 1.30 (d, 3J5,6 = 6.3 Hz, 3 H, H-6Fuc), 1.45-2.33 (m, 7 H, H-2Cyc, 
H-5a+bCyc, H-6a+bCyc, H-7a+bCyc), 1.44 (ddd, J = 3.1 Hz, 10.4 Hz, 14.8 Hz, 1 H, H-1aCyc), 2.13 
(ddd, J = 4.0 Hz, 11.9 Hz, 14.8 Hz, 1 H, H-1bCyc), 4.25 (dq, 3J4,5 = 1.5 Hz, 3J5,6 = 6.3 Hz, 1 H, 
H-5Fuc), 4.67 (ddd, J = 3.1 Hz, 5.6 Hz, 11.9 Hz, 1 H, H-1Fuc), 5.60 (dd, J = 1.8 Hz, 10.0 Hz, 1 
H, H-3Cyc), 5.73 (m, 1 H, H-4Cyc), 5.74 (dd, 3J3,4 = 3.1 Hz, 3J4,5 = 1.5 Hz, 1 H, H-4Fuc), 5.80 (dd, 
3J2,3 = 10.0 Hz, 3J3,4 = 3.1 Hz, 1 H, H-3Fuc), 5.86 (dd, 3J1,2 = 5.6 Hz, 3J2,3 = 10.0 Hz, 1 H, H-
2Fuc), 7.25-8.12 (m, 15 H, 3 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 16.4 (C-6Fuc), 21.3, 25.3, 28.2 (3 C, C-5Cyc, C-6Cyc, C-7Cyc), 
31.5 (C-2Cyc), 31.6 (C-1Cyc), 66.0 (C-5Fuc), 69.3 (C-3Fuc), 69.4 (C-2Fuc), 70.9 (C-1Fuc), 71.8 (C-
4Fuc), 128.2, 128.6, 128.8, 128.9, 129.7, 129.9, 130.0, 130.2, 130.3, 133.2, 133.4, 133.5 (18 
C, 3 C6H5), 129.3 (C-4Cyc), 133.2 (C-3Cyc), 166.0, 166.2, 166.4 (3 COO). 
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(3S)-3-(2,3,4-tri-O-pivaloyl-α-L-fucopyranosyl-methyl)-
cyclohexene (157) (II-71, cm123):  
A solution of 129a (50.0 mg, 0.097 mmol) in pyridine/CH2Cl2 (3 
ml, 1:2) was cooled to 0°C under argon. 
Trifluoromethanesulfonic acid anhydride (55.0 mg, 33.0 µl, 
0.200 mmol) was added slowly by a syringe and the reaction mixture was stirred at 0°C for 2 
h. The reaction mixture was then diluted with CH2Cl2 (20 ml), poured onto ice and the organic 
layer was washed with aqueous 10% HCl (2 x 20 ml) and satd. aqueous NaHCO3 (20 ml). 
Drying with Na2SO4, evaporation of the solvents and purification of the crude product by silica 
gel chromatography (petroleum ether/ethyl acetate 10:1) yielded 157 (33.0 mg, 0.067 mmol, 
67 %).   
 
Rf = 0.42 (petroleum ether/ethyl acetate 10:1); 
 
[ ]22 D α  = -57.2 (c = 0.6, CHCl3); 
 
1H NMR (500 MHz, CDCl3): δ 1.15 (d, 3J5,6 = 6.3 Hz, 3 H, H-6Fuc), 1.15, 1.23, 1.26 (3 s, 27 H, 
3 CMe3), 1.26 (m, 1 H, H-1aCyc), 1.86 (m, 1 H,H-1bCyc), 1.50-2.21 (m, 7 H, H-2Cyc, H-5a+bCyc, H-
6a+bCyc, H-7a+bCyc), 4.99 (dq, 3J4,5 = 0.5 Hz, 3J5,6 = 6.3 Hz, 1 H, H-5Fuc), 4.33 (ddd, 3J1,1a-Cyc= 2.8 
Hz, 3J1,1b-Cyc = 11.8 Hz, 3J1,2 = 5.7 Hz, 1 H, H-1Fuc), 5.25 (dd, 3J2,3 = 9.8 Hz, 3J3,4 = 3.4 Hz, 1 H, 
H-3Fuc), 5.27 (dd, 3J3,4 = 3.4 Hz, 3J4,5 = 0.5 Hz, 1 H, H-4Fuc), 5.35 (dd, 3J1,2 = 5.7 Hz, 3J2,3 = 9.8 
Hz, 1 H, H-2Fuc), 5.52 (dd, 3J2,3 = 10.4 Hz, 3J3,4 = 2.0 Hz, 1 H, H-3Cyc), 5.71 (ddd, 3J3,4 = 2.0 
Hz, 3J4,5a = 5.7 Hz, 3J4,5b = 9.7 Hz, 1 H, H-4Cyc);  
 
13C NMR (125 MHz, CDCl3): δ 16.1 (C-6Fuc), 21.1 (C-2Cyc), 25.3, 27.1, 28.0 (3 C, C-5Cyc, C-
6Cyc, C-7Cyc), 27.1, 27.2, 27.3 (9 C, 3 CMe3), 31.4 (C-1Cyc), 38.0, 39.6, 40.7 (3 CMe3), 65.8 (C-
5Fuc), 68.1 (C-2Fuc), 68.8 (C-3Fuc), 70.6 (C-4Fuc), 70.8 (C-1Fuc), 127.7 (C-4Cyc), 131.8 (C-3Cyc), 
175.4, 176.1, 177.5 (3 COO). 
 
elemental analysis calcd (%) for C28H46O7 (494.66): C 67.99, H 9.37, O 22.64;  
found: C 67.49, H 9.36, O 23.15. 
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(3R)-3-(2,3,4-tri-O-pivaloyl-α-L-fucopyranosyl-methyl)-
cyclohexene (158) (II-70, cm122):  
Under argon, a solution of 129b (30.0 mg, 0.058 mmol) in 
pyridine/CH2Cl2 (3 ml, 1:2) was cooled to 0°C. 
Trifluoromethanesulfonic acid anhydride (33.0 mg, 19.5 µl, 0.120 mmol) was added slowly by 
a syringe and the reaction mixture was stirred at 0°C for 2 h and at room temperature for 16 
h. The reaction mixture was then diluted with CH2Cl2 (20 ml), poured onto ice and the organic 
layer was washed with aqueous 10% HCl (2 x 20 ml) and satd. aqueous NaHCO3 (20 ml). 
Drying with Na2SO4, evaporation of the solvents and purification of the crude product by silica 
gel chromatography (petroleum ether/ethyl acetate 10:1) yielded 158 (25.0 mg, 0.051 mmol, 
88 %).   
 
Rf = 0.42 (petroleum ether/ethyl acetate 10:1); 
 
[ ]22 D α  = -92.3 (c = 0.65, CHCl3); 
 
1H NMR (500 MHz, CDCl3): δ 1.15 (d, 3J5,6 = 6.3 Hz, 3 H, H-6Fuc), 1.15, 1.22, 1.27 (3 s, 27 H, 
3 CMe3), 1.38 (m, 1 H, H-1aCyc), 1.80 (m, 1 H, H-1bCyc), 1.55-2.20 (m, 7 H, H-2Cyc, H-5a+bCyc, H-
6a+bCyc, H-7a+bCyc), 4.99 (dq, 3J4,5 = 1.7 Hz, 3J5,6 = 6.3 Hz, 1 H, H-5Fuc), 4.35 (ddd, 3J1,1a-Cyc= 2.8 
Hz, 3J1,1b-Cyc = 14.3 Hz, 3J1,2 = 5.4 Hz, 1 H, H-1Fuc), 5.25 (dd, 3J2,3 = 9.7 Hz, 3J3,4 = 3.4 Hz, 1 H, 
H-3Fuc), 5.27 (dd, 3J3,4 = 3.4 Hz, 3J4,5 = 1.7 Hz, 1 H, H-4Fuc), 5.33 (dd, 3J1,2 = 5.4 Hz, 3J2,3 = 9.4 
Hz, 1 H, H-2Fuc), 5.60 (dd, 3J2,3 = 10.3 Hz, 3J3,4 = 2.2 Hz, 1 H, H-3Cyc), 5.69 (ddd, 3J3,4 = 2.2 
Hz, 3J4,5a = 3.4 Hz, 3J4,5b = 9.7 Hz, 1 H, H-4Cyc); 
 
13C NMR (125 MHz, CDCl3): δ 16.5 (C-6Fuc), 21.5 (C-2Cyc), 25.7, 30.1, 31.9 (3 C, C-5Cyc, C-
6Cyc, C-7Cyc), 27.5, 27.6, 27.7 (9 C, 3 CMe3), 31.5 (C-1Cyc), 38.0, 39.6, 40.7 (3 CMe3), 66.0 (C-
5Fuc), 68.2 (C-2Fuc), 68.8 (C-3Fuc), 70.6 (C-4Fuc), 70.9 (C-1Fuc), 128.2 (C-4Cyc), 130.3 (C-3Cyc), 
175.0, 175.6, 177.1 (3 COO); 
 
elemental analysis calcd (%) for C28H46O7 (494.66): C 67.99, H 9.37, O 22.64;  
found: C 67.99, H 9.45, O 22.56. 
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1-(2,3,4-tri-O-benzoyl-α-L-fucopyranosyl-methyl)-
cyclohexene (159) (II-82, cm134):  
Under argon, 128d (80.0 mg, 0.140 mmol) and DMAP (10.0 mg, 
0.080 mmol) were dissolved in a mixture of pyridine and CH2Cl2 
(10 ml, 1:1) and cooled to 0°C. Triflic acid anhydride (52.0 µl, 88.0 
mg, 0.312 mmol) was added slowly with a syringe and the reaction was stirred for 3 h at 0°C. 
The mixture was poured onto ice water, extracted with CH2Cl2 (2 x 50 ml). The organic layer 
was washed with 7% aqueous HCl (2 x 50 ml) and satd. aqueous NaHCO3 (2 x 50 ml), dried 
with Na2SO4, filtered, concentrated and dried under high vacuum. Purification by silica gel 
chromatography (toluene/ethyl acetate 30:1) yielded 159 (75.0 mg, 0.135 mmol, 96%). 
 
Rf = 0.14 (petroleum ether/ethyl acetate 10:1); 
 
[ ] 21 D α  = -214.0 (c = 0.55, CHCl3); 
 
1H NMR (500 MHz, CDCl3): δ 1.27 (d, 3J5,6 = 6.3 Hz, 3 H, H-6Fuc), 1.51-1.62 (m, 6 H, H-
5a+bCyc, H-6a+bCyc, H-7a+bCyc), 1.96 (m, 2 H, H-4a+bCyc), 1.35 (dd, 3J1a,1b = 14.5 Hz, 3J1a,1Fuc = 2.2 
Hz, 1 H, H-1aCyc), 2.64 (dd, 3J1a,1b = 14.5 Hz, 3J1b,1Fuc = 10.4 Hz, 1 H, H-1bCyc), 4.27 (dq, 3J4,5 = 
1.2 Hz, 3J5,6 = 6.3 Hz, 1 H, H-5Fuc), 4.71 (ddd, 3J1,1aCyc = 2.2 Hz, 3J1,1bCyc = 10.4 Hz, 3J1,2 = 4.7 
Hz, 1 H, H-1Fuc), 5.53 (m, 1 H, H-3Cyc), 5.74 (m, 1 H, H-4Fuc), 5.83 (m, 2 H, H-2Fuc, H-3Fuc), 
7.26-8.11 (m, 15 H, 3 C6H5); 
 
13C NMR (125 MHz, CDCl3): δ 16.3 (C-6Fuc), 22.2, 22.8, 25.3, 27.9 (4 C, C-4Cyc, C-5Cyc, C-
6Cyc, C-7Cyc), 34.8 (C-1Cyc), 66.1 (C-5Fuc), 69.3 (C-2Fuc), 69.4 ( C-3Fuc), 70.9 (C-1Fuc), 71.7 (C-
4Fuc), 124.4 (C-3Cyc), 128.2, 128.6, 128.8, 128.9, 129.7, 129.9, 130.0, 130.2, 130.3, 133.2, 
133.4, 133.5 (18 C, 3 C6H5), 133.3 (C-2Cyc), 165.6, 165.8, 165.9 (3 COO). 
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(1R,2S) 2-(2,3,4-Tri-O-benzoyl-α-L-fucopyranosyl-methyl)-
cyclohexyl p-bromo-benzoate (160) (II-89, cm141):  
A solution of 128b (50.0 mg, 0.088 mmol) in pyridine (5 ml) 
was cooled to 0°C and p-bromo-benzoylchloride (39.0 mg, 
0.180 mmol) was added. The reaction was stirred at 0°C for 3 
h and further 10 min after addition of methanol (10 ml) to 
quench the excess of benzoylchloride. The reaction mixture 
was diluted with CH2Cl2 (50 ml), washed with 7% aqueous HCl (70 ml) and H2O (40 ml), the 
organic layer was dried with Na2SO4, filtered and concentrated. Purification of the crude 
product by silica gel chromatography (petroleum ether/ethyl acetate 5:1) yielded 160 (46.0 
mg, 0.061 mmol, 70%).  
 
Rf = 0.71 (petroleum ether/ethyl acetate 2:1); 
 
[ ] 21 D α  = -26.8 (c = 1.35, CHCl3); 
 
1H NMR (500 MHz, CDCl3): δ 1.262.12 (m, 6 H, H-5a+bCyc, H-6a+bCyc, H-7a+bCyc), 1.26 (d, 3J5,6 = 
6.3 Hz, 3 H, H-6Fuc), 1.35 (m, 1 H, H-4aCyc), 1.81 (m, 2 H, H-1aCyc, H-2Cyc), 1.93 (m, 1 H, H-
1bCyc), 2.12 (m, 1 H, H-4bCyc), 4.22 (dq, 3J4,5 = 1.2 Hz, 3J5,6 = 6.3 Hz, 1 H, H-5Fuc), 4.61 (ddd, 
3J1,2 = 5.6 Hz, J = 2.5 Hz, 10.4 Hz, 1 H, H-1Fuc), 4.76 (ddd, J = 4.4 Hz, 10.0 Hz, 10.3 Hz, 1 H, 
H-3Cyc), 5.67 (m, 2 H, H-3Fuc, H-4Fuc), 5.76 (dd, 3J1,2 = 5.6 Hz, 3J2,3 = 10.0 Hz, 1 H, H-2Fuc), 
7.18-8.09 (m, 19 H, 3 C6H5, C6H4); 
 
13C NMR (125 MHz, CDCl3): δ 16.6 (C-6Fuc), 24.8, 25.7, 32.0 (3 C, C-5Cyc, C-6Cyc, C-7Cyc), 
27.3 (C-1Cyc), 32.3 (C-4Cyc), 41.7 (C-2Cyc), 66.4 (C-5Fuc), 69.4 (C-2Fuc), 69.5 (C-3Fuc), 72.1 (C-
4Fuc), 74.4 (C-1Fuc), 78.4 (C-3Cyc), 128.2, 128.7, 128.8, 129.1, 129.4, 129.8, 129.9, 130.1, 
130.3, 131.2, 131.3, 131.9, 132.2, 133.5, 133.7, 133.8 (24 C, 3 C6H5, p-Br-C6H4), 165.6, 
165.8, 166.1, 166.3 (4 COO). 
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(1R,2S)-2-(2,3,4-Tri-O-benzoyl-α-L-fucopyranosyl-
methyl)-cyclohexyl p-nitro-benzoate (161) (II-88, 
cm140):  
A solution of 128b (50.0 mg, 0.088 mmol) in pyridine (5 
ml) was cooled to 0°C and p-nitro-benzoylchloride (32.0 
mg, 0.180 mmol) was added. The reaction was stirred at 
0°C for 1 h and further 10 min after addition of methanol 
(10 ml) to quench the excess of benzoylchloride. The reaction mixture was then diluted with 
CH2Cl2 (50 ml), washed with 7% aqueous HCl (70 ml) and H2O (40 ml), the organic layer was 
dried with Na2SO4, filtered and concentrated. Purification of the crude product by silica gel 
chromatography (petroleum ether/ethyl acetate 5:1) yielded 161 (51.0 mg, 0.071 mmol, 
82%).  
 
Rf = 0.62 (petroleum ether/ethyl acetate 2:1); 
 
[ ] 21 D α  = -51.2 (c = 1.27, CHCl3); 
 
1H NMR (500 MHz, CDCl3): δ 1.19-2.11 (m, 6 H, H-5a+bCyc, H-6a+bCyc, H-7a+bCyc), 1.21 (d, 3J5,6 = 
6.3 Hz, 3 H, H-6Fuc), 1.32 (m, 1 H, H-4aCyc), 1.73 (m, 1 H, H-1aCyc), 1.79 (m, 1 H, H-2Cyc), 1.85 
(m, 1 H, H-1bCyc), 2.06 (m, 1 H, H-4bCyc), 4.16 (dq, 3J4,5 = 1.2 Hz, 3J5,6 = 6.3 Hz, 1 H, H-5Fuc), 
4.57 (ddd, 3J1,2 = 5.6 Hz, 3J1,1a-Cyc = 2.8 Hz, 3J1,1b-Cyc = 10.4 Hz, 1 H, H-1Fuc), 4.73 (ddd, J = 4.4 
Hz, 10.0 Hz, 10.3 Hz, 1 H, H-3Cyc), 5.61 (m, 1 H, H-4Fuc), 5.65 (m, 2 H, H-2Fuc, H-3Fuc), 7.09-
8.02 (m, 19 H, 3 C6H5, C6H4); 
 
13C NMR (125 MHz, CDCl3): δ 16.6 (C-6Fuc), 24.7, 25.7, 32.2 (3 C, C-5Cyc, C-6Cyc, C-7Cyc), 
27.4 (C-1Cyc), 32.1 (C-4Cyc), 41.7 (C-2Cyc), 66.5 (C-5Fuc), 69.2 (C-2Fuc), 69.7 (C-3Fuc), 72.0 (C-
4Fuc), 74.3 (C-1Fuc), 79.4 (C-3Cyc), 123.8, 128.7, 128.8, 129.0, 129.1, 129.4, 129.7, 129.8, 
130.1, 130.3, 130.7, 130.8, 133.6, 133.7, 135.8, 150.6 (24 C, 3 C6H5, p-NO2-C6H4), 164.5, 
165.7, 166.1, 166.3 (4 COO); 
 
elemental analysis calcd (%) for C41H39NO11 (721.76): C 68.23, H 5.45, O 24.38, N 1.94; 
found: C 67.85, H 5.90, O 24.41, N 1.84 
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6.   Crystal structure data of compound 158 
 
        Data deposition        Roche intranet structure No. 1252 
        WWW address         http://rbaw01.bas.roche.com:8080/apps/sxray/sxray.html 
 
        Empirical formula                   C28H46O7  
        Formula weight                      494.65  
        Temperature                        293(2) K  
        Wavelength                          0.71073 Å  
        Crystal system, space group        Orthorhombic,  P2(1)2(1)2(1)   
        Unit cell dimensions               a = 6.5656(13) Å    α = 90 deg.  
                                           b = 15.839(3) Å     β = 90 deg.  
                                           c = 29.157(6) Å    γ = 90 deg.  
   
        Volume                              3032.1(10) Å3  
        Z, Calculated density               4,  1.084 mg/m3  
        Absorption coefficient              0.076 mm-1  
        F(000)                              1080  
        Crystal size                        0.3 x 0.1 x 0.05 mm  
        Theta range for data collection    2.46 to 22.40 deg.  
        Limiting indices                    -6 ≤ h ≤ 6, -16 ≤ k ≤ 16, -31 ≤ l ≤ 31  
        Reflections collected / unique     21027 / 3735 [R(int) = 0.1334]  
        Completeness to theta = 22.40      95.7 %  
        Refinement method                   Full-matrix least-squares on F2  
        Data / restraints / parameters     3735 / 0 / 326  
        Goodness-of-fit on F2              0.797  
        Final R indices [I>2σ(I)]       R1 = 0.0532, ωR2 = 0.0941  
        R indices (all data)                R1 = 0.1442, ωR2 = 0.1191  
        Absolute structure parameter       -2(2)  
        Largest diff. peak and hole         0.178 and -0.128 e. Å -3  
 
 
Table 8: Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2 x 103). 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________ 
                            x            y              z            U(eq)  
_________________________________________________________________  
   
          O(1)          8042(7)        4135(2)        2213(1)        69(1)  
          O(2)          7800(7)        3785(2)        1276(1)       68(1)  
          O(3)          9558(11)      3175(5)         734(2)       185(4)  
          O(4)          8569(6)        5416(2)         982(1)        69(1)  
          O(5)         11920(10)     5640(4)         871(2)       124(2)  
          O(6)          6761(7)        6214(2)        1720(1)        67(1)  
          O(7)          3540(7)        5939(3)        1924(2)        85(1)  
          C(8)          7510(9)        4996(3)        2230(2)        63(2)  
          C(9)         7181(9)        5327(3)        1734(2)        60(2)  
          C(10)         9002(9)       5165(3)        1449(2)        56(2)  
          C(11)         9522(10)     4224(4)        1460(2)        60(2)  
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          C(12)         9777(11)     3940(4)        1951(2)        71(2)  
          C(13)            10125(12)        2999(4)          1999(2)          102(3)  
          C(14)         7967(14)       3300(4)         912(2)        87(2)  
          C(15)         5908(13)       2927(5)         772(3)        93(2)  
          C(16)         4644(13)       3640(5)         566(3)       149(4)  
          C(17)         6172(13)       2237(5)         424(3)       146(3)  
          C(18)         4812(15)       2603(6)        1196(3)       180(5)  
          C(19)        10158(15)     5662(4)         727(2)        78(2)  
          C(20)         9603(14)       5895(5)         242(2)        92(2)  
          C(21)         7347(17)       5886(6)         150(2)       180(5)  
          C(22)        10220(20)     6750(6)         168(3)      291(10)  
          C(23)        10450(30)     5275(8)         -60(3)       353(12)  
          C(24)         4812(12)       6446(4)        1801(2)        67(2)  
          C(25)         4474(13)       7389(4)        1718(3)        90(2)  
          C(26)         5299(16)       7629(4)        1252(3)       156(4)  
          C(27)         2151(14)       7539(4)        1722(3)       146(4)  
          C(28)         5487(17)       7842(4)        2100(3)       192(5)  
          C(29)         8998(9)        5535(3)        2509(2)        69(2)  
          C(30)        9413(12)       5152(4)        2982(2)        84(2)  
          C(31)        11304(12)     5468(5)        3189(2)       108(2)  
          C(32)        11619(14)     5165(5)        3676(3)       129(3)  
          C(33)         9922(19)       5449(6)        3963(3)       155(4)  
          C(34)         7922(16)       5359(5)        3750(3)       132(3)  
          C(35)         7694(11)       5217(4)        3296(2)       104(2) 
________________________________________________________________  
 
 
 
 
Table 9:  Bond lengths [Å] and angles [°]. 
________________________________________________________________  
            O(1)-C(12)                    1.405(6)  
            O(1)-C(8)                      1.409(5)  
            O(2)-C(14)                    1.316(7)  
            O(2)-C(11)                    1.432(6)  
            O(3)-C(14)                    1.183(9)  
            O(4)-C(19)                    1.338(7)  
            O(4)-C(10)                    1.448(6)  
            O(5)-C(19)                    1.231(8)  
            O(6)-C(24)                    1.352(7)  
            O(6)-C(9)                      1.434(5)  
            O(7)-C(24)                    1.214(7)  
            C(8)-C(29)                    1.532(7)  
            C(8)-C(9)                      1.553(7)  
            C(9)-C(10)                    1.478(7)  
            C(10)-C(11)                  1.529(7)  
            C(11)-C(12)                  1.512(6)  
            C(12)-C(13)                  1.514(7)  
            C(14)-C(15)                  1.530(10)  
            C(15)-C(17)                  1.502(8)  
            C(15)-C(18)                  1.518(10)  
            C(15)-C(16)                  1.525(9)  
            C(19)-C(20)                  1.508(9)  
            C(20)-C(22)                  1.430(9)  
            C(20)-C(23)                  1.431(10)  
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            C(20)-C(21)                  1.505(10)  
            C(24)-C(25)                  1.528(8)  
            C(25)-C(28)                  1.484(9)  
            C(25)-C(26)                  1.510(9)  
            C(25)-C(27)                  1.544(10)  
            C(29)-C(30)                  1.531(7)  
            C(30)-C(35)                  1.457(8)  
            C(30)-C(31)                  1.469(8)  
            C(31)-C(32)                  1.511(9)  
            C(32)-C(33)                  1.464(10)  
            C(33)-C(34)                  1.459(11)  
            C(34)-C(35)                  1.350(9)  
            C(12)-O(1)-C(8)            115.6(5)  
            C(14)-O(2)-C(11)          121.3(5)  
            C(19)-O(4)-C(10)          116.6(5)  
            C(24)-O(6)-C(9)            116.3(5)  
            O(1)-C(8)-C(29)            113.6(5)  
            O(1)-C(8)-C(9)              109.2(4)  
            C(29)-C(8)-C(9)            113.2(4)  
            O(6)-C(9)-C(10)            108.0(5)  
            O(6)-C(9)-C(8)              112.7(4)  
            C(10)-C(9)-C(8)            110.6(5)  
            O(4)-C(10)-C(9)            108.8(5)  
            O(4)-C(10)-C(11)           109.3(4)  
            C(9)-C(10)-C(11)           109.7(5)  
            O(2)-C(11)-C(12)           107.3(5)  
            O(2)-C(11)-C(10)           106.9(5)  
            C(12)-C(11)-C(10)         109.5(5)  
            O(1)-C(12)-C(11)           111.0(5)  
            O(1)-C(12)-C(13)           106.8(5)  
            C(11)-C(12)-C(13)         113.4(5)  
            O(3)-C(14)-O(2)             121.7(7)  
            O(3)-C(14)-C(15)           126.8(7)  
            O(2)-C(14)-C(15)           111.5(7)  
            C(17)-C(15)-C(18)         110.9(7)  
            C(17)-C(15)-C(16)         109.6(7)  
            C(18)-C(15)-C(16)         108.3(8)  
            C(17)-C(15)-C(14)         111.0(7)  
            C(18)-C(15)-C(14)         109.5(6)  
            C(16)-C(15)-C(14)         107.4(7)  
            O(5)-C(19)-O(4)            122.4(7)  
            O(5)-C(19)-C(20)           123.6(7)  
            O(4)-C(19)-C(20)           113.8(8)  
            C(22)-C(20)-C(23)         116.5(10)  
            C(22)-C(20)-C(21)         105.2(9)  
            C(23)-C(20)-C(21)         105.6(9)  
            C(22)-C(20)-C(19)         107.7(7)  
            C(23)-C(20)-C(19)         108.3(7)  
            C(21)-C(20)-C(19)         113.7(7)  
            O(7)-C(24)-O(6)            121.6(6)  
            O(7)-C(24)-C(25)           126.4(7)  
            O(6)-C(24)-C(25)           112.0(6)  
            C(28)-C(25)-C(26)         113.2(8)  
            C(28)-C(25)-C(24)         106.7(6)  
            C(26)-C(25)-C(24)         109.6(6)  
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            C(28)-C(25)-C(27)         111.2(7)  
            C(26)-C(25)-C(27)         108.8(8)  
            C(24)-C(25)-C(27)         107.0(6)  
            C(30)-C(29)-C(8)           111.8(5)  
            C(35)-C(30)-C(31)         111.8(6)  
            C(35)-C(30)-C(29)         113.7(6)  
            C(31)-C(30)-C(29)         112.7(6)  
            C(30)-C(31)-C(32)         113.2(6)  
            C(33)-C(32)-C(31)         109.5(7)  
            C(34)-C(33)-C(32)         114.3(8)  
            C(35)-C(34)-C(33)         122.2(8)  
            C(34)-C(35)-C(30)     122.8(7)  
___________________________________________________________________  
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